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Genome-wide RNAi screening has emerged as a powerful tool for loss-of-
function studies that may lead to therapeutic target discovery for human 
malignancies in the era of personalized medicine. However, due to high false-
positive and false-negative rates arising from noise of high-throughput 
measurements and off-target effects, powerful computational tools and additional 
knowledge are much needed to analyze and complement it. Availability of high-
throughput genomic data including gene expression profiles, copy number 
variations from large-sampled primary patients and cell lines allows us to tackle 
underlying drivers causally associated with tumorigenesis or drug-resistance.  
In my dissertation, I have developed a framework to integrate functional RNAi 
screens with systems biology of cancer genomics to tailor potential therapeutics 
for reversal of drug-resistance or treatment of aggressive tumors. I developed a 
series of algorithms and tools to deconvolute, QC and post-analyze high-
throughput shRNA screening data by next-generation sequencing technology 
(shSeq), particularly a novel Bayesian hierarchical modeling approach to 





methods. In parallel, I developed a systems biology algorithm, NetBID2, to infer 
disease drivers from high-throughput genomic data by reverse-engineering 
network and Bayesian inference, which is able to detect hidden drivers that 
traditional methods fail to find.  
Integrating NetBID2 with functional RNAi screens, I have identified known and 
novel driver-type therapeutic targets in various disease contexts. For example, I 
discovered that AKT1 is a driver for glucocorticoid (GC) resistance, a problem in 
the treatment of T-ALL. The inhibition of AKT1 was validated to reverse GC-
resistance. Additionally, upon silencing predicted master regulators of GC 
resistance with shRNA screens, 13 out of 16 were validated to significantly 
overcome resistance. In breast cancer, I discovered that STAT3 is required for 
transformation of HER2+ breast cancer, an aggressive breast tumor subtype. 
The suppression of STAT3 was confirmed in vitro and in vivo to be an effective 
therapy for HER2+ breast cancer. Moreover, my analysis revealed that STAT3 
silencing only works in ER- cases. Using my framework, I have also identified 
potential therapeutic targets for ABC or GCB-type DLBCL and subtype-based 
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Chapter 1 Introduction 
Personalized medicine is coming of age [1, 2]. Traditional clinical diagnosis and 
treatment of diseases are based on patients‘ phenotypic information including 
clinical signs and symptoms, medical and family history, and data from laboratory 
tests and imaging evaluation [1, 3, 4]. The phenotypic information is often too 
vague to make the diagnosis and treatment precise and accurate. Moreover, 
clinical phenotypes are often late outcomes of disease progress and 
development, which makes treatment starts only after the signs and symptoms 
appear. Advances in human genetics and molecular medicine have enabled 
more detailed and more personalized characteristics of disease so that diagnosis 
and treatment based on such information at molecular level has emerged as a 
new field, i.e. personalized medicine or tailed therapeutics [1-10]. Personalized 
medicine is rational design of therapeutic approaches based on the specific 
genetic and other molecular characteristic information of the patient and/or 
patient‘s disease to maximize the clinical benefits and minimize risks, or in a 
simple explanation, personalized medicine is healthcare targeted to you, and just 
you. It means your individual health interventions — prevention, diagnosis and 
treatment — are custom-tailored specifically for you, based on your personal 
DNA, the expression of powerful proteins and each of you unique biological 






1.1 Personalized Medicine in Cancer Treatment 
One major focus of personalized medicine or tailed therapeutics during the past 
one or two decades is on human cancer treatment [11-13]. In cancer treatment, 
we are moving from conventional approaches including chemotherapy, 
radiotherapy and surgery based on tumor characteristics such as size lymph 
node, cell grade and patient fitness such as age, weight, general health, 
menopausal status, which are usually vague, to the emerging targeted 
therapeutic approaches based on patients‘ genetic information and specific 
molecular biomarkers, which are more precise and more personalized [1, 4, 14]. 
1.1.1 Problems of conventional cancer treatment approaches 
There are significant problems with traditional phenotype-based therapeutic 
approaches for cancer treatment. First, the toxicity of chemotherapy or 
radiotherapy is usually high [15-17]. For example, chemotherapy that uses drugs 
to destroy cancer cells often kills adjacent normal tissues as well. Therefore, it 
often makes patients suffering tremendous side effects such as nausea, vomiting, 
hair loss, fatigue, anemia, mouth sores, taste and smell changes, infection, 
diarrhea, menopause, infertility, etc. Secondly, a significant number of patients 
are initially resistant to chemo- or radio-therapies, or relapse to develop 
resistance quickly. For example, in treatment for T-cell acute lymphoblastic 
leukemia (T-ALL), glucocorticoids are commonly-used chemotherapeutic agents 
in clinic due to its inducement of apoptosis in leukemia cells [18, 19], however, 





majority acquires resistance after treatment [18, 20-24]. Another example is 
cisplatin, a widely used chemotherapeutic agent against solid tumors such as the 
cancers of the testis, ovary, head, neck and lung [25, 26]. Although, cisplatin 
shows outstanding efficacy in the treatment of testicular cancers where regimens 
including this drug afford cure rates of greater than 95%, its effectiveness in the 
treatment of other cancers is more limited because of acquired or intrinsic 
resistance [27-33]. 
Therefore, we need tumor-selective therapeutic approaches or reversal of drug 
resistance for cancer treatment. In Chapter 7 and Chapter 8 of this dissertation, I 
will demonstrate in details how we identify therapeutic targets to overcome 
glucocorticoid resistance in T-ALL treatment. In Chapter 12, I will also show you 
a study of overcoming cisplatin resistance in lung cancer. 
1.1.2 Problems of targeting oncogenes for cancer treatment 
In the past decade of personalized cancer medicine, one main strategy that has 
been developed is to target oncogenes. Oncogenes are genes that have the 
potential to cause cancer, and in tumor cells, they are constitutively amplified or 
over-expressed because of aberrant genetic alternations, for example, HER2 
(Human Epidermal Growth Factor Receptor 2) in breast cancer [34], EGFR 
(epidermal growth factor receptor) in lung cancer [35] and NOTCH1 (Notch 
homolog 1, translocation-associated), a transmembrane receptor, in T-cell 
leukemia [36, 37]. New molecular testing methods have enabled the testing for 





cells from patients. Targeting oncogenes will most likely benefit the patients with 
active oncogenic proteins. 
Tremendous efforts have been invested to develop drugs or small-molecules to 
target aberrant oncogenes in a subset of patients with a given cancer type and 
many drugs are approved by Food and Drug Administration (FDA). For 
example, trastuzumab (marketed as Herceptin) and two other drugs – 
pertuzumab and lapatinib – are used in the treatment of women with breast 
cancer in which HER2 protein is amplified or overexpressed [38]. New drugs 
such as cetuximab, IRESSA and Tarceva that directly target the EGFR are used 
for EGFR positive lung cancer patients with a 60% responsive rate [35, 39]. 
Gamma secretase inhibitors such as RO4929097 and MK-0752 targeting 
NOTCH1 are being used for treatment of T-ALL [40, 41]. Also tyrosine 
kinase inhibitors such as imatinib (marketed as Gleevec) blocking activity of ABL 
are used to treat chronic myeloid leukemia (CML), in which the BCR-ABL fusion 
is present in >95% of cases [42]. 
However, targeting oncogenes as therapeutics of cancer treatment has 
significant problems as well. First, patients who receive such treatment usually 
develop resistance very quickly. For example, 50% of HER2+ breast cancer 
patients are resistant to Herceptin treatment initially, and the other 50% of 
patients treated with Herceptin will eventually develop resistance very quickly, 
within one or two years [43]. Secondly, many oncogenes are undruggable, 





sarcoma viral oncogene homolog), a well-studied oncogene in cancers of colon 
[44], pancreas [45] and lung [46], and MYC, another well-known oncogene that is 
constitutively activated in Burkitt's lymphoma, breast cancer, neuroblastoma and 
many other cancers [47]. Thirdly, the toxicity of some therapeutics targeting 
oncogenes is also high. For example, in treatment of T-ALL, gamma secretase 
inhibitors that block NOTCH1 activity have been shown to induce lethal gut 
toxicity [24]. 
The above limitations of targeting oncogenes for cancer treatment motivate us to 
search for alternative new therapeutic approaches or overcoming resistance of 
existing ones. In Chapter 9 of my dissertation, I will demonstrate an example of 
discovering novel therapeutic targets for HER2 positive breast cancer, and in 
Chapter 12, I will show you a study of searching for therapeutics to overcome 
PARP inhibitor resistance for BRCA1-mutated breast cancer. 
1.2 Functional Genomics: Genome-wide RNAi Screening 
In the era of personalized medicine, genome-wide RNA interference (RNAi) 
screening has been widely used to discover therapeutic targets for human 
malignancies. RNAi has emerged as one of the standard techniques for studying 
phenotype-specific gene function from plants to fungi to animals via suppression 
of gene expression [48-51]. RNAi-based gene silencing can be achieved by the 
use of short interfering RNAs (siRNAs) or short hairpin RNA (shRNA) expression 
vectors. Among the two approaches, shRNA is more feasible because siRNA 





transfection into non-dividing cells; however, shRNA can be stably integrated into 
a target cell genome via retroviral or lentiviral gene transfer, resulting in the 
permanent reduction of the targeted gene product. Several shRNA expression 
libraries targeting entire human genome have been generated to facilitate 
functional analysis of the whole transcriptome through loss-of-function genetic 
studies [52-55]. 
In genome-wide shRNA screening, a large population of cells is infected or 
transfected with a pool of different shRNA lentiviral vectors and shRNA hairpins 
are integrated into cell genomes. After that, there are two common applications 
of these transduced cells. One is growing the cells for a sufficient number of 
doubling times, extracting the genomic DNA at initial time (T0) and after 
harvesting (T10), and then comparing quantity of shRNAs in these two time-
points. This usage is to identify genes that are essential for cell survival or growth, 
thus making potential therapeutic targets for cancer and other type of human 
diseases, and hairpins of those lethal genes will be depleted or under-
represented in T10 population. The other application is splitting infected cells into 
two groups, treating the two groups differently, for example treating one group 
with drug and nothing to the other as control. After this selective pressure, grow 
cells from both populations and then compare shRNAs extracted from genomic 
DNA of each population. This approach is to identify genes that modulate 
response to the perturbation. In the example of drug treatment, this screen can 





1.2.1 Microarray-based shRNA screening 
To read out shRNA hairpins extracted from genomic DNA, microarray 
hybridization is commonly used with the advantage of low cost and flexibility. It 
employs PCR-amplified shRNA template sequence pools extracted from shRNA 
library-transduced cells under test as well as reference conditions. Each PCR 
fragment is labeled with a different fluorophore, followed by hybridization of both 
pools to the same array, or labeled with the same fluorophore followed by 
hybridization to multiplex arrays. Taking the two-color microarray as example, the 
ratio of signal intensities of two colors (Cy3, Cy5) for each probe sequence 
reflects the relative abundance of cells expressing the corresponding shRNA 
construct under test condition as compared to the reference. Consequently, 
shRNA hairpins that sensitize cells in the selective condition will be depleted from 
the pool, showing low values of signal ratio, whereas shRNA constructs that 
render cells resistant will be enriched, showing high values of signal ratio. Three 
types of molecular tags have been used as microarray probes, namely full-length 
hairpin, half hairpin, and external barcode sequence. Half hairpin is able to 
overcome the self-annealing problem during PCR amplification happening to full-
length hairpin, and correspondingly has more efficient labeling and microarray 
hybridization than full-length hairpin [51, 56]. Barcodes are not necessary for 
enrichment screens or positive selections such as designs to detect shRNA 
constructs for cell proliferation [57], but are critical for depletion screens or 
negative selections such as studies designed to detect cell-lethal or drug-





1.2.2 NGS-based shRNA screening 
Next generation sequencing (NGS) has recently emerged as a cost-effective 
technology of quantitatively measuring abundance of short-length DNA or RNA in 
a short time. This massively parallel sequencing has been used in pooled shRNA 
screens[61-63], and comparing to microarray-based approaches, it offers several 
potential advantages in terms of coverage of targeting genes, flexibility of input 
library, scalability and dynamic range. Moreover, barcode-based sequencing is 
commonly used to increase the multiplicity and efficiency by mixing multiple 
samples together and sequencing at once. As the cost of NGS is rapidly 
decreasing, this means might dominate high-throughput shRNA screening in the 
near future. 
In my dissertation, I will discuss computational analysis of both microarray and 
NGS-based shRNA screening data. In particular, I will introduce a novel 
computational pipeline to deconvolute and analyze NGS-based shRNA screening 
(shSeq) data because shSeq is relatively new comparing with microarray data 
analysis and there are no established tools and algorithms to analyze it. This 
pipeline includes software packages and algorithms for quality assessment (QA) 
of raw sequencing data, deconvolution of raw reads, preprocessing and 
normalization, quality controls (QC) of processed data, differential representation 
analysis at both individual shRNA level and integrated gene level, and other post-
analysis of shSeq data such as functional enrichment analysis and sensitivity 
analysis. Especially, I will introduce a new statistical algorithm to integrate 





hierarchical modeling approach, and will show that this new approach 
outperforms existing ones. 
1.2.3 Limitations of high-throughput RNAi screening 
Despite the powerfulness of high-throughput RNAi screening, there are a number 
of limitations and problems with current version of this emerging technology. For 
example, high false-positive and false-negative rates are usually associated with 
RNAi screening. A long list of candidates is often reported from a pooled shRNA 
screen, in which only a small percentage are true hits. It‘s impossible to follow up 
all identified thousands of candidates, and it‘s also heuristic to pick up top hits 
because the scores of top candidates are very close to each other. The reasons 
could be because of off-targets, i.e. designed shRNA construct targeting 
unexpected genes by sequence similarity, and low knock-down efficacy of 
shRNAs. Furthermore, noise and small sample size of high-throughput 
measurements makes the estimation of statistical metrics to score hairpins or 
genes inaccurate. Therefore, powerful computational analysis and additional 
knowledge are much needed to complement it. 
1.3 Cancer Genomics and Systems Biology 
Advances in human genetics and molecular medicine have driven progress in 
our understanding of cancer biology. Development and improvement in DNA 
copy number, gene expression, and next-generation sequencing (NGS) 
technologies have resulted in more comprehensive characterization and accurate 





complexity and heterogeneity. This has led to the emerging field of cancer 
genomics to study human cancer genome. It is a systematic search within cancer 
families and patients for the full collection of genes and genetic or epigenetic 
alternations – both inherited and sporadic – that contribute to the development of 
a cancer cell and its progression from a localized cancer to one that grows 
uncontrolled and metastasizes. 
Cancer genomics can also be extended and generalized to proteomics, 
epigenetics and epigeomics. Advances in proteomics with mass-spectrum 
technology have enabled comprehensive analysis and characterization of all of 
the proteins and protein isoforms encoded by the human genome that may have 
a significant impact on cancer biology as well. This is because while the DNA 
genome is the information archive, it is the proteins that do the work of the cell: 
the functional aspects of the cell are controlled by and through proteins, not 
genes. Progress in characterizing post-transcriptional and post-translational 
modifications has led to identification of epigenetic factors that governed 
important biological functions: growth, death, cellular movement and localization, 
differentiation, etc. Those proteins form a potential class of therapeutic targets for 
cancer treatment. 
The cancer genomic data provides us significant molecule insights into genes, 
proteins and pathways that are causally associated with tumorigenesis, 
progression, or drug-resistance. We can use this information to complement 





and, more importantly, to identify novel oncogenes or tumor suppressor genes as 
therapeutic targets for cancer treatment.  
1.3.1 Collaborative projects on cancer genomics 
A significant number of community-driven collaborative research projects or 
programs on cancer genomics using high-throughput genomic technologies have 
been launched to provide systematic, comprehensive genomic characterization 
and sequence analysis of multiple types of human cancers, both primary 
samples and cell lines, and to facilitate cancer discoveries among scientists. 
Below are a few examples: 
 The Cancer Genome Atlas (TCGA) is a pilot project of the National 
Cancer Institute (NCI) and the National Human Genome Research 
Institute (NHGRI) since 2005 [64]. It covers almost major types of human 
tumors including glioblastoma multiforme (GBM), squamous carcinoma of 
the lung, and ovarian serous cystadenocarcinoma, breast invasive 
carcinoma, kidney renal clear cell carcinoma, colon adenocarcinoma, etc. 
Data type includes copy number variants, DNA methylation, exon 
expression, gene expression, protein expression, miRNA expression, SNP, 
and somatic mutation. 
 The International Cancer Genome Consortium (ICGC) has been 
organized to launch and coordinate a large number of international cancer 
genome research projects [65]. It provides comprehensive catalogues of 





and epigenetic modifications in tumors from 50 different cancer types 
and/or subtypes. 
 Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) is initiated by NCI and is dedicated to identify valid 
therapeutic targets in pediatric cancers including acute lymphoblastic 
leukemia (ALL), acute myeloid leukemia (AML), neuroblastoma (NBL), 
high-risk Wilms tumor and osteosarcoma (OS) [66]. Data type includes 
gene expression, copy number variants, epigenetics, whole genome 
sequencing and exome sequencing. 
 The Cancer Cell Line Encyclopedia (CCLE) project is an effort between 
the Broad Institute and the Novartis Institutes for Biomedical Research to 
conduct a detailed genetic characterization of a large panel of 1000 
human cancer cell lines [67]. It includes DNA copy number, mRNA 
expression and mutation data. 
 The Connectivity Map (CMAP) is a project launched by The Broad 
Institute to study the connections between genes, drugs and cancer [68]. 
It‘s a collection of genome-wide transcriptional expression data from 
human cells treated with bioactive small molecules. The second version 
contains more than 7,000 expression profiles representing 1,309 
compounds on 5 human cancer cell lines. 
1.3.2 Systems biology 
To identify causally-associated genes or pathways from large-sampled high-





required. Because of the high dimension and noise from large-scaled genomic 
data, traditional methods of analysis at single factor level in such context might 
not work well. Taking gene expression data as an example, classical signature 
analysis of two phenotypes from two independent datasets designed to study the 
same cancer problem might produce very different results [69]. This has led to a 
new filed of systems biology, which integrates and aggregates multiple 
perspectives of ―omics‖ data to define a system and then performs analysis of the 
behavior of the system from a global view or network point. 
Systems biology approaches have been successfully applied to high-dimensional 
data of cancer genomics. It has been shown that computationally inferred 
context-specific maps of transcriptional or post-translational molecular 
interactions from large-scaled gene expression profiles (GEPs) allow the 
elucidation of cryptic driver proteins whose gain or loss is necessary and 
sufficient for tumor initiation or progression [70-73]. Such master regulators or 
drivers are more robust than traditional signatures to distinguish phenotypes [69]. 
Therefore, we suggest that systematic inference of driver-type regulators from 
genomic data complementing with RNAi screen technology will give a more 
comprehensive molecular understanding of mechanisms of tumor progression or 
drug-resistance and provide novel targets for therapeutics. 
In my dissertation, I will introduce a systems biology framework, Network-based 
Bayesian Inference of Disease Drivers (NetBID2), to infer disease drivers from 





inference. I will demonstrate that this framework performs more robust than 
classical signature analysis, and is able to detect not only known drivers of 
various cancer contexts, but also hidden drivers that conventional methods fail to 
find. The prediction rate of this algorithm is also high based on experimental 
validations. 
1.4 Integration of Functional Genomics with Cancer Genomics 
As discussed above, genome-wide high-throughput RNAi screening is a powerful 
technology to identify therapeutic targets for cancer treatment, however, due to 
high false-positive and false-negative rates arising from off-target effects, low 
silencing efficiency, and noise, the technology itself might not be good enough to 
work alone. Availability of large-sampled public cancer genomic data enables us 
to discover tumor-associated genes or pathways. Particularly, systems biology 
analysis of cancer genomics, by utilizing network strength, is capable of 
identifying underlying drivers of tumorigeneis or drug-resistance with a high 
successful rate. This motivates the integration of systems biology of cancer 
genomics with functional RNAi screens to tailor driver-type therapeutic targets for 
cancer treatment. 
In my dissertation, I have developed a framework to integrate functional RNAi 
screens with systems biology of cancer genomics to tailor potential therapeutics 
for reversal of drug-resistance or treatment of aggressive tumors. I have been 
working intensively on shRNA screening with Dr. Jose Silva, who developed 





of algorithms and tools to deconvolute, QC and post-analyze high-throughput 
shRNA screening data by next-generation sequencing technology (shSeq). My 
pipeline has become the standard for this type of analysis at Columbia‘s Genome 
Center. I have analyzed all shSeq data generated at Columbia so far in 
collaboration with over ten labs. 
In parallel, I developed a systems biology algorithm, NetBID2, to infer disease 
drivers from high-throughput genomic data by reverse-engineering network and 
Bayesian inference, which is able to detect hidden drivers that traditional 
methods fail to find. Integrating NetBID2 with functional RNAi screens, I have 
identified known and novel driver-type therapeutic targets in various disease 
contexts. 
For example, I discovered that AKT1 is a driver for glucocorticoid (GC) resistance, 
a problem in the treatment of T-ALL. From mass-spectrum data, we found that 
GC-resistance derives from AKT1‘s phosphorylation of the GC receptor, thereby 
blocking its translocation to nucleus. The inhibition of AKT1 was validated to 
reverse GC-resistance. Additionally, upon silencing predicted master regulators 
of GC resistance with shRNA screens, 13 out of 16 were validated to significantly 
overcome resistance. 
In breast cancer collaborating with Dr. Jose Silva, I discovered that STAT3 is 
required for transformation of HER2+ breast cancer, an aggressive breast tumor 





effective therapy for HER2+ breast cancer. Moreover, my analysis revealed that 
STAT3 silencing only works in ER- cases. 
In collaboration with Dr. Riccardo Dalla-Favera, I applied a similar approach to 
DLBCL. The integration of RNAi screens, ABC or GCB-type expression profiles 
and CNV data enabled the identification of known master regulators such as 
BCL6 and IRF4, as well as novel drivers specific to ABC or GCB-type. These 
potential therapeutic targets are currently being validated. 
My integrative framework has also been applied to subtype-based breast cancer 
in collaboration with Dr. Jose Siva. Integrating shRNA screens of a panel of 16 
breast cancer cell lines with systems biology of TCGA breast cancer expression 
profiling data, we identified therapeutic target candidates specific for luminal, 
basal A, basal B or HER2+ form of breast cancer, which are currently being 
validated. 
1.5 Overview of the Dissertation 
This dissertation is dedicated to develop algorithms and tools to integrate 
functional genome-wide RNAi screening data with systems biology of cancer 
genomics to discover drivers and therapeutic targets for human malignancies to 
meet the need of personalized medicine. Chapter 2 and Chapter 3 focus on 
genome-wide RNAi screening technology. Specifically, I will introduce a 
computational pipeline with a series of algorithms and tools for NGS-based 





analysis of shRNA screening data to report gene level activity in Chapter 3. In 
Chapter 4, I will introduce a novel systems biology framework, NetBID2, to infer 
disease drivers from cancer genomic data with an improved enrichment analysis 
method, BSEA detailed in Chapter 5. Chapter 6 is an example of using systems 
biology approach – Bayesian network – to infer drug-induced apoptosis pathways 
from CMAP data. Chapter 7 and 8 are on studies of identifying therapeutic 
targets to overcome glucocorticoid resistance in T-ALL. Specifically, in Chapter 7, 
my NetBID2 framework discovers AKT1 as a therapeutic target to reverse the 
resistance as validated biochemically and pharmacologically; and in Chapter 8, I 
will describe how we integrate genome-wide RNAi screens with systems biology 
to discover promising regulatory drivers as therapeutics to reverse glucocorticoid 
resistance in T-ALL. In Chapter 9, I will demonstrate another example of 
integrating RNAi screens with computational analysis of genomic data to tailor 
therapeutics for ERBB2/HER2+ breast cancer, in which we identify and validate 
STAT3 as an effective target. Chapter 10 and Chapter 11 are two more 
examples with preliminary results of applying my integrative framework to DLBCL 
and subtype-based breast cancer. In Chapter 12, I will briefly describe more 
examples of applying shSeq technology. In Chapter 13, I will introduce a user-
friendly and dynamic web system I developed to manage collaborative projects 
and to facilitate and speed up our research. Finally Chapter 14 is a summary of 





Chapter 2 Computational Analysis of Next Generation 
Sequencing-based shRNA Screening (shSeq) Data 
2.1 Introduction 
RNA interference (RNAi) has emerged as one of the standard techniques for 
phenotype-specific gene function studies from plants to fungi to animals via 
suppression of gene expression [48-51] and has been widely used for 
therapeutic target discovery [50, 74-79]. RNAi-based gene silencing can be 
achieved by the use of short interfering RNAs (siRNAs) or short hairpin RNA 
(shRNA) expression vectors, among which shRNA is more feasible than siRNA. 
It‘s because siRNA has the problem of transient inhibition of gene expression 
and inefficient transfection into non-dividing cells; however, shRNA can be stably 
integrated into a target cell genome via retroviral or lentiviral gene transfer, 
resulting in the permanent reduction of the targeted gene product. Several 
shRNA expression libraries targeting entire human genome have been generated 
to facilitate functional analysis of the whole transcriptome through loss-of-function 
genetic studies [52-55]. 
In genome-wide shRNA screening, a large population of cells is infected or 
transfected with a pool of different shRNA lentiviral vectors and shRNA hairpins 
are integrated into cell genomes. After that, there are two common applications 





doubling times, extracting the genomic DNA at initial time (T0) and after 
harvesting (TX), and then comparing quantity of shRNAs in these two time-points. 
This usage is to identify genes that are essential for cell survival or growth, thus 
making potential therapeutic targets for cancer and other type of human diseases, 
and hairpins of those lethal genes will be depleted or under-represented in T10 
population. The other application is splitting infected cells into two groups, 
treating the two groups differently, for example treating one group with drug and 
nothing to the other as control. After this selective pressure, grow cells from both 
populations and then compare shRNAs extracted from genomic DNA of each 
population. This approach is to identify genes that modulate response to the 
perturbation. In the example of drug treatment, this screen can help to identify 
genes that increase sensitivity or resistance of cells to the drug. 
To read out shRNA hairpins extracted from genomic DNA, microarray 
hybridization and Next generation sequencing (NGS) are commonly used. 
Microarray has a long history and is well-developed whereas NGS based on 
sequencing-by-synthesis has recently emerged as a cost-effective technology of 
quantitatively measuring abundance of short-length DNA or RNA in a short time. 
This massively parallel sequencing has been used in pooled shRNA screens [61-
63], and comparing to microarray-based approaches, it offers several potential 
advantages in terms of coverage of targeting genes, flexibility of input library, 
scalability and dynamic range. As the cost of NGS is rapidly decreasing, this 





In this chapter, I will mainly focus on analysis of NGS-based shRNA screening 
(shSeq) data because this is relatively new and there are no standard tools to 
deconvolute and analyze such data. But for analysis of microarray-based RNAi 
screening data, please refer to the book chapter [80] in Appendix A I wrote for 
Methods in Molecular Medicine. In this analytical pipeline of shSeq data analysis 
(Error! Reference source not found.), I will introduce multiple quality 
ssessment metrics for NGS raw  
 
Figure 2-1 An overview of the pipeline for shSeq data analysis including a series 
of software packages and algorithms 
QA of Raw Seq Data (ShortRead+) 
Deconvolution of Raw Reads (shScanner) 
Annotation, Normalization, QC (shSEQ) 
shRNA Level Differential Representation (shADER) 
Gene Level Activity (shMA / BHM) 






data, an efficient algorithm to decode shRNA NGS data, preprocessing of 
screening data including background correction and normalization, quality 
controls of processed data to detect biological artifacts of experiments, statistical 
methods for differential representation analysis at individual shRNA level and 
gene level to identify candidates of interest and additional post-analysis of 
shRNA screens including functional enrichment and sensitivity analysis. 
Note: all NGS-based shRNA screening data in this dissertation is on Illumina 
HiSeq platform and outputted by Genome Analyzer IIx. 
2.2 shRNA Library 
Thermo Scientific Open Biosystems GIPZ Lentiviral human shRNAmir library is 
used to illustrate the analysis of shSeq data. The library is composited of 58,493 
hairpin constructs, in which 39,458 shRNAs are known to target 18,661 human 
genes, about 75% of the genome. In the GIPZ library, one gene might have 
multiple shRNAs and as shown in the distribution table of number of shRNAs per 




1 2 3 4 5 6 7 8 9 10 11 13 total 
Frequency 
of Genes 
6,931 5,986 3,635 1,355 481 168 60 24 12 4 4 1 18,661 





2.3 ShortRead+: QA of Raw NGS Data 
The first thing to do after we have raw sequencing data is to check the overall 
quality of sequencing data and make sure there are no technical mistakes. I 
develop an R package, ShortRead+ to do quality assessment (QA) based on the 
existing ShortRead package. ShortRead package was designed for input, quality 
assurance, and basic manipulation of `short read' DNA sequence produced by 
different platforms such as Solexa, 454, Illumina HiSeq, and related technologies. 
It is working well for small data set, for example, a sequence run with less than 
10 million total reads, however, it‘s extremely time and space consuming for big 
data such as a sequence run with over 100 million reads, which is commonly 
obtained from shSeq experiments. Therefore it‘s not duable to process 100 or 
200 million of reads by ShortRead. That‘s why ShortRead+ is developed. It 
overcomes the drawbacks and limitations of ShortRead and also improves some 
plotting features from classical R lattice [81] plotting to more popular ggplot2 
framework [82]. 
2.3.1 Format transformation of raw NGS data (QSEQ to FASTQ) 
ShortRead takes NGS data in FASTQ format as input. FASTQ is currently a 
standard format of Genome Analyzer output; however, in old version of Genome 
Analyzer, the default output of raw data is in QSEQ format. In this situation, we 
need to transform data from QSEQ to FASTQ format. Example raw NGS data in 
QSEQ and FASTQ formats are shown in Table 2-2 and Table 2-3. QSEQ format 





columns are defined as in Table 2-4. One thing to be careful is that the quality 
score in QSEQ format sometimes is in Phrd64 format, which is different from the 
quality score (Phred33) in FASTQ format. A transformation is also needed. 
Functions for both transformation of QSEQ to FASTQ including quality score 
format are supported by ShortRead+. 
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Table 2-2 Example of raw NGS data in QSEQ format 
    





Table 2-3 Example of raw NGS data in FASTQ format 
Field Description 
Machine Name Identifier of the sequencer. 
Run Number Number to identify the run on the sequencer. 
Lane Number Positive integer (currently 1-8). 
Title Number Positive integer. 
X 
X coordinate of the spot. Integer. 
As of RTA 1.6, OLB 1.6, and CASAVA 1.6, the X and Y 
coordinates for each clusters are calculated in a way that makes 
sure the combination will be unique. The new coordinates are the 


















Y coordinate of the spot. Integer. As of RTA 1.6, OLB 1.6, and 
CASAVA 1.6, the X and Y coordinates for each clusters are 
calculated in a way that makes sure the combination will be unique. 
The new coordinates are the old coordinates times 10, +1000, and 
then rounded. Index Index sequence or 0. For no indexing, or for a 
file that has not been emultiplexed yet, this field should have a 
value of 0. 
Read Number 
1 for single reads; 1 or 2 for paired ends or multiplexed single 
reads; 1, 2, or 3 for multiplexed paired ends. 
Sequence Called sequence of read. 
Quality The calibrated quality string. 
Filter Did the read pass filtering? 0 - No, 1 - Yes. 
Table 2-4 QSEQ format of raw NGS data: column filed descriptions 
2.3.2 Phred quality score 
In output of Genome Analyzer, i.e. raw NGS data, each nucleotide of a single 
read has a matched quality score indicating the error rate of base calling, which 
is in Phred format [83]. The transformation of base-calling error rate to reported 
quality score by Genome Analyzer follows equation in Figure 2-2. In generally, a 
base with a quality score over 30, corresponding base-calling error rate under 






Figure 2-2 Equation of transforming base-calling error rate or probability (P) to 
Phred Quality Score (Q) 
ShortRead+ takes raw NGS data in FASTQ format (Phred33 for quality score) 
and checks the following quality metrics with plots and html report. 
2.3.3 Overall quality of raw NGS data 
The overall quality of one single read can be represented by the average Phred 
quality scores of all nucleotides in such read. Then we can check the distribution 
of overall quality of all reads. Figure 2-3 shows density distribution plot of overall 
quality scores from four different lanes. If the sequencing data is in good quality, 
you would expect a strong peak on the right, meaning that the majority of reads 






Figure 2-3 Density distribution plot of overall quality scores of all reads. The 
overall quality score of each read is calculated by averaging Phred scores of all 
nucleotides inside. A strong peak on the right indicates good overall quality of the 
sequencing data. 
Otherwise, a peak on the left such as s_7 in the example indicates problems of 
the overall quality and you might want to check whether there is any flaw during 





2.3.4 Cycle-based quality distribution 
We can also check the overall quality of each cycle by looking at the distribution 
of cycle-based or position-based quality scores. As shown in Figure 2-4, 
 
Figure 2-4 Cycle-based quality distribution (boxplot) of four different sequencing 
runs. The dashed short line ―-― at each cycle indicates the median quality score, 
and the dark blue region at each cycle represents the 95% interval of quality 





the quality goes up and stays stable in the middle and then goes down with 
increasing cycles. The bad overall quality of some cycles in s_7 lane explains the 
left peak in distribution plot of averaged overall quality. 
2.3.5 Distribution of read count 
It‘s also important to check the distribution of read count, especially to check the 
portion of low-frequent or high-frequent reads. One way to do that is to plot 
cumulative distribution curve (Figure 2-5) of how coverage is distributed amongst 
reads. Ideally, the cumulative proportion of reads will transition sharply from low 
to high. Portions on the left represent low-count reads and might correspond 
roughly to sequencing or sample processing errors. Portions to the right 
represent reads that are over-represented compared to expectation. Broad 
transitions from low to high cumulative proportion of reads might reflect 
sequencing bias or perhaps intentional features of sample preparation resulting 






Figure 2-5 Cumulative distribution plot of read count. A point on the curve 
indicates the portion of reads (the score on the y axis) that has less than or equal 
to a certain number of count (the number on the x axis, log10 transformed). 
Portions on the left are for low-frequent reads and portions on the right 





2.3.6 Cycle-based base calls 
 
Figure 2-6 Cycle-based base calls or base count. N is for undermined bases, 
which should have a low-count curve in good-quality sequencing data. 
Per-cycle base call should usually be approximately uniform across cycles. A 
constant count in the middle (around cycle 40) of the four example lanes (Figure 
2-6) is because those cycles are the 19 common nucleotides of a shRNA 





2.3.7 Example of a bad sequence run 
Multiple QA metrics provided by ShortRead+ can help you to detect bad quality 
sequencing runs which might come from technical mistakes. For example in 
Figure 2-7, there is a significant peak on the left of averaged quality distribution 
(A) indicating that there is a large portion of low-quality reads. Cycle-based 
quality distribution and base call plots point out the reason: after cycle about 30, 
the quality of sequencing drops to almost 0, resulting in bad overall quality. After 
careful investigation of the process, it turns out that this is due to a failure of a 
agent kit during the sequencing. However, if you skipped this QA steps and 

















Figure 2-7 Example of a bad sequence run shown by (A) density distribution of 
averaged quality scores (B) cycle-based boxplot of quality distribution and (C) 
cycle-based base calls or base count. 
2.4 shScanner: Deconvolution of Raw NGS Reads 
After confirming the quality of raw sequencing reads is relatively good, the next 
step of shSeq analysis is to deconvolute each short read by identifying which 
sample it represents and which hairpin it comes from. According to the 
construction of each 50nt or 100nt-length sequence read (Figure 2-8), the first 6 
nucleotides (in blue) are used to mapping back to the barcodes for multiple 
samples representing different experimental conditions, and the 22 nucleotides 
(in red) in the middle are used to identify shRNA hairpin in the library it belongs to. 
 
Figure 2-8 Sequence structure decomposition of each shSeq read. The first 6 
bases in blue are from barcodes of experimental design and the 22nt bases in 
red are from sequences of shRNA hairpins in the library, out of which 19 
nucleotides in the middle are perfectly matched to the genome sequence. 
Decoding a single read is easy in this context. Deconvolution of barcode and 
hairpin follows the same procedure. Take decoding hairpin as an example, it has 





1) Extract the hairpin sequence from the read (position 26 to 47) 
2) Align the hairpin sequence with reference sequences in the library 
3) Calculate the score of the alignment between each reference sequence 
and query sequence 
4) Identify the reference sequences which has maximum alignment score 
5) If there is only reference sequence identified, i.e. having maximum 
alignment score, report this sequence as the hairpin source of this read; if not, 
mark this read as ambiguous 
The score of alignment is calculated by counting the number of exact matches 
between two sequences. A parameter of maximum number of mismatches (the 
default is 6 for barcode and 22 for hairpin) is introduced to control reads with a 
large number of mismatches. 
However, to decode 100 million of reads, it would be extremely time and space-
consuming if you do it one by one. shScanner implements a parallel computing 
framework under Titan clustering system [84] at Columbia C2B2 IT department. 
With the parallel computing technique, shScanner is able to decode 100M reads 
in just a few hours and only requires a 1G memory size for each job. 
In deconvolution results, shScanner reports an identification table representing 
the count of each hairpin (rows) under each sample (column). In general, over 75% 
of total reads can be identified (Table 2-5). The distribution of total identified 
reads across barcoded samples depends on the number of cells mixed when 






Table 2-5 A summary table of deconvolution results for 6 shSeq runs. Each run 
contains 6 samples (T0 and T10 in replicate A-C), in which the total identified 
reads (the first rows in each run) and averaged count per shRNA (the second 
row in each run) are reported. Identification rate is the percentage of identified 
reads. The numbers in red indicate a case of low signals which might cause the 
data noisy. T10/T0 is the ratio of total identified reads at T10 and T0. 
2.5 shSEQ: Processing, Normalization and QA of 
Deconvoluted shSeq Data 
Deconvolution of raw shSeq data generates a table representing abundance of 
hairpins under each sample. However, before comparing different conditions, e.g. 





data, normalize it and perform a secondary QA of normalized data. I develop a 
package, named shSEQ to do these jobs. 
2.5.1 Preprocessing 
Hairpin abundance in the shSeq data is count-based, thus there could be zeros, 
especially if the total number of identified reads is low. To obtain robust results of 
later comparisons and to avoid zero or infinite value when calculating fold change 
to represent the difference, a pseudo-count (default 1) is added to the abundance 
table. This is equivalent to putting a uniform or flat prior to the likelihood of such 
discrete data. 
2.5.2 Normalization 
Due to the discrete nature of shSeq count data, the normalization of such data is 
different from microarray data. The first step of shSeq data normalization is 
scaling the count to make each sample have the same total number of reads so 
that count between different samples is comparable. With the capacity of GIPZ 
library, 10 million of total reads is commonly used to do scale normalization, 
therefore each hairpin has about 170 reads on average. The scale-normalized 
count of one hairpin is proportional to the percentage of its abundance in a fixed 
size cell population. This step is similar to the background correction in 
microarray data preprocessing. After scale normalization, all replicates are 
scaled to have the same center roughly as shown in Figure 2-9 and Figure 2-10. 
However, scale normalization doesn‘t reduce the variance within replicates as 





variance within replicates is an important source of noise for shSeq data and 
needs to be controlled. Therefore, a novel normalization procedure is proposed 
to reduce the variance of replicates by correcting outliers among replicates for 
each hairpin. Hairpins that have outlier count are determined by standard 
deviation ranking. By default, 25% of total hairpins are considered to contain 
outliers. For a hairpin with outlier count value, the outlier is decided as the one 
which causes the largest increase of standard deviation. The other two or more 
count values are used to fit a Gaussian distribution for the count value under this 
condition, which is then used to simulate a new corrected count for the outlier. If 
zero standard deviation occurs, the median of standard deviations of all hairpins 
is used instead. 
After normalization by replicates (NBR), the variance within replicates is reduced 











Figure 2-9 Scatter (A), density (B) and CDF (C) plots of data before normalization. 
(A) Scatter plots and correlations between biological replicates. Plots in the 
dialogue are density distributions of data in each replicate. Texts in the upper 













Figure 2-11 Scatter (A), density (B) and Cumulative distribution function (C) plots 





2.5.3 QA of normalized data 
After preprocessing and normalization of shSeq count data, we need to do a 
second QA to check the quality in biological perspective, i.e. the relations 
between different biological conditions and replicates.  
The shSEQ package incorporates and extends QA metrics for microarray data 
[85] and checks the following aspects of normalized shSeq data. 
2.5.3.1 MA plot 
M and A are defined as: 
                
  
             
 
 
V1 is the shRNA count (sequencing data) of the sample studied, and V2 is for a 
"pseudo"-sample that consists of the median across all samples. Generally, we 
expect the mass of the distribution in an MA plot to be concentrated along the M 
= 0 axis, and there should be no trend in M as a function of A. If there is a trend 
in the lower range of A, this often indicates that the samples have different 
background signals; this may be addressed by background correction. A trend in 
the upper range of A can indicate saturation of the measurements; in mild cases, 






Figure 2-12 MA plot of shSeq data of multiple samples. 
2.5.3.2 Distribution of hairpin count 
Distribution plots including boxplot and density plot are commonly used to check 
the average strength of signal and noise level. Boxplots (Figure 2-13) represent 
summaries of the signal distributions of the samples. Each box corresponds to 
one sample. Typically, we expect the boxes to have similar positions and widths. 
If the distribution of a sample is very different from the others, this may indicate 
an experimental problem. Outliers based on the Kolmogorov-Smirnov statistic 
between each sample's distribution and the distribution of the pooled data, are 






Figure 2-13 Boxplot of shSeq count in each sample. 
Density plots (Figure 2-14) are smoothed histograms of the data. Typically, the 
distributions of the samples should have similar shapes and ranges. Outliers, 






Figure 2-14 Density plot of hairpin count in each sample. 
2.5.3.3 Consistence of biological replicates 
One important perspective we need to check in the second QA of normalized 
shSeq data is the consistence of biological replicates. There are several ways of 
doing this supported by shSEQ package. 
A straight-forward approach is to look at the correlation of replicates condition by 
condition. As shown in Figure 2-9, Figure 2-10 and Figure 2-11, empirical 
distribution of each replicate sample is plotted in the dialogue, and they are 
expected to have similar shape and scale as indicated in part B and part C 
(cumulative distribution plot). In part A, upper triangle shows the Pearson and 






Heatmap (Figure 2-15) of between sample distances and dendrogram of sample 
clustering (Figure 2-16Error! Reference source not found.) can help to detect 
batch effects, as well as clustering of samples based on biological effects. The 
color scale is chosen to cover the range of distances encountered in the dataset. 
Datasets for which the sum of the distances to the others is much different from 
the others are detected as marked by * as outliers. The distance between two 
samples is the mean absolute difference (L1-distance) between the vectors of M-












Figure 2-16 Hierarchical clustering of samples. Each row represents a condition 
while boxes on each rows are replicates under that condition. Dots on the upper 
left plot indicates where to split the three to obtain specific number of clusters, in 
which the yellow one is for the current plot; colors are for different clusters. 
2.5.3.4 PCA plot 
Scatter plot of the samples along the first two principal components (Figure 2-17) 
is used to check whether the samples cluster, and whether this is because of an 
intended biological or experimental factor, or according to unintended reasons 
such as "batch effects". Outliers, according to the same criterion as in the 







Figure 2-17 PCA plot of samples. 
2.5.3.5 Variance-mean dependence plot 
Variance-mean dependence plot (Figure 2-18) is the standard deviation of the 
representation values across samples on the y-axis versus the rank of their mean 
on the x-axis. The red dots, connected by lines, show the running median of the 
standard deviation. Typically, one expects the red line to be approximately 





hand of the x-axis can be observed and is symptomatic of a saturation of the 
measurements. 
 
Figure 2-18 Variance-Mean dependence plot. 
2.6 Comparison of NGS with Microarray Platform for RNAi 
Screening 
With the above QA metrics, one interesting question we can ask is how shSeq 
data is comparing with classical microarray-based pooled shRNA screening. 
Using the metric of consistence between replicates, we observe that shSeq data 





microarray data, both barcode-probed with a correlation of 0.6 to 0.7 and hairpin-
probed with a correlation of 0.7 to 0.8 (Figure 2-19). However, the shSeq data 
could be noisy as well, especially if the data doesn‘t have enough total identified 
reads as shown in Figure 2-20, which directly affects signal representation.  
 
Figure 2-19 Consistence of replicates for RNAi screening data by barcode-






Figure 2-20 An example of bad shSeq run. The numbers on the bottom-right are 
total number of identified reads for each replicate. Low total numbers (in red) for 
replicate B and C reduces the signal representation, thus making the data noisy. 
2.7 shADER: shRNA-level Differential Representation Analysis 
Once shSeq is normalized and secondary QA shows good results, we are ready 
to conduct differential representation analysis by comparing shRNA abundance 
at TX with T0, to identify hairpins or genes that are either essential for cell 
proliferation or survival, i.e. depleted ones, or suppressors of cell growth, i.e. 
enriched ones. In negative pooled hairpin screens, we are more interested in 
depleted or under-represented candidates because those genes are potential 
therapeutic targets of diseases such as cancer. Because there are multiple 





individual shRNA level or at gene level by integrating multiple hairpins for the 
same gene. 
In literature, there are a number of different metrics to estimate the differential 
representation of individual shRNAs. For example, straight-forward such as fold 
change, log-transformed fold change, signal to noise ratio, difference of means 
can be used for simple analysis. To estimate the fold change between case and 
control samples, one need to calculate the mean within case or control samples. 
Two methods can be used: arithmetic or geometric mean, and the latter one is 
suggested for robustness. 
2.7.1 Bayesian linear model 
However, the above methods doesn‘t take statistical significance into account, 
therefore Student‘s t-test or moderated t-type test [86, 87] can be used to test the 
statistical significance, or a linear modeling approach [88] can be used to fit the 
data. For the modeling approach, the likelihood needs to be regularized by 
classical Frequentist‘s stabilization method [87], Bayesian or empirical Bayesian 
approach [88] due to small sample size issue. The regression coefficient 
represents the level of difference between case and control groups, and the 
statistical significance can be estimated by Chi-square test or Wald‘s z-test. 
In my dissertation, I develop a method, shADER, to do shRNA level analysis of 
differential representation. It‘s essentially a linear model under Bayesian 
framework. The reason to do it with Bayesian inference is because shSeq data is 





overcomes those problems very well. Because of the discrete nature of shSeq 
count data, a Poisson distribution (Figure 2-21) is employed to model the data, 
but for microarray data which is continuous, a Gaussian distribution (Figure 2-22) 
is commonly used. In shADER, it supports multiple priors for the coefficient or the 
slope including Gaussian prior [89], t-prior [90] and g-prior [91]. In general, 
Markov Chain Monte Carlo (MCMC) computing techniques are used to simulate 
the posterior distribution and estimate parameters in the model by posterior 
mean or median. 
 
Figure 2-21 A Bayesian linear Poisson model. Y is hairpin abundance in count, 
which follows a Poisson distribution with a log-link. X indicates the condition, e.g. 
T10 or T0. The coefficient of linear model β represents the magnitude of 
differential representation, and α is the intercept. The noise follows a Gaussian 
distribution with mean 0 and standard deviation σ. Priors for this model is a 
conjugate one, in which coefficients, β and α use a Gaussian distribution, and 
variance of noise σ2 follows Inverse Chi-square prior[89]. 
 
Figure 2-22 A Bayesian linear Gaussian model. Y is hairpin abundance in 
continuous value, which follows a Gaussian distribution. X indicates the condition, 
Bayesian Linear Poisson Model Priors





e.g. T10 or T0.The coefficient of linear model β represents the magnitude of 
differential representation, and α is the intercept. The noise follows a Gaussian 
distribution with mean 0 and standard deviation σ. Priors for this model is a 
conjugate one, in which coefficients, β and α use a Gaussian distribution, and 
variance of noise σ2 follows Inverse Chi-square prior. 
2.7.2 Summarizing differential representation results 
With the linear modeling approach, the slope is generally used to represent the 
magnitude of differential representation, but a summarized z-score is more 
robust to represent the differential representation results by taking the variance of 
the slope into account, especially when the data is noisy. Corresponding p-value 
will also be reported for statistical significance. The Z-score is calculated by 
estimate of regression coefficient over its standard deviation, which 
asymptotically follows a standard Gaussian distribution, therefore the two-tailed p 
value for statistically significance can be calculated based on this null distribution. 
This is essentially Wald‘s z-test. 
FDR for correction of multiple comparisons in shADER is calculated by BH 
procedure [92]. 
The package of shADER also supports multiple visualization of the results. For 
example, density plot of z-scores (Figure 2-23) and histogram of p values (Figure 
2-24) give overall distribution of depleted or enriched hairpins, also significance 
and non-significance. A uniform distribution of non-significant hairpins is 





shRNAs using z-scores (Figure 2-25) or original shSeq data (Figure 2-26) 
visualizes the pattern of differentiated shRNA-silencing effects such as similarity 
between genes or samples. 
 
Figure 2-23 Distribution of z-scores indicating differential representation results 
from four different shSeq data sets. Positive z-score means enrichment of 






Figure 2-24 Distribution of p-values indicating differential representation results 






Figure 2-25 Heatmap of z-scores of significant depleted hairpins. Euclidian or 









Figure 2-26 Heatmap of shSeq data of significant hairpins in different conditions. 
Euclidian or correlation can be used for distance metrics and Wald method is 
suggested for hierarchical clustering. 
2.8 shMA / BHM: Scoring Gene Level Activity by Integrating 
Multiple Hairpins Targeting the Same Gene 
The final goal of genome-wide of RNAi screening is to identify candidate genes 





level activity from RNAi screening data. Because of the fact that multiple shRNAs 
targets the same gene in the shRNA library, statistical methods are needed to do 
gene-level differential representation analysis by integrating all hairpins for the 
same gene. I develop a package shMA (shRNA meta-analysis) using Bayesian 
hierarchical modeling (BHM) approach to combine multiple shRNAs targeting 
one gene. See Chapter 4 for more details about this algorithm. 
2.9 Post-Analysis 
With results of differential representation analysis or selected candidates, there 
are multiple post-analysis we can do, for example, functional enrichment analysis 
and sensitivity analysis. 
2.9.1 Functional enrichment analysis 
One interesting question we can ask about the selected candidates is that what 
functions or pathways they are enriched in. The way to answer it is to perform 
enrichment analysis in known functional categories or pathways. 
There are multiple sources of functional databases we can use: 
 The Gene Ontology [93] includes annotations of biological process, 
molecular function and cellular component for entire human or mouse 
genome. 
 Pathway commons [94] is a collection of biological pathway information 
from public pathway databases including BioGRID, Nature Pathway, 





 Molecular signatures database (MSigDB) [95] is collection of annotated 
gene sets for use with GSEA software. 
Various available methods or tools for enrichment analysis we can use include: 
 DAVID [96] supports gene-annotation enrichment analysis using Fisher‘s 
exact test. 
 Gene Set Enrichment Analysis (GSEA) [97] is K-S statistic based 
enrichment analysis method developed at Broad Institute. 
 Gene Set Analysis (GSA) [98] introduces a new ―maxmean‖ statistic for 
enrichment score by Brad Efron. 
GSEA-type enrichment analysis of pathways or GO terms (Figure 2-27) uses 
differential representation results of all shRNAs or genes as the reference, for 
example, ranking from the most enriched to the most depleted. Classical 
weighted can be used to estimate the enrichment score, and gene label shuffling 
is commonly used to estimate significance in this small sample size situation. 
I develop a new enrichment analysis method, Bayesian Set Enrichment Analysis 
(BSEA), using Efron‘s ―maxmean‖ statistic and Bayesian inference. It 






Figure 2-27 An example GSEA plot of pathway or GO gene sets in differentially-
represented shRNAs. Y axis shows the z score of differential representation at 
shRNA level or gene level. The red dashed lines indicate normalized Enrichment 
Score (nES) and P value. 
2.9.2 Sensitivity analysis 
Another interesting analysis we can do with high-throughput shRNA screening 
data is sensitivity analysis, particularly when we have a number of RNAi screens 
across multiple cell types or disease contexts. Basically it asks a very general 
question: how sensitive is a cell line to respond to RNAi perturbation, or how 
difficult to kill certain type of cells by RNAi? The way to answer it is simply 





line. The larger the number of significantly depleted genes, the more sensitive 
this cell line is to respond to RNAi perturbation, or the easier to kill this cell line by 
RNAi.  
Based on this methodology, a sensitivity analysis plot can be generated by 
plotting the number of depleted hairpins of each cell line at different p-value 
cutoffs. Figure 2-28 shows the sensitivity analysis plot for a panel of 16 breast 
cancer cell lines covering major subtypes of breast cancer. The larger the area 
under the curve (AUC), the more sensitive the cell line is. So we can see that the 
most sensitive cell line is MCF10A, which is a normal line, while the most 
resistant one is SUM149PT, which is inflammatory breast cancer, probably the 
most aggressive form of breast cancer. If we group them into subtypes, there is a 
pattern of decreasing sensitivity from normal, to luminal to Basal A to Basal B 
type of breast cancer, or it is harder to kill Basal B than Basal A than Luminal 
than Normal cells, which is consistent with the aggressiveness we know about 
those forms of breast cancer. This pattern can be seen more clearly in the left 
panel of Figure 2-30. 
Similarly, we can do the same thing for enriched hairpins which corresponds to 
genes that are suppressors of cell growth or survival such as tumor suppressors. 
However, as shown in Figure 2-29 and the right panel of Figure 2-30, there is no 
such pattern we observed in depleted hairpins. This might reflect the difference 





preference of cell types to make the cell grow better, but to kill them depends on 
the cell type, which has a specific defense system. 
 
Figure 2-28 Sensitivity analysis. Number of significant depleted haiprins (y axis) 
in each of 16 breast cell lines at different p-value cutoffs (x axis). Cell lines 
represented by lines in different colors are classified into four groups represented 






Figure 2-29 Sensitivity analysis of looking at depleted, enriched or both hairpins 






Figure 2-30 Statistical comparisons of sensitivity analysis results of 16 breast cell 
lines in both depleted and enriched cases. A Student‘s t-test is used to do the 
comparisons. 
The sensitivity analysis of different cell types can be viewed in another 
perspective by counting the number of cell lines in each group that share certain 
number of depleted hairpins or genes (Figure 2-31). The lower the percentage at 
certain number of depleted genes, the more resistant this type of cells, or given a 
percentage of cell lines, the larger the number of depleted genes they share, the 






Figure 2-31 The percentage (y axis) of cell lines in each group share a certain 






Chapter 3 Meta-Analysis of High-throughput RNAi 
Screening Data (the BHM algorithm) 
3.1 Summary 
Genome-wide RNA interference (RNAi) screening has emerged as a standard 
tool for systematic loss-of-function studies and therapeutic target discovery. 
Short hairpin RNA (shRNA) is commonly used because of its stableness 
compared to small inference RNA (siRNA) that suffers transient silencing. 
However, due to high false-positive and false-negative rates, statistical analysis 
of high-throughput shRNA screening data remains challenging, particularly meta-
analysis of multiple shRNAs targeting the same gene in the library to report 
gene-level activity. Here we propose a Bayesian hierarchical modeling (BHM) 
approach to tackle this challenge and validate that this novel ―modeling-all-
together‖ strategy outperforms classical ―separate-and-combine‖ approaches. 
Surprisingly, our BHM algorithm works extremely well when applied to relatively 
low-quality screens, which is observed in about 80% of shRNA screens. 
Moreover, this hierarchical modeling framework can be useful in similar 
applications. 
Keywords: Bayesian hierarchical modeling, high-throughput RNAi 







RNA interference (RNAi) has emerged as a standard technique for studying 
phenotype-specific gene function in many organisms (e.g. plants, fungi and 
animals) via suppression of gene expression [48-51]. RNAi-based gene silencing 
can be achieved by the use of small interfering RNAs (siRNAs) or short hairpin 
RNA (shRNA) expression vectors. Between the two approaches, shRNA is more 
feasible due to the siRNA-specific problem of transient inhibition of gene 
expression and inefficient transfection into non-dividing cells. However, shRNA 
can be stably integrated into a target cell genome via retroviral or lentiviral gene 
transfer, resulting in the permanent reduction of the targeted gene product. Two 
major shRNA expression libraries, GIPZ library [52-54] and TRC library [55] that 
target the entire human genome have been generated to facilitate functional 
analysis of the whole transcriptome through loss-of-function genetic studies.  
In a genome-wide shRNA screen, a large population of cells is transfected with a 
pool of different shRNA lentiviral vectors and shRNA hairpins which subsequently 
integrate into cells‘ genomes. These transduced cells can be used for two main 
applications. One is to identify genes that are essential for cell survival or growth, 
thus representing potential therapeutic targets for cancer and other human 
diseases. Hairpins of such essential genes will be dropped out or under-
represented as time evolves. The other is to identify genes that modulate 
response to cell perturbation, such as chemotherapeutic agents. To do this the 





the other with a vehicle control. With this selective pressure, depleted or enriched 
hairpins will represent candidates that increase sensitivity or resistance of cells to 
a therapeutic agent. 
To quantify and analyze shRNA hairpins extracted from genomic DNA, 
microarray hybridization is commonly used with the advantage of low cost and 
flexibility. It employs PCR-amplified shRNA template sequence pools extracted 
from shRNA library-transduced cells under test as well as reference conditions. 
Each PCR fragment is labeled with a different fluorophore, followed by 
hybridization of both pools to the same array, or labeled with the same 
fluorophore followed by hybridization to multiplex arrays. Taking the two-color 
microarray as example, the ratio of signal intensities of two colors (Cy3, Cy5) for 
each probe sequence reflects the relative abundance of cells expressing the 
corresponding shRNA construct under the sample condition as compared to the 
reference. Consequently, shRNA hairpins that target essential genes for cell 
viability will be depleted from the pool, showing low values of signal ratio, 
whereas shRNA constructs that target genes inhibiting cell growth such as tumor 
suppressors will be enriched, showing high values of signal ratio. 
Because each gene represented in the shRNA library is targeted by an average 
of 2-3 hairpins in GIPZ library and 5 hairpins in TRC library, we must integrate 
evidences of all shRNAs for one gene to uncover the gene-level activity. 
Traditional methods usually employ a ―separate-and-combine‖ approach – 





high score or combining scores of all shRNAs targeting the same gene. Different 
algorithms that select or combine shRNAs have been proposed including 
choosing the second best or most depleted shRNA [59] (RIGER_SB), averaging 
the best two shRNAs[59] (RIGER_WS), performing enrichment analysis of all 
shRNAs targeting one gene against all shRNAs in the library [59] (RIGER_KS), 
or probability-based averaging of all shRNAs per gene [99] (RSA). A limitation 
with these types of approaches is that they rely on accurate estimation of 
individual shRNA activity which is very difficult to achieve in common large-
scaled shRNA screens with a small sample size. Also off-target effects, low 
silencing efficiency, small differences among shRNAs targeting one gene, and 
microarray noise will make heuristic selection of shRNAs to represent gene-level 
behavior problematic and cause high false-positive rates. 
To overcome the above drawbacks, in this study we propose a novel Bayesian 
hierarchical modeling (BHM) algorithm to report gene-level activity. Hierarchical 
modeling [89, 100], also known as multilevel modeling, has been increasingly 
used in large-scaled `omics studies for its robustness [101]. In this context, BHM 
algorithm puts all shRNAs targeting the same gene together, instead of 
separating them, and then fits a linear mixture model by allowing variation of 
activities among different hairpins, also known as random effects. This ‗modeling-
all-together‘ strategy improves parameter estimation by increasing sample size 
and reduces prediction error and false-positive rate by integrating information of 
all shRNAs. Furthermore, we employ Bayesian inference with Markov chain 





scoring metrics. Evaluation results based on benchmark shRNA screens 
designed for profiling essential genes suggest that our BHM method outperforms 
classical ‗separate-and-combine‘ algorithms significantly on sensitivity and 
precision, and especially BHM dominates the others when the data is of low 
quality, which accounts for about 80% cases of normal high-throughput shRNA 
screens. 
3.3 Profiling Cell Essential Genes by Microarray-based RNAi 
Screens 
As described in the previous section, negative genome-wide RNAi screening is 
commonly used to identify essential genes for proliferation and viability in cancer 
cells. A typical procedure of microarray-based pooled shRNA screening to profile 
cell essential genes is shown in Figure 3-1-A. The pool of shRNA plasmid 
vectors is transfected into a target cell population at a multiplicity of 0.3 to 
achieve one shRNA per cell. Infected cells are then harvested for X doubling 
times in triplicates. Genomic DNAs are extracted from cells collected at T0 and 
TX, PCR-amplified, labeled and hybridized to multiplex microarray. 
Analysis of microarray readout involves several steps (Figure 3-1-B). Signals 
representing shRNA relative abundance are extracted and processed with 
background correction and normalization. Differential representation analysis 
(DRA) on processed data at TX and T0 time points are performed to identify 
under-represented shRNAs at TX time whose target genes are potential 





the library, DRA can be conducted at individual shRNA level and integrated gene 
level. Classical ―separate-and-combine‖ approaches score shRNAs for one gene 
separately and then combine them to derive gene level score; however, our 
newly-proposed ―modeling-all-together‖ methodology skips the individually 
scoring step and fits a hierarchical model into all data for one gene to estimate 
gene level activity directly. Associated statistical metrics with gene-level 
behaviors including fold-change, p-value, false discovery rate or z-score will be 










Figure 3-1 Outline of microarray-based shRNA screens to profile cell essential 
genes (A) experimental procedures and (B) analysis pipelines 
3.4 Classical “Separate-And-Combine” Approach 
All previous methods to estimate activity of genes targeted by multiple shRNAs in 
large-scale shRNA screening data are based on a ―separate-and-combine‖ 
strategy as illustrated in an example from benchmark datasets that a gene is 
targeted by three shRNA clones (Figure 3-2-A). There are two well-developed 
algorithms for this type of approach: RNAi gene enrichment ranking [59] (RIGER) 
and redundant siRNA activity [99] (RSA). RIGER has three sub-algorithms to 
integrate multiple shRNA scores including Kolmogorov-Smirnov statistic-based 
enrichment analysis (RIGER_KS), weighted sum of the best two hairpins 
(RIGER_WS) and the second best hairpin (RIGER_SB). RSA employs a 
hypergeometric distribution or Fisher‘s exact test-based statistical method to rank 
gene activities. These algorithms can be reclassified into summarizing all 
shRNAs targeting the same gene (RIGER_KS and RSA) and heuristic selection 






Figure 3-2 Separate-and-combine approach. (A) An example of three shRNAs 
targeting KPNB1 gene from MCF7 dataset is selected to illustrate this approach. 
A Bayesian linear model is fit into data of each shRNA respectively. Estimated 
parameters (fitted lines in red) and summary statistical metrics are displayed on 
bottom left of each shRNA plot. Z scores and p-values are calculated by Wald 
test using a standard Gaussian as null distribution. Individual shRNA scores as 
input for algorithms to combine them can be calculated by t (Student‘s t-statistic), 
z (z-statistic of β in linear model), β (the coefficient in the linear model), signal-
noise ratio (mean difference of TX vs. T0 over sample standard deviation), logFC 
(logarithm of fold change of TX vs. T0) and diff.mean (mean difference of TX vs. 
T0). (B) In the linear regression model under Bayesian framework, yi indicates 
time point, TX or T0, and xi represents shRNA abundance for sample i; m is the 
sample size of the corresponding shRNA; noise follows a Gaussian distribution 
with mean 0 and variance σ2; β is the parameter of interest, indicating the 
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two-variable multi-Gaussian is set for coefficients and an Inverse-Gamma is for 
variance. 
Various metrics have been proposed to score individual shRNA behavior (Figure 
3-2-A) at TX and T0 time points including Student‘s t-statistic, z-statistic, 
coefficient of linear regression model, signal to noise ratio, logarithm of fold 
change, and difference of mean. Student‘s t-statistic or z-statistic of coefficient in 
linear model is commonly used due to their statistical integration of replicate 
variance. Student‘s t-test is equivalent to a linear model with Gaussian noise. 
However, with the fact that the sample size in this context is usually small, a 
Bayesian linear model with a Gaussian prior for coefficients (Figure 3-2-B) is 
suggested for its robustness. 
3.5 Our “Modeling-All-Together” Approach: Bayesian 
Hierarchical Model 
Instead of two-step analysis, we propose a ―modeling-all-together‖ approach to fit 
a complex hierarchical or multilevel model into data of all shRNAs targeting the 
same gene. Particularly, we establish the model within Bayesian framework to 
overcome inaccurate estimation problems from small sample size and microarray 
noise. Bayesian hierarchical model (BHM) introduces an additional level to the 
classical linear model with parameter of coefficient corresponding to silencing 
effect of shRNA group (indexed by j) and the parameter is assigned its own 





hairpin classes in a similar manner. Additionally, our Bayesian analysis requires 
us to specify prior distributions for the parameters of coefficients and variance, 
which follow Gaussian and Inverse-Wishart or Inverse-Gamma distribution 
respectively (Figure 3-3-A). The multilevel model can be rewritten as a linear 
mixture model (Figure 3-3-B), in which ―fixed effect‖ corresponds to gene-level 
activity and ―random effect‖ reflects the variation of silencing effects from different 
shRNA classes targeting the same gene. 
Using the same example in previous section, the data of three shRNA classes (in 
three different colors) is modelled together and parameters are estimated by 
MCMC simulations (Figure 3-4). The red solid line indicates the integrated 
behavior of all three shRNA groups, and each dashed line reflects individual 
shRNA-level behavior by adding random deviations to fixed gene-level activity on 
both slope and intercept.  
The hierarchical model can be viewed and interpreted from another conceptual 
perspective. As shown in Figure 3-5, a middle layer is introduced to indicate the 
shRNA level, thus forming the hierarchy structure of the model. All data points for 
one shRNA are clustered together, but all shRNAs targeting the same gene are 






Figure 3-3 Modeling-all-together approach. Bayesian hierarchical modeling (A) 
The data of all shRNAs targeting one gene can be fit by a hierarchical model, in 
which the extra level is indexed by j, indicating the shRNA group the sample 
belongs to. Sample index i is up to n, the total number of samples for one gene; j 
is up to J, the number of shRNA classes. Parameter µ, a vector of slope and 
intercept, reflects the gene-level activity and allows variation for each shRNA 
class. Conjugate priors are set for parameters. (B) The model can be rewritten to 
a two-component mixture model in which ―fixed effect‖ corresponds to gene-level 
behavior and ―random effect‖ indicates the noise of each shRNA group. 











Figure 3-4 Modeling-all-together approach. Bayesian hierarchical modeling. A 
practical application of the Bayesian hierarchical model to the example in Figure 
2 is summarized in the plot. Red solid line indicates fitted gene-level/fixed effects 
in the model. Estimated parameters and summary statistics including z-statistic 
and p-value are displayed on bottom middle. Each colored dashed line reflects 







Figure 3-5 A different representation of the hierarchical model. A middle layer is 
introduced to indicate the shRNA level. All data points for one shRNA are 
clustered together, but all shRNAs targeting the same gene are fit in the same 
model with allowance of their internal difference. 
3.6 Benchmark Datasets and Validations 
To benchmark different algorithms for meta-analysis of shRNAs targeting the 
same gene, we selected three representative datasets from a panel of 72 RNAi 



















cancer cell lines [102] using 80K pooled TRC library targeting 16K human genes 
with an average of 5 shRNAs per gene. In the original study [102], cells at three 
time points including T0 were collected for each cell line to investigate the 
dynamics of shRNA behaviors. However, due to our interest in detecting 
depleted genes essential for cell viability, we only selected the final time point 
and T0. This aids in the detection of depleted genes that are essential for cell 
viability, no matter whether they are dropped out early or late, and early depleted 
shRNAs would still remain under-represented in later time point. This two-time-
point design is also generally applied in literature for cost consideration, but a 
long evolution time is usually required to capture late-dropped-out genes. In 
Figure 2, the three types of tumors selected, MCF7, HPAFII and OVCAR5 for 
breast, pancreatic, and ovarian cancer respectively, are represented by three 
lines. More importantly, they also represent high (MRC: minimum replicate 
correlation > 0.9), medium (MRC between 0.8 - 0.9) or low (MRC < 0.8) data 
quality categories in terms of the consistence between replicates (Figure 3-7), 
each of which accounts for 22%, 50% and 28% of the total 72 screens (Figure 
3-6). 
Without a gold standard in place for selecting human essential genes, 
housekeeping and evolutionary-conserved genes likely to be critical for cell 
viability were used to benchmark methods of probing essential genes [102]. We 
followed this validation method to compare our new BHM approach with existing 
algorithms of reporting gene-level potency to be essential genes from shRNA-





references – two adapted from previous study [102] and two more recent studies 
on human housekeeping genes [103, 104]. Housekeeping or ortholog genes that 
were not present in the shRNA library were filtered out. We then determined the 
percentage of overlapped genes of reference set with top k hits predicted as 
essential genes by each method. To avoid selection bias on k, we sampled k 
from 0 up to 1000 with a sliding widow of 5. The larger intersection with reference 






Figure 3-6 Distribution of data quality (MRC: minimum replicate correlation) for 
the panel of 72 shRNA screens: High (MRC>0.9): 22%, Medium (MRC in 0.8-0.9): 










Figure 3-7 Quality of benchmark datasets. Each dataset has two time points (T0 
and TX) and three replicates (A, B and C). Each sub-figure displays the scatter 
plots on bottom left and correlations (Pearson_Spearman) on upper right 
between any two replicates of the corresponding group, and density distribution 
of shRNA abundance in each replicate on the diagonal. Low variability of scatter 
plots, high correlations and high similarity of distribution plots indicate good 
consistence of replicates, thus good quality of the data. The label (High, Medium 
or Low) after each cell line name indicates the data quality group it belongs to, 
defined by MRC (minimum replicate Pearson correlation), the ―bottle-neck‖ of 
each dataset. MCF7 (MRC > 0.9), HPAFII (MRC between 0.8-0.9), and OVCAR5 
(MRC < 0.8) represent 22%, 50% and 28% of 72 screens respectively. 
3.7 Evaluation Results 
3.7.1 BHM dominates RIGER and RSA 
To evaluate the performance of our BHM algorithm compared with classical 
RIGER (RIGER_KS, RIGER_SB, RIGER_WS) and RSA methods, we applied 
the validation strategy of using housekeeping and conserved genes as ―gold 
standard‖ for essential genes to three benchmark dropout shRNA screens. In 
RIGER and RSA methods, we used t-statistic for individual shRNA scoring that 
was commonly used in their software packages. We plotted the intersection 
percentage of each reference gene set against top 0 up to 1000 hits inferred as 
essential genes by each algorithm in each testing dataset (Figure 3-8). The Y-
axis corresponds to sensitivity or recall rate while the X-axis reflects precision or 





proportional to its power to identify a large percentage of true hits while 
maintaining a high precision. 
 
Figure 3-8 Evaluation results of final time point data. Housekeeping or conserved 
ortholog genes can be used as reference gene set to evaluate algorithms to 
detect essential genes from RNAi screens. Each colored curve shows the 
percentage of each reference set (―name‖_―number of genes in the set‖) 
intersected by top 0 to 1000 hits predicted as essential genes by the 
corresponding algorithm in each dataset. The slope of ―Random‖ method line (in 
purple) is proportional to the frequency of the reference set out of all genes in the 
library. The greater the area under the curve, the more powerful the algorithm is. 
From the evaluation plot results (Figure 3-8), first we noticed that all methods in 





all paired comparisons against random method by Student‘s t-test (also used by 
the following similar comparisons) < 4.4E-10. This was expected as it indicated 
that all three pooled shRNA screens were informative to detect human essential 
genes. Second, AUC curves of RIGER_KS, RIGER_WS, RIGER_SB and RSA 
were mixed together in all situations without clear separation. This suggested 
that there was little difference among ―separate-and-combine‖ type of methods. 
Third, BHM dominates RIGER and RSA in HPAFII and OVCAR5 studies (HPAFII: 
P < 0.05 in all 16 comparisons and P < 0.01 in 14 cases; OVCAR5: P < 1.7E-8 in 
all 16 comparisons), though it had unclear advantage in screen of MCF7 cells (P 
< 0.05 in 6 comparisons, P > 0.05 in the other 10 cases), which was actually 
explained by the association with data quality later. 
The above conclusions are also supported by the analysis of the data at a 






Figure 3-9 Evaluation results using middle time point data. Housekeeping or 
conserved ortholog genes can be used as reference gene set to evaluate 
algorithms to detect essential genes from RNAi screens. Each colored curve 
shows the percentage of each reference set (―name‖_―number of genes in the 
set‖) intersected by top 0 to 1000 hits predicted as essential genes by the 
corresponding algorithm in each dataset. The slope of ―Random‖ method line (in 
purple) is proportional to the frequency of the reference set out of all genes in the 
library. The greater the area under the curve, the more powerful the algorithm is. 
Interestingly, we observed that the advantages of BHM over RIGER or RSA were 
monotonically increasing from studies of MCF7 to HPAFII to OVCAR5, which 
exactly matched the decreasing pattern – from high to medium to low replicate 





expectation that our ―modeling-all-together‖ strategy with BHM algorithm 
consistently outperformed classical ―separate-and-combine‖ approaches on 
statistical power and robustness. More importantly, about 80% of shRNA screens 
in the panel of 72 cancer cell lines had medium or low data quality, in which BHM 
dominated the other methods significantly. If the data quality of the screens were 
high such as MCF7 in this study, methods would not matter too much because all 
methods reached the optimum. However, high quality data in high-throughput 
RNAi screens was rarely achieved due to off-target effects, measurement noise, 
and small sample size, which made our improved BHM method extremely 
valuable to produce trustable hit decisions. 
3.8 Discussion 
Meta-analysis of shRNA screening data to report robust gene-level behaviors 
remains difficult. We proposed a novel ―modeling-all-together‖ strategy, 
specifically a Bayesian hierarchical modeling algorithm, to address this problem. 
The evaluation results demonstrated that our BHM method outperformed 
traditional ―separate-and-combine‖ approaches (RIGER and RSA) dramatically in 
general, and especially dominated all the other methods in about 80% cases 
when the data was in relatively low quality. 
Hierarchical modeling, also known as partial pooling, can be viewed as a 
compromise between two extremes. One extreme, complete pooling, assumes 
the equal knockdown effect across all shRNA classes targeting the same gene. 





shRNA group and treat each hairpin replicate separately. The assumptions of 
these two extreme methods are too strong for shRNA screening design to be 
considered for integration of multiple shRNA evidences because different 
shRNAs targeting the same gene in the library might have significantly different 
silencing efficiencies. Hierarchical modeling comprises two extremes by allowing 
between-group variance and considering within-group effects, thus making an 
appropriate solution to this question. 
The problem of multiple comparisons can also disappear in Bayesian hierarchical 
models [105]. Partial pooling in hierarchical models shifts estimates toward each 
other whereas classical procedures for multiple comparison correction typically 
adjust p-values corresponding to intervals of fixed width. Thus BHM fitting results 
in reliable and conservative estimates for main effects or gene-level effects in this 
context.  
For ―separate-and-combine‖ strategy, a few other possible algorithms might be 
considered to integrate shRNA-level scores for the same gene, for example, 
Fisher‘s method [106] to combine signed p-values, or Stouffer‘s method to 
combine z-statistics [107]. However, these integrating p-values or z-scores 
methods easily over-estimate the significance of gene-level activity and generate 
a long list of significant candidates. Also, they ignore the magnitude of 
knockdown effects for each hairpin by only considering the statistical significance 





these methods might not be comparable to our BHM algorithm, or could be even 
worse than the other ―separate-and-combine‖ methods. 
Additionally, other enrichment analysis algorithms such as GSA [98] have been 
used in this context [108] and might perform better than KS-based GSEA method; 
however, these algorithms still bear the drawbacks of ―separate-and-combine‖ 
strategy, making them less powerful than BHM. The valuable point from 
enrichment-type methods that might improve BHM is to borrow information from 
all shRNAs or genes in the library because current BHM algorithm only considers 
shRNAs corresponding to one gene. Looking at entire list of candidates might 
produce more robust statistics for cut-off based hits selection, but probably would 
not change the rank of a gene as a potential candidate. 
Next generation sequencing (NGS) has recently emerged as a cost-effective 
technology for quantitatively measuring the abundance of short-length DNA or 
RNA in a short time, and this large-scale parallel sequencing has been used in 
pooled shRNA screens [61, 108]. Compared to microarray-based approaches, 
NGS offers several potential advantages in terms of coverage of targeting genes, 
flexibility of input library, scalability and dynamic range, which might make it 
dominate the technology for RNAi screening in the near future. In this study, we 
only focused on microarray-based shRNA screening data. However, our 
approach can be extended to analyze NGS-based shRNA screens by employing 





sequence count-based shRNA screening data, instead of Gaussian model 
generally used for continuous microarray data. 
In summary, we developed a novel hierarchical modeling algorithm within 
Bayesian framework for meta-analysis of shRNA screening data. This ―modeling-
all-together‖ strategy dominates classical ―separate-and-combine‖ methodology 
to analyze such noisy high-throughput data. However, this approach can be 
generalized and applied to any similar meta-analysis problem in which multilevel 







Chapter 4 NetBID2: Network-based Bayesian Inference of 
Disease Drivers 
4.1 Introduction and Motivation 
4.1.1 The era of post-genomics in cancer 
Advances in human genetics and molecular medicine have driven progress in 
our understanding of cancer biology. Development and improvement in DNA 
copy number, gene expression, and next-generation sequencing (NGS) 
technologies have resulted in more comprehensive characterization and accurate 
classification of human tumors and provided insights into cancer genome 
complexity and heterogeneity. This has led to the emerging field of cancer 
genomics to study human cancer genome. It is a systematic search within cancer 
families and patients for the full collection of genes and genetic or epigenetic 
alternations – both inherited and sporadic – that contribute to the development of 
a cancer cell and its progression from a localized cancer to one that grows 
uncontrolled and metastasizes. 
A significant number of community-driven collaborative research projects or 
programs on cancer genomics using high-throughput genomic technologies have 
been launched to provide systematic, comprehensive genomic characterization 
and sequence analysis of multiple types of human cancers, both primary 





example, The Cancer Genome Atlas (TCGA) [64] and The International Cancer 
Genome Consortium (ICGC) [65] provide comprehensive characterization 
including gene expression, copy number variants, SNP of major types of human   
cancers; Therapeutically Applicable Research to Generate Effective Treatments 
(TARGET) [66] focuses on pediatric cancer; The Cancer Cell Line Encyclopedia 
(CCLE) [67] is a collection of genomic data for a large panel of human cancer cell 
clines; The Connectivity Map (CMAP) [68] provides genomic profiles of 
perturbation experiments by thousands of small-molecules. 
All these cancer genomic data provide us significant molecule insights into genes, 
proteins and pathways that are causally associated with tumorigenesis, 
progression, or drug-resistance. We can use this information to complement 
genome-wide RNAi screens to shortlist candidates coming from RNAi screening, 
and, more importantly, to identify novel oncogenes or tumor suppressor genes as 
therapeutic targets for cancer treatment. 
The genomic data I focus on to develop computational algorithms or framework 
is gene expression profiles or transcriptome data which is widely available with 
mature microarray or NGS technologies. However, the methods or computational 
framework I developed can be extended to other types of genomic data. 
4.1.2 Gene expression signature is not robust 
To identify causally-associated genes or pathways from large-sampled high-
throughput cancer genomic data such as gene expression profiles, what people 





phenotypes, tumor or normal, drug-sensitive or drug-resistant, signature genes 
are usually defined as differentially expressed between the two phenotypes 
(Figure 4-1). However, the problem with conventional signature analysis is that 
they are not robust. Here is an example: Two groups were studying the same 
disease problem, metastasis in breast cancer, and each of them identified a 
group of signature genes based on their own large-sampled gene expression 
profiles, however, there is only one overlap out of about each 70 signature genes 
(Figure 4-2). One paper was published in Nature [109] while the other was in 
Lancet [110]. 
Another example is the following: we aim to identify a gene expression signature 
for ERBB2 mutation. To do that, we generate profiles for two cell lines – ERBB2 
mutated one and the wild type. However, if we culture exactly the same cells in 
2D or 3D environments, we would expect to see similar results because they 
represent the same cell types, however, we get very different results of signature 
genes. For example, there are about 30% of differentially expressed genes 
showing opposite directions in 2D and 3D systems (Figure 4-3) with individual 
examples as shown in Figure 4-4. Also if we looked at top over-expressed genes 
in 2D and 3D signatures as in the Venn diagram of Figure 4-3, there are only 
about 5 or 6 percent of top genes that are overlapped. We see the same pattern  
As shown in the above examples, traditional methods of signature analysis at 
single factor level in such context might not work well because of the high 





gene expression itself. However, it doesn‘t mean the expression data is useless. 
We just need to develop better method to dig into it. So we have to go beyond 
gene expression signature and develop better methods to identity more robust 
biomarkers or genes that are associated with cancer progression or drug 
resistance. And it‘s more interesting to identify ―driver‖ genes of the phenotypes 
instead of ―passenger‖ ones. 
 







Figure 4-2 Example of that master regulators are more robust than gene 
expression signature genes. Two groups were studying the same disease 
problem, metastasis in breast cancer, and each of them identified a group of 
signature genes, but there is only one overlap. However, in our predicted drivers 
for each of the datasets, the overlap improves dramatically from 1 out of 70 to 6 






Figure 4-3 Example of that gene expression signature is not robust. Signature 
genes (z > 1.96 or < -1.96) were plotted for both 2D (x axis) and 3D (y axis). 






Figure 4-4 Individual examples of that gene expression signature is not robust. 
The first two genes are over-expressed in mutated cells with 2D culture, but are 
under-expressed in mutated cells with 3D culture. The last two genes are on 
opposite. 
4.1.3 Systems biology 
The problems with conventional gene expression signature have led to the 
development of systems biology approaches which integrate multiple pieces of 
information and utilize the strength of networks. Systems biology approaches 
have been successfully applied to high-dimensional data of cancer genomics to 
identify driver-type genes [70-73]. We have shown that computationally inferred 
context-specific maps of transcriptional or post-translational molecular 





elucidation of cryptic driver proteins whose gain or loss is necessary and 
sufficient for tumor initiation or progression [70-73]. Such master regulators or 
drivers are more robust than traditional signatures to distinguish phenotypes [69].  
In this chapter, I will introduce a novel systems biology framework, Network-
based Bayesian Inference of Disease Drivers (NetBID2), to infer disease drivers 
from high-throughput genomic data based on reverse-engineering network and 
Bayesian inference. It improves and extends existing MARINa algorithm [70-73]. 
I will demonstrate that this framework performs more robust than classical 
signature analysis, and is able to detect not only known drivers of various cancer 
contexts, but also hidden drivers that conventional methods fail to find. The 
prediction rate of this algorithm is also high based on experimental validation 
results. 
4.2 Explanation of NetBID2 using a Social Example 
Before going to details about NetBID2 algorithm, I would like to explain the idea 






Figure 4-5 A social or non-scientific example to explain NetBID2 algorithm. 
Imaging there is a gang group in the New York City (NYC) which has a 
relationship network structure like this. All gang members listen to the god father 
or Mafia. This gang group is responsible for a number of criminals such as a 
killing like this. Well, the New York Police Department (NYPD) wants to capture 
those bad guys who committed the crime. What the police would do is to 
investigate the crime scene and collect evidences. Actually this is very similar to 
what we scientists do to study cancer or drug resistance. The police profile 
people to identify suspects, and we do gene expression profiling to identify genes 
that are associated with diseases. However, if the police only look at evidences 
directly associated with the crime, most-likely they will identify some small guys 





all these crimes because there is no evidence directly pointing to him. He is the 
guy who NYPD really wants to put in jail. To capture the big fish, the NYPD has 
to collect extra information and build a relationship network like this. Then they 
can borrow the strength of this network and apply the rule of ―guilty-by-
association‖ to get to him. These small players are like signature genes which 
are not robust because in this crime, the police might get this one, but in another 
crime, a different guy will be caught. What NetBID2 does is similar to this: it 
constructs a network first and instead of identifying those small signature genes, 
it looks for genes that are highly associated with so-called signature genes which 
are potential to be drivers.  
Actually those hidden driver genes, especially signaling proteins, are promising 
therapeutic targets. There is an old saying in Chinese, ―destroy the leader and 
the gang will collapse‖, and the crime will stop, at least committed by this gang 
group. Similarly to crack cancer or drug-resistance, we would like to target those 
hidden drivers. And most likely, the deeper this big fish hide, the more promising 
it is to be a therapeutic target. 
To summarize the example, the key idea of NetBID2 is to utilize the strength of 
networks to search for candidates that are highly connected with unstable 
signature genes instead of looking at individual signature genes. So we do use 





4.3 The NetBID2 Framework 
In NetBID2 framework (Figure 4-6), there are basically three steps to infer drivers 
of phenotypes from gene expression data: (1) reverse-engineering network (2) 
signature analysis of phenotypes and (3) gene set enrichment analysis of 
Subnetwork of driver candidates in phenotype signature. Details about each step 
are discussed as below. 
4.3.1 Reverse-engineering regulatory or signaling networks (Step 1) 
The first step of NetBID2 is to reconstruct a biological network from gene 
expression data. It has been shown that context-specific maps of transcriptional 
or post-translational molecular interactions can be computationally inferred from 
large-scaled gene expression profiles (GEPs) and allow the elucidation of cryptic 
driver proteins whose gain or loss is necessary and sufficient for tumor initiation 
or progression [70-73]. In this step, we use a well-developed reverse-engineering 
algorithm, ARACNe (Algorithm for the Reconstruction of Accurate Cellular 
Networks) [111]. ARACNe method uses mutual information to measure and 
construct pairwise connection between two genes but applies an information 
theory of data processing inequality (DPI) to eliminate the vast majority of indirect 
interactions typically inferred by pairwise analysis. On synthetic datasets 
ARACNE achieves extremely low error rates and significantly outperforms 
established methods, such as Relevance Networks and Bayesian Networks [111]. 





demonstrates ARACNE‘s ability to infer validated transcriptional targets of the c-
MYC proto-oncogene [70]. 
The original version of ARACNe only focused on tackling transcriptional 
regulatory network or transcription factor (TF)-centered network. However, in 
NetBID2, we extend ARACNe to reconstruct signaling molecule centered 
network by treating signaling protein genes as TFs in the original ARACNe setup. 
Actually it‘s more appropriate for ARACNe to reverse-engineer signaling network 
than transcriptional network for the following reasons. 
First, the novel part of ARACNe is to use DPI to eliminate indirect directions. DPI 
says if three genes follow a Markov-chain network structure, i.e. A->B->C or C-
>B->A, then I(A; C) <= I(A; B) or I(B; C). Based on the theory, ARACNe removes 
edges between A and C if I(A; C) <= I(A; B) or I(B; C). However, the underlying 
assumption is that A, B, C follows the Markov-chain structure, which is actually 
rare in transcriptional regulatory networks because of large amounts of feed-back 
and feed forward loops [112] for their importance in regulation of biological 
processes. Without holding the assumption, ARACNe will remove a significant 
number of true edges between TFs. There has been an increasing awareness of 
this problem [113].  However, in signaling transduction networks, Markov chain 
structures are everywhere whereas feed-forward loops are rare because the time 
scale of signaling transduction reactions is too small to have feed forward or 
feed-back loops. So DPI is more appropriate to remove redundant interactions 





Second, using ARACNe to reconstruct both transcription regulatory networks and 
signaling networks share a common assumption: the activity of proteins such as 
transcription factor or signaling molecules can be inferred from their gene 
expression level information, which is reasonable in many cases. The more 
mRNAs the cell produces for a gene, the more protein copies it generates. 
However, there is low or no correlation between gene expressions at mRNA level 
with protein level due to the dynamic nature of transcription and translation 
processes and the internal or external noise. However, this is a common 
limitation using gene expression data to reconstruct transcriptional network or 
signaling network, which can only be overcome by improving technology and 
using protein level data. 
In the discussion section, I will demonstrate that the targets or regulons inferred 
by ARACNe-predicted signaling network have a consistently higher precision 
than TF-centered network. Because the regulon size in TF-centered network is 
much bigger than signaling molecule centered network, the inferred interacting 
partners in signaling network are much cleaner and more informative than those 






Figure 4-6 The NetBID2 framework. Step 1 uses reverse-engineering algorithm, 
ARACNe to reconstruct TF or Signaling centered networks from gene expression 
profiles. Step 2 utilizes phenotype information to perform signature analysis using 
a Bayesian Probit model approach. Step 3 applies gene set enrichment analysis 
for each driver candidate by taking its first neighbors as a gene set and using 





4.3.2 Signature analysis of diseases by Bayesian Probit model (Step 2) 
The second step of NetBID2 is signature analysis of phenotypes. Signature 
analysis is to measure a correlation between each individual gene with the 
phenotypes such as tumor or drug resistance, and it can be performed by 
differential gene expression analysis between the phenotype of interest with the 
control phenotype, such as tumor vs. normal, drug resistant vs. sensitive 
samples, etc. In NetBId2, to generate a robust reference signature of these two 
phenotypes, we used a Bayesian Probit regression model for each individual 
gene [89] (Figure 4-7). Probit model has the advantage of detecting weak signals 
and has a nice tail behavior comparing with linear model or logistic model [89]. 
Bayesian inference with Markov Chain Monte Carlo (MCMC) computing 
techniques help to overcome sample size problem and help to estimate 
parameters more accurately and robustly from noisy high-throughput microarray 
data. For Bayesian inference of parameters, a t-distribution prior or weakly-
informative prior is used due to its robustness and its ability to handle outliers 
[90]. Gibbs sampling of MCMC technique is used to simulate the posterior 
distribution of parameters and posterior mean or median can be used as 
estimate of parameters, especially beta, the slope of the model, which measures 







Figure 4-7 The Bayesian Probit Model for gene expression signature analysis. 
Distribution details about the model is on the left and on the right is a graphical 
representation of the Probit model. Nodes in solid square are observation 
variables, in solid eclipse with white background are direct parameters of Probit 
model, in dashed eclipse are latent variables and the others are hyper-
parameters for priors. Y is an indicator variable for phenotypes, X is expression 
level of gene X, Z is a latent variable in Probit model. Inside the white box is 
likelihood section, while outside is for priors. Parameters are estimated by a 
Gibbs sampling procedure.  
4.3.3 Gene set enrichment analysis to infer disease drivers (Step 3) 
The final step of NetBID2 is to perform gene set enrichment analysis for each 
driver candidate and estimate their potency to be a good driver of the disease of 
interest. For driver candidates, NetBID2 only considers transcription factors or 
signaling molecules which have the function to be drivers. In the first step, 





ARACNe. In the diver inference step, for each driver candidate, we take all its 
first neighbors from its subnetwork as a gene set and test whether this set is 
enriched in the signature of disease produced in the second step. If there is a 
significant enrichment pattern, we consider and report the driver of testing as a 
good driver of this disease by controlling top signature genes. 
There are tons of methods to do enrichment analysis such as classical GSEA 
(Gene Set Enrichment Analysis) [97] developed at Broad Institute, GSA (Gene 
Set Analysis) [98] by Brad Efron and so on. However, I develop a new set 
enrichment analysis algorithm, BSEA (Bayesian Set Enrichment Analysis), using 
Efron‘s ―maxmean‖ statistic for enrichment score and Bayesian inference, which 
outperforms both GSEA and GSA. See details in Chapter 5. 
Enrichment analysis will report an enrichment score (ES) or normalized 
enrichment score (nES) with corresponding value to indicate the evidence of the 
candidate being a driver of the disease. Positive ES indicates the genes 
associate with this driver are enriched in up-regulated or over-expressed genes 
in the disease phenotype, vice versa, negative ES means those regulon genes of 
the driver are over-represented in down-regulated or under-expressed genes. 
However, the sign of enrichment score doesn‘t necessarily positively correlate 
with the activity of the driver gene. For example, a positive ES for a significant 
driver candidate doesn‘t necessarily mean this driver is active in the disease 
phenotype side. It‘s highly possible that the driver is repressed in the disease 





these neighbors enriched in the positive direction. What we can roughly conclude 
with the enrichment output is that whether this driver candidate has a strong 
association with the disease or not, but we cannot tell accurately whether the 
driver is active or inactive to cause the disease phenotype. The reason is 
because we are using gene expression data to infer the activity of genes at 
protein level. In many cases, there is a clear negative correlation of mRNA 
expression with protein expression due to feed-back loops and dynamics of gene 
transcription and translation. To tell the direction correctly, we need more 
information at lower genetic DNA level or upper protein level, or experimental 
validations of perturbation by either silencing or over-expressing driver 
candidates. 
4.4 Evaluation of NetBID2 
We evaluate the performance of this new framework, NetBID2 to discover 
disease drivers from gene expression data in several perspectives as shown 
below. 
4.4.1 NetBID2 is more robust than expression signature 
First, we compare NetBID2 method with conventional signature analysis to 
characterize the relationship between genes and the disease of study. In the 
example of identifying genes associated with ERBB2 mutation from expression 
profiles of 2D and 3D cultured cells as we discussed in introduction section 
(4.1.2), the signature analysis showed dramatically different results, especially 





differentially-expressed genes. So we applied NetBID2 to this example by 
identifying drivers that are associated with ERBB2 mutation using 2D or 3D data. 
Surprisingly, there is a dramatic increase of overlaps between drivers inferred 
from 2D expression data with 3D data (Figure 4-8), about 1/3 out of top inferred 
master regulators or signaling modulators. Therefore, the dramatic difference 
between 2D and 3D signatures cannot be explained only by the difference of 
environments. Actually the methods count a lot. NetBID2 is able to generate a 
more robust list of genes that are potential drivers of ERBB2 mutation no matter 
what culturing environment is used. 
 
Figure 4-8 Venn diagram of NetBID2 inferred drivers (both TF and Signaling 
factors) from 2D or 3D expression data of ERBB2 mutated MCF10A cells. 
Fisher‘s exact test is used to test the significance of overlaps. Total number is the 





4.4.2 Ability to identify known drivers 
Another way to test how NetBID2 performs is to ask whether it can detect known 
drivers. And the answer is yes. We applied NetBID2 to predict TF or signaling 
drivers for Basal vs. Luminal breast cancer, HE2+ vs. HER2– breast cancer, and 
ABC vs. GCB-DLBCL (Diffuse large B cell lymphoma). As shown in Table 4-1, 
among top 30 NetBID2-predicted drivers, most known drivers from literature are 
identified (highlighted in red). For example, FOXA1, GATA3, ESR1, PGR are 
well-studied drivers for Luminal breast cancer. ER and PR are also signaling 
molecules, and they show up in the top list of signaling drivers. For HER2+ 
breast cancer, ERBB2 itself definitely should be on the top without surprise. And 
FGFR4, GRB7 are also commonly amplified or over-expressed with ERBB2. 
ZBTB4 is a newly-identified tumor-suppressor in aggressive breast cancer. It 
shows up in both Basal vs. Luminal, and HER2+ breast cancer. Also for DLBCL, 
BCL6, IRF4 are known master regulators of ABC or GCB subtype. So NetBID2 is 
able to detect known drivers of diseases. However, it‘s not surprising because 
the evidences for all those drivers are so strong that you don‘t need to do 
complicated analysis to identify them. Most of them are also significantly 
differentially-expressed in the phenotypes which can be identified by signature 
analysis. There are duplicated names in the list because the analysis was done 
at probe or transcript level. One gene could have multiple probes in expression 
data representing different transcripts, but more probes for the same gene 






Table 4-1 Top 30 NetBID2-preditcted TF or Signaling drivers for Basal vs. 
Luminal breast cancer, HER2+ vs. HER2- breast cancer, and ABC vs. GCB-type 
of DLBCL. Genes in red are known drivers of corresponding diseases reported in 
literature. Duplicate gene names are for different probes or transcripts. 
4.4.3 Ability to identify “hidden” drivers 
We showed that NetBID2 is able to find known drivers of diseases; however, the 
true power of this network-based framework is to detect ―hidden‖ drivers that 
classical methods such as signature analysis fail to find. For example, we 
identified and validated AKT1 as a good driver for glucocorticoid resistance in T-





shows some anti-evidence to be active in resistant samples. So based on 
traditional differential expression analysis, AKT1 will never ever be identified. See 
details about this example in Chapter 7. 
 
Figure 4-9 NetBID2 identifies AKT1 as a driver for glucocorticoid resistance in T-
ALL (left), but there is no evidence from expression of AKT1 itself. 
Another example is STAT3 for HER2+ breast cancer. By NetBID2, we identified 
STAT3 as a significant master regulator and signaling modulator of ERBB2 
induced breast cancer, however, there is no expression change of STAT3 itself 
between ERBB2+ and control cells. Again, conventional signature analysis will 






Figure 4-10 NetBID2 identifies STAT3 as a driver for ERBB2+ breast cancer (red 
line), but there is no evidence from expression of STAT3 itself (blue line). 
4.4.4 High prediction rate by experimental validations 
The most straightforward way to evaluate the prediction of NetBID2 is to do 
experiments. Basically we perturb the predicted driver by silencing or over-
expressing it and check whether the perturbation can change the phenotype. We 
validated top 30 predicted TF drivers or master regulators for glucocortcoid 
resistance in T-ALL by siRNA. Surprisingly, only 7 (two have p value like 0.05) or 
5 predicted drivers showed no effects on changing resistance upon silencing 
(Figure 4-11). Over 76% or 80% of predicted drivers have significant effects on 
either reversing resistance or increasing resistance upon silencing. The validated 
drivers with positive scores are potential targets to reverse resistance by 





need to be overexpressed or activated to reverse the resistance. In summary, the 
prediction rate of NetBID2 for disease drivers is strikingly high. 
 
Figure 4-11 Validation results by siRNA for top 30 NetBID2-predicted TF drivers 
of glucocorticoid resistance in T-ALL. (A) top 30 candidates (in red) together with 
positive controls (in blue) and negative controls (in green) are ranked by the 
score (central dot) for capability to reverse GC-resistance upon silencing with 
uncertainty (range line crossing the central dot, thick line for one standard 





interval). The color of candidate label on x axis is associated with calibrated p-
value: dark red for P<0.005, red for P≈0.05. (B) Bar plots of apoptosis level 
induced by combined treatment of RNAi with DEX (in red), and control, RNAi with 
DMSO (in light blue) for 30 predicted candidates, positive controls (labeled in red) 
and negative controls (labeled in blue). All genes are ranked the same as in 
panel A. The label on top of bar plot represents the increased apoptosis level of 
candidate gene comparing with average of negative controls (normalized by its 
own DMSO control and averaged over triplicates) and associated statistical 
significance level (*** for P<0.005, * for P≈0.05). 
4.5 Evaluation of ARACNe Predictability 
4.5.1 Using STAT3 as an example to evaluate ARACNe predictability 
In NetBID2, we use ARACNe, an information theory-based algorithm to 
reconstruct transcription factor or signaling factor-centered networks. The key 
idea is to apply DPI to eliminate interactions between a TF and an indirect target 
or between a signaling molecule gene and its indirect downstream or upstream 
factor. We consider neighbors of a TF in the inferred regulatory network or a 
signaling protein in predicted signaling network as its regulons or targets or 
interacting partners. So how does ARACNe to predict targets of a TF or 
interacting proteins of a signaling factor? One way to answer this question is to 
do experiments to define a set of true targets and then use it as a gold standard 
to check the predictability of ARACNe. 
We used the example of STAT3 which is both a TF and a signaling protein to 





silencing or activating STAT3 biochemically and defined the most changed genes 
after perturbation as downstream targets or effectors of STAT3. Then we used 
the perturbation results as a gold standard to evaluate ARACNe-predicted 
targets or interacting partners from either regulatory network (STAT3 as a TF) or 
signaling network (STAT3 as a signaling protein).  
4.5.2 Overall prediction of ARACNe is good 
First, we noticed that ARACNe-predicted targets, as both TF and signaling factor, 
are significantly enriched in experimentally-generated gold standard. Six 
ARACNe-inferred target sets (three probes for STAT3, two types of network) 
showed strong enrichment in activated target side, in consistent with STAT3 






Figure 4-12 Enrichment of ARACNE-predicted targets of STAT3 in 
experimentally-identified targets. TF is for predicted targets in transcription 
regulatory network. Sig is predicted targets from signaling network. Three sets of 
inferred targets are for different transcripts or probes of STAT3. 
4.5.3 The direction of interaction defined by correlation might be 
misleading 
One of the key steps in MARINa [69, 71, 72] algorithm is to define positive and 
negative regulons of each TF after obtaining ARACNe-generated network 





distributions which is nonnegative.  If the inferred a regulon or target has a 
significant positive correlation with the TF of study, it‘s defined in MARINa as an 
activated target. Similarly, negative correlation is to define repressed targets. 
However, this method might be misleading because correlation only captures 
linear relationship between a TF and its target which might not be true in many 
cases due to the dynamics of feedback or feed-forward loops.  
 
Figure 4-13 Enrichment of ARACNE-predicted positive targets of STAT3 in 
experimentally-identified targets. Positive is defined by the positive correlation 
between the target and STAT3 expression. TF is for predicted targets in 





Three sets of inferred targets are for different transcripts or probes of STAT3. 
Green check sign indicates P < 0.05. 
 
Figure 4-14 Enrichment of ARACNE-predicted negative targets of STAT3 in 
experimentally-identified targets. Negative is defined by the negative correlation 
between the target and STAT3 expression. TF is for predicted targets in 
transcription regulatory network. Sig is predicted targets from signaling network. 
Three sets of inferred targets are for different transcripts or probes of STAT3. 





Therefore, we use the example of STAT3 to check how good the direction 
defined by correlation. As shown in Figure 4-13, three out of six positive target 
sets predicted by ARACNe with correlation-defined signs are significantly 
(P<0.05) enriched in experimentally identified activated targets of STAT3, out of 
which two are from signaling network and one is from TF network. However, as 
shown in Figure 4-14, all six negative target lists predicted by ARACNe with 
correlation post-analysis showed the wrong direction with gold standard negative 
targets of STAT3, or in another words, those negative targets defined by 
correlation are actually positive targets. This suggests that correlation-defined 
positive or negative targets on ARACNe-outputted network might be misleading 
and it‘s not a good idea to use mutual information to capture nonlinear 
relationships but then only considering linearly-related pairs. 
In NetBID2, there is no classification of positive or negative sets defined by linear 
correlation. That‘s why we identified STAT3 as a driver, however, if we separated 
activated or repressed targets for STAT3, we would have definitely missed it 
because all predicted negative targets are actually positive ones and dilute the 
signal of STAT3 being an activator. 
4.5.4 Signaling network prediction is more precise than TF network 
One novel part of NetBID2 is that it extends the network from transcriptional 
regulatory network to signaling network by applying ARACNe against signaling 





which is both a TF and a signaling factor, we can compare and evaluate the 
quality of TF network and signaling network generated by ARACNe. 
First, the number of targets in TF-subnetwork of STAT3 is about twice as large 
as the number in signaling networks, though the number varies among the three 
probes of STAT3. So in signaling network, ARACNe removes more interactions 
than TF network.  
 
Figure 4-15 Number of target size for STAT3 (three probes at x axis) from TF 





Second, we checked the overlap of predicted targets from TF network or 
signaling network with top ―gold standard‖ targets from experiments. Interestingly, 
the targets or interacting proteins in signaling network consistently demonstrated 
larger overlaps with gold standards than TF network. This suggests that signaling 
network is more precise than TF network. Since signaling network has a much 
smaller size than TF network, but identifies more true targets, it infers that 
signaling network has more power of identifying true positive interactions and 






Figure 4-16 Number of targets (in percentage, upper panel) from TF (blue) or 
signaling (red)-centered network predicted by ARACNe that are overlapped with 
top experiment-identified targets for STAT3 (three probes in three columns) and 
odds ratio of Fisher‘s exact test for the overlap (lower panel). The higher the 
overlap is, or the higher the odds ratio is, the more powerful or more precise the 
prediction is. 
4.6 Conclusion 
In this chapter, I introduced a computational framework, NetBID2, based on 
network inference of both regulatory and signaling networks and Bayesian 
statistics, to infer disease drivers from large-scaled gene expression data. We 
demonstrated that this new framework is much more robust to capture disease-
associated driver-type genes, is able to detect not only known drivers but more 
importantly, ―hidden‖ drivers with a very high prediction rate based on validation 
results. I also evaluated one novel part of NetBID2, extension to signaling 
network, by using an experimentally-defined gold standard and confirmed that 
signaling network predicted by ARACNe has more power to capture true positive 





Chapter 5 BSEA: Bayesian Set Enrichment Analysis 
5.1 Introduction 
Advances in techniques such as deep sequencing and high-throughput 
gene/protein profiling have transformed biological research by enabling 
comprehensive monitoring of a biological system. Analysis of such high-
throughput data typically yields a list of differentially expressed genes or proteins. 
This list is extremely useful in identifying genes that may have roles in a given 
phenomenon or phenotype. However, the candidate list is usually too long to 
investigate all of them. Researches are more interested in identifying underlying 
biological mechanisms or processes involved by a group of differentially 
expressed genes or proteins. That led to the development of pathway analysis or 
functional enrichment analysis. 
Pathway enrichment analysis helps to gain insight into the underlying biology of 
differentially expressed genes and proteins by reducing complexity and 
increasing explanatory power. Additionally, identifying active pathways that differ 
between two conditions can have more explanatory power than a simple list of 
different genes or proteins. 
During the evolution of pathway analysis in the past decade [114], three major 
classes of methods have been developed sequentially (Figure 5-1, Table 5-1). 





geometric distribution based Fisher‘s exact test on the overlap of top 
differentially-expressed genes with known member genes in the pathway. 
However, this type of methods gives equal weight of differentially expression to 
the member genes in the pathway and highly depends on the selection threshold 
of top representative genes. That led to the second group of methods, functional 
class scoring or gene set enrichment analysis [97, 98]. This type of methods 
uses entire list of genes with differential expression scores as the reference 
instead of putting some threshold and selecting top differentially expressed 
genes and consider the genes in pathway as a gene set to test the enrichment of 
this set in the reference. It overcomes the unrobustness from heuristic selection 
and overcomes the equal weight problem by using differential expression scores 
weighting genes differently. A new generation of pathway analysis utilizes the 
pathway topology [115] to weight genes. However, this type of methods highly 
depends on the knowledge of the pathways. So in this chapter, we mainly focus 
on the second class of methods, set enrichment analysis. 
 
Figure 5-1 Three major categories of functional enrichment analysis methods. 






Table 5-1 A collection of available tools and methods for functional pathway 
enrichment analysis. Adapted from Khatri, et al, 2012 [114]. 
The first and the most popular enrichment analysis methods, GSEA (Gene Set 
Enrichment Analysis) [97, 98], was based on a signed version of the 
Kolmogorov-Smirnov (KS) statistic to summarize set enrichment. Later Brad 
Efron developed a different approach, GSA (Gene Set Analysis) [97, 98], by 
using a novel ―maxmean‖ statistic to summarize enrichment and a few other 





expression have been used including signal noise ratio, t-statistic, z-statistic, FC, 
logFC, diff mean, etc.  
However, in this chapter, I will introduce a new set enrichment analysis method, 
BSEA (Bayesian Set Enrichment Analysis). It utilizes the ―maxmean‖ enrichment 
score statistic and Bayesian modeling techniques. I will demonstrate that this 
new method outperforms GSEA and GSA by using the meta-analysis of RNAi 
screening data. As mentioned in Chapter 4, one of the key steps in NetBID2 
framework is enrichment analysis, for which BSEA is the default method. 
5.2 The BSEA Algorithm 
The key features of BSEA algorithm include ―maxmean‖ statistic to summarize 
enrichment score, restandarization for measuring statistical significance and 
Bayesian modeling for scoring individual gene, as discussed below. 
5.2.1 “Maxmean” statistic 
―Maxmean‖ statistic was developed by Brad Efron in his GSA method [97, 98] to 
summarize the enrichment of a gene set. The idea is explained in Figure 5-2. For 
a gene set S, we separate its member genes into positive and negative groups 
according to the sign of their individual scores between phenotype 1 and 
phenotype 2, i.e. member genes with positive scores belong to positive set while 
negative ones form the other set. The adjusted mean is calculated for each 
positive or negative subset. The adjusted mean is different from general mean in 





is divided by the size of the entire set (union of positive or negative subsets) 
instead of its own subset size. And out of the two means, the one with maximum 
absolute value is used as the enrichment score for the full set. 
 
Figure 5-2 ―Maxmean‖ statistic developed by Efron. The genes in the set (blue 
bars on the bottom) are divided into positive (red on the right) and negative (blue 
on the left) according to the sign of their individual scores between phenotype 1 
and phenotype 2 (y axis). The adjusted mean (divided by the size of the entire 
set) of each subset is calculated, and the one with maximum absolute value is 
used as the enrichment score for this set. 
According to Efron‘s simulation results as shown in the ROC curves of Figure 5-3, 
―maxmean‖ statistic outperforms KS-statistic based GSEA method in both 





we also confirmed Efron‘s conclusion that ―maxmean‖ method is indeed more 
powerful than KS statistic to summarize enrichment of a set. 
 
Figure 5-3 Efron‘s simulation results (sensitivity vs. specificity) on comparison of 
Maxmean statistic with KS-based GSEA. Adapted from Figure 8 in Efron, et al, 
2007 [97, 98].  
5.2.2 Restandarization 
Another key technique BSEA adapted from GSA method is restandarization that 
incorporates both sample shuffling and gene shuffling for statistical significance 
measurement. In general to estimate a statistical significance of an enrichment 
score when we do gene set enrichment analysis, we use permutation test by 
either shuffling sample labels or shuffling gene labels. Sample permutation has 





perturbs the correlation between two genes. However, sample permutation 
requires a large size of samples and usually has a high false discovery rate 
especially when the gene sets are similar with each other. To overcome these 
problems, Efron developed a novel statistical technique named restandarization, 
to balance sample permutation and gene permutation. The basic idea is that in 
each sample permutation, all calculated enrichment scores are scaled according 
to the distribution of current enrichment scores, i.e. subtracting the mean and 
dividing by the standard deviation of all enrichment scores in this permutation 
(Figure 5-4). 
 
Figure 5-4 Restandarization technique for statistical significance estimation. 
Adapted from Efron, et al, 2007 [97, 98]. 
5.2.3 Bayesian inference 
The only difference between BSEA and GSA lies in the usage of Bayesian 
statistics for individual gene scoring. The motivation is to use Bayesian 
techniques to overcome inaccurate estimation problems of parameters by 
traditional metrics to score individual genes such as signal noise ratio, t-statistic, 





replying on large samples and good data quality, which is rare in reality. 
Especially in the high-throughput experiments, data is usually noise and the 
sample size is small. In this situation, conventional fold change or maximum 
likelihood estimated parameters will be problematic. To overcome this problem, 
BSEA utilizes the advantage of Bayesian modeling methods for its robustness 
and ability to deal with noisy data, small sample size and outliers. 
In NetBID2 algorithm, I already introduced a Bayesian Probit model method for 
differential expression analysis at individual gene level, but Probit model might 
require a relative large sample size. The alternative model is Bayesian linear 
model (Figure 5-5) and Gaussian prior or weakly-informative t-prior is commonly 
used for coefficients in the model. A z-score for the slope and corresponding p 
value will be reported to represent the statistical strength of differential 






Figure 5-5 A Bayesian linear Gaussian model for individual gene scoring with 
Gaussian or t distribution as prior for coefficients and inverse Chi-square or 
Gamma distribution as prior of noise variance. 
5.3 Benchmark and Evaluation using Meta-Analysis of RNAi 
Screening Data 
As discussed in Chapter 3, the integration of multiple hairpins targeting the same 
gene to estimate gene level activity from high-throughput RNAi screening data, 
one category of methods to combine multiple shRNAs for a gene is to do 
enrichment analysis by treating all hairpins of a gene as a set and using all 
shRNAs in the library as the reference. And there, we introduced an evaluation 
strategy by using house-keeping or evolutionarily-conserved genes as a gold 
standard of essential genes that RNAi screening is designed to search for (3.6). 
So here, we follow the same idea and evaluate enrichment analysis methods 
only for integration of multiple shRNAs to estimate gene level activity.  









Here we use exactly the same data sets, three shRNA screens (MCF7, HPAFII, 
OVCAR5) and four independent gene sets as references – two adapted from 
previous study [102] and two more recent studies on human housekeeping 
genes [103, 104]. Again the percentage of overlapped genes of reference set 
with top k hits predicted as essential genes by each enrichment method is 
calculated. To avoid selection bias on k, we sampled k from 0 up to 1000 with a 
sliding widow of 5. The larger intersection with reference gene set the algorithm 
produces consistently, the more powerful the method is. 
5.4 Results 
With the benchmark RNAi screening datasets and evaluation strategy, we 
compare three enrichment analysis methods, my BSEA, Efron‘s GSA and 
Broad‘s GSEA. GSEA is equivalent to RIGER_KS method discussed in Error! 
eference source not found.. GSA method was used by Allen Ashworth to report 
gene level activity from shRNA screens [108]. 
5.4.1 “Maxmean”-based GSA outperforms KS-based GSEA 
First, we checked whether ―maxmean‖ statistic proposed by Efron in his GSA 
method performs better to summarize enrichment score than KS statistic used by 
traditional GSEA, as Efron reported based on his simulation studies. We 
compared GSA with GSEA only first, and indeed GSA showed consistently larger 
AUC (Area Under the Curve) than GSEA (Figure 5-6) to identity true positives 






Figure 5-6 ―Maxmean‖ statistic (GSA) vs. KS statistic (GSEA) for summarization 
of enrichment score. Housekeeping or conserved ortholog genes can be used as 
reference gene set to evaluate algorithms to detect essential genes from RNAi 
screens. Each colored curve shows the percentage of each reference set 
(―name‖_―number of genes in the set‖) intersected by top 0 to 1000 hits predicted 
as essential genes by the corresponding algorithm in each dataset. The slope of 
―Random‖ method line (in purple) is proportional to the frequency of the reference 
set out of all genes in the library. The greater the area under the curve, the more 
powerful the algorithm is. 
5.4.2 BSEA >= GSA > GSEA 
As shown in the comparisons of BSEA with GSA and GSEA (Figure 5-7), first, 
we noticed that GSEA (the blue curve) is the worst in all cases, indicating KS 





two datasets, BSEA and GSA are kind of mixed together. One reason for that is 
because the data of the first two screens is relatively good (Figure 3-7). However, 
for the third one, BSEA beats GSA as expected, because BSEA uses Bayesian 
statistics which is much more robust than maximum likelihood statistics used by 
GSA. So overall, BSEA is the best enrichment analysis method comparing with 
GSA and GSEA. 
 
Figure 5-7 Evaluation results of BSEA, GSA and GSEA. Annotation is the same 





5.4.3 BSEA dominates GSEA 
If we only compare BSEA with GSEA, as shown in Figure 5-8, GSEA 
dominates GSEA in all cases. 
 
Figure 5-8 Evaluation results of BSEA vs. GSEA. Annotation is the same with 
Figure 5-6. 
5.4.4 Bayesian vs. Frequentist 
Remember that the only difference between BSEA and GSA is that BSEA uses 
Bayesian statistics while GSA uses classical Frequentist‘s maximum likelihood 
approaches. So we compared these two techniques by fixing all parameters but 





Frequestist‘s t score approach. As expected shown in Figure 5-9, there is no 
difference between Bayesian and Frequentist‘s method when the data is good 
(the first two screens), both of which converges the optimum, however, when the 
data is noisy such as the third example, Bayesian shows its super power 
compared to Frequentist‘s method. So overall, Bayesian method is much more 
robust than classical maximum likelihood methods. 
 
Figure 5-9 Evaluation results of Bayesian vs. Frequentist methods for individual 






5.4.5 BSEA cannot beat BHM 
In Chapter 3, we developed a novel Bayesian Hierarchical Modeling (BHM) 
approach for meta-analysis of multiple shRNAs targeting the same gene from 
RNAi screening data and demonstrated it‘s the best comparing with GSEA 
(RIGER). In this chapter, we developed BSEA, a better enrichment approach 
than GSEA, so we asked whether BSEA can beat BHM. Unfortunately, the 
answer is no. As shown in Figure 5-10, BSEA is getting close to BHM, but still 
under it. The reason might be that BHM uses the strategy of ―modeling-all-
together‖, while BSEA is still under the framework of ―separate-and-combine‖.  
 
Figure 5-10 Evaluation results of BHM (Bayesian Hierarchical Model), BSEA, and 






To summarize this chapter, I developed a novel approach for set enrichment 
analysis by using ―maxmean‖ statistic and Bayesian inference. Based on the 
evaluation results using RNAi screening data, I have demonstrated that BSEA 
outperforms existing GSA and GSEA, especially when the data is noisy. I 
confirmed that ―maxmean‖ is more powerful than KS for set enrichment score, 
and Bayesian is more robust than classical statistic for scoring at individual level. 
Although BSEA cannot beat BHM for meta-analysis of RNAi screening data due 
to the problem of ―separate-and-combine‖ strategy, overall, BSEA is the best 





Chapter 6 Recovering Drug-Induced Apoptosis 
Subnetwork from Connectivity Map Data via a 
Bayesian Network Approach 
6.1 Summary 
The Connectivity Map project profiled human cancer cell lines exposed to a 
library of anti-cancer drugs or chemical compounds with the goal of connecting 
cancer with underlying genes and potential treatments. Since the therapeutic 
goal of most anti-cancer drugs is to induce tumor-selective apoptosis, it is critical 
to understand the specific cell death pathways that are activated by drugs. This 
can help to better understand the mechanism of how cancer cells respond to 
chemical stimulations and improve the treatment of aggressive human tumors. In 
this study, using Connectivity Map microarray data from breast cancer cell line 
MCF7, we applied a Gaussian Bayesian network modeling approach and 
identified apoptosis as a major drug-induced cellular-pathway. In order to reduce 
computational complexity without losing generality, we focused on 13 apoptotic 
genes that showed significant differential expression across all drug-perturbed 
samples. In our predicted subnetwork, 9 out of 15 high-confidence interactions 
were validated in literature, and our inferred network captured two major cell 
death pathways by identifying BCL2L11 and PMAIP1 as key interacting players 





apoptosis pathway. Our inferred apoptosis network also suggested the role of 
BCL2L11 and TNFAIP3 as ‗gateway‘ genes in the drug-induced intrinsic and 
extrinsic apoptosis pathways. Our study extended the usage of Connectivity Map 
data and applied a Bayesian network framework to recover underlying drug-
induced biological programs for a better understanding of the mechanism of 
action of cancer drugs, and provided potential targets in the apoptosis pathway 
for better cancer treatment.  
6.2 Introduction 
One goal of biomedical research is to better understand human diseases such as 
cancer by studying gene patterns associated with diseases and using them to 
find the best potential treatments. Recently, Todd Golub and his colleagues at 
the Broad Institute initialized the ―Connectivity Map‖ project (CMAP) [116, 117] to 
make these disease-gene-drug connections by utilizing microarray technology. 
High-throughput microarrays are able to profile gene expression at the level of 
the whole-genome, and can be used to detect signatures under certain 
perturbations or phenotypes in cells [118]. Since the therapeutic goal of most 
anti-cancer drugs is to induce tumor-selective cell death [119], it is reasonable to 
hypothesize that apoptosis may be a major cellular mechanism targeted by anti-
cancer drugs. It is therefore critical to understand the specific cell death 
pathways that are activated by drugs. This would help to better understand the 
mechanism of how cancer cells respond to chemical stimulations and improve 





Apoptosis in mammalian cells is induced by intracellular cysteine proteases 
known as caspases. Caspases are first synthesized as largely inactive zymogens 
known as procaspases, and are later activated through post-translational 
mechanisms. Two principal pathways of caspsase activation have been 
recognized [120, 121]. One pathway, which is of more ancient origin and 
evolutionarily conserved, is known as the stress pathway, mitochondrial pathway, 
or intrinsic pathway [120, 121]. It is induced by developmental cues and diverse 
intracellular stresses. This pathway begins with the activation of caspase-9 on a 
scaffold formed by Apaf-1 in response to cytochrome c release from damaged 
mitochondria. It is known to be regulated primarily by proteins from the Bcl-2 
family. The other pathway is known as the extrinsic pathway, and is triggered by 
so-called ‗death receptors‘ on the cell surface. The death receptors are engaged 
by cognate ligands of the tumor necrosis factor (TNF) family. This pathway 
begins with the activation of caspase-8 (and caspase-10 in human cells), via 
adaptor proteins including Fas-associated death domain protein (FADD) [120, 
121]. Once activated, caspase-9 in the intrinsic pathway or caspase-8 (-10) in the 
extrinsic pathway activates downstream 'effector caspases' including caspases-3, 
-6 and -7. In an expanding cascade, these caspases carry out the execution 
phase of cell death. 
Because the CMAP database contains profiles from a large collection of human 
cancer cell lines that capture information of how cells respond to chemical 
stimulations, it can be used to test the hypothesis that the apoptosis pathway 





can do this by enrichment analysis of apoptotic genes in drug-responsive genes 
or in differentially-expressed genes in drug-exposed cancer cells. CMAP data 
also contains dynamic transcriptional activities of most genes across diverse 
conditions, giving sufficient data for associating the activities of genes of interest 
with each other, and for reconstructing parts of the apoptosis pathway in the 
context of drug-exposed cancer cells. In this study, we used CMAP gene 
expression profiles to test the hypothesis that apoptosis may be a major drug-
induced cellular mechanism. We then employed a Gaussian Bayesian network 
modeling approach to reconstruct the subnetwork of the drug-induced cell death 
pathway. To minimize the effects of heterogeneity from different tumor types, our 
study focused on a single breast cancer cell line, MCF7. 
To better understand whether anti-cancer drugs target the intrinsic and extrinsic 
apoptosis pathways, and identify specific pathways or interactions activated by 
anti-cancer drugs, we crossed our predicted drug-triggered apoptosis network 
with literature-validated interactions. We were able to identify key players as well 
as interactions in the drug-induced intrinsic and extrinsic pathways. Our results 
shed light on the mechanism of action of drugs in cancer cells and may lead to 
improved treatments that target key apoptotic proteins that are most related to 
drug response. 
6.3 CMAP Data 
The CMAP "build 02" gene expression dataset (http://www.broad.mit.edu/cmap/) 





perturbations by 1,309 compounds, and contain data from  five human cancer 
cell lines: MCF7, PC3, SKMEL5, HL60 and ssMCF7. The microarray platforms 
used include Affymetrix HT_HG-U133A and HT_HG-U133A_EA. To avoid the 
effects of tumor heterogeneity and multiple microarray platforms, to avoid the 
heterogeneity of different cellular contexts, we only focused on samples from the 
breast cancer cell line MCF7 that were profiled using the Affymetrix HT_HG-
U133A platform. The dataset is composed of 404 control and 2,417 compound-
perturbed samples. The HT_HG-U133A microarray platform contains 22,268 
Affymetrix probe sets representing 13,262 genes. The GCRMA method [122] 
was used to normalize the data. 
6.4 Drug-Response Signature Analysis 
To identify drug-responsive signature genes at a transcriptional level in cancer 
cells, one approach is to perform differential gene expression analysis by 
comparing drug-perturbed samples with controls. However, since the dataset 
contains samples tested with over 1,000 chemical perturbations, it is important 
we take into account the diverse mechanisms of actions of the different 
compounds. One solution would be to perform differential expression analysis for 
each compound separately and then combine the results together using a p-
value-based Fisher's method or Stouffer‘s z-score approach to obtain the overall 
differential expression level for each gene across all compounds. However, a 
limitation with this type of analysis has to do with the fact that each compound 





control samples. This would cause the statistical power to be extremely low for 
individual compound analysis, and would result in an inaccurate estimation of 
parameters and a high false positive rate. In addition, another known issue with 
this type of 'Separate-then-Combine' analysis is a low precision rate, which 
means there is a high occurrence of false positives among the most differentially 
expressed genes or top-hits. One way to overcome this drawback is to combine 
all compounds together at the beginning, as known as ‗complete pooling‘ method. 
Although different drugs may have distinct mechanisms of action and different 
target proteins, it may still be reasonable to group them together. One reason is 
that there are a relatively limited number of pathways or mechanisms through 
which cells respond to chemical stimulations. Also, compounds tested for cancer 
treatment are known to share some common characteristics. For example, a 
large number of anti-cancer drugs are known to induce cell death or repress cell 
growth programs. In addition, the combination or ‗complete pooling‘ strategy 
increases the sample size from less than 5 to thousands, dramatically increasing 
the statistical power for inferring true responsive genes across all compounds. 
This assumption is also confirmed by the fact that most perturbed profiles are 
clustered together as shown in Figure 6-2. These results indicate that the 
variability of transcriptional profile for the same type of cell (MCF7 in this study) 







Figure 6-1 Heatmap of top differentially-expressed genes (FDR<0.05) in drug-
perturbed and control samples. The genes are ranked from most up-regulated 
(labeled in dark red on right panel) to most down-regulated (labeled in dark green) 
in drug-perturbed samples, and the 13 selected apoptotic genes are labeled on 






Figure 6-2 The heat map of distances between profiles of CMAP data including 
randomly-selected 100 control and 100 drug-perturbed samples. 
To estimate the effect of each compound on gene expression and to test the 
significance of differential expression for each probe set, we used a linear 
modeling method with empirical Bayes moderated t-test [123]. A non-parametric 
Bonferroni procedure was employed for multiple comparison correction. Using a 
false-discovery-rate (FDR) threshold of 0.05, we identified 137 up-regulated and 
90 down-regulated probe sets, representing 112 over-expressed and 79 under-





6.5 Enrichment of Apoptosis Pathway 
As described previously, one of the most important mechanisms through which 
cancer drugs act is the inducement of cell death programs. More specifically, we 
hypothesized that the apoptosis pathway may be a major drug-induced program. 
Enrichment analysis was proposed to validate this hypothesis. By searching the 
Gene Ontology database [93, 124], we obtained a list of 380 human genes that 
were annotated with apoptosis-related GO terms. 211 genes were annotated as 
pro-apoptotic by induction of apoptosis, positive regulation of apoptosis, and 
negative regulation of anti-apoptosis. 194 genes were annotated as anti-
apoptotic by negative regulation of apoptosis and positive regulation of anti-
apoptosis. 25 genes were involved in both positive and negative regulation of 
apoptosis. We then performed enrichment analysis with differentially-expressed 
genes of drug-perturbation in the apoptosis pathway. Two methods were 
employed to do this analysis: the first method was the Fisher's exact test to 
validate whether known apoptotic genes were overrepresented in a selected 
differentially-expressed drug-responsive gene set. The second method was to 
test the known apoptotic genes using Gene Set Enrichment Analysis (GSEA) 
which does not perform a selection on differentially-expressed genes, but instead 
considers the entire set of genes and their differential expression as the 
background. For Fisher‘s exact test, a set of previously-identified 191 signature 
genes with a threshold of FDR<0.05, and all 12,632 genes in the microarray were 
used to fit the null hyper-geometric distribution. For GSEA, the mean of absolute 





genes could be either up- or down-regulated in drug-perturbed samples. The 
significance of the enrichment scores were tested against 10,000 permutations of 
gene names. 
There are 13 genes Table 6-1 that overlap between the 191 drug-inducement 
signature genes and the 368 human apoptotic genes in our dataset. The 
significance level of Fisher‘s exact test for this overlap is approximately 0.001 (), 
consistent with the result from GSEA, which had a p-value of 0.002 (Figure 6-3). 
Therefore, both methods confirm that the pre-identified drug-induced signature 
genes are significantly enriched in the human apoptosis pathway. In other words, 
we were able to validate our hypothesis that the apoptosis pathway is a major 
cellular mechanism targeted by anti-cancer drugs. Furthermore, separate 
analysis of pro- or anti-apoptotic genes (Figure 6-4, Figure 6-5) showed that 
drug-responsive genes were enriched in both positively- or negatively-regulated 
apoptosis gene sets. Since the analysis was done using the combination or 
‗complete pooling‘ strategy, the significance of these results suggests that 13 
drug-induced apoptotic genes in our gene set are responsible for a highly 















PMAIP1 204285_s_at 5366 0.32 7.46 1.19E-13 2.64E-09 pro 
VEGFA 210512_s_at 7422 0.18 6.15 8.88E-10 1.98E-05 anti 
SERINC3 221471_at 10955 0.06 5.62 2.08E-08 4.64E-04 pro 
TNFAIP3 202644_s_at 7128 0.24 5.39 7.61E-08 1.70E-03 anti 
BNIP3L 221479_s_at 665 0.12 5.04 4.88E-07 1.09E-02 both 
GCLC 202923_s_at 2729 0.08 4.91 9.42E-07 2.10E-02 anti 
BCL2L11 222343_at 10018 0.14 4.83 1.41E-06 3.14E-02 pro 
TAX1BP1 200976_s_at 8887 0.07 4.76 2.01E-06 4.47E-02 anti 
SON 214988_s_at 6651 -0.06 -4.75 2.11E-06 4.71E-02 anti 
NUP62 202153_s_at 23636 -0.11 -4.83 1.41E-06 3.14E-02 anti 
NOL3 59625_at 8996 -0.13 -5.32 1.13E-07 2.53E-03 anti 
TUBB 212320_at 203068 -0.09 -5.55 3.11E-08 6.92E-04 pro 
MSH6 202911_at 2956 -0.09 -6.40 1.87E-10 4.16E-06 pro 
Table 6-1 The 13 selected differentially-expressed or drug-responsive apoptotic 
genes. *: pro: annotated by GO terms: induction of apoptosis, positive regulation 
of apoptosis, negative regulation of anti-apoptosis; anti: annotated by GO terms: 






Figure 6-3 Summary of (A) Fisher‘s Exact Test and (B) Gene Set Enrichment 
Analysis (GSEA) to test whether apoptosis pathway with 368 apoptotic genes is 
enriched in drug-induced signature genes. For GSEA method, absolute mean 
was used to summarize the enrichment and 10,000 gene permutations were 






Figure 6-4 Summary of (A) Fisher‘s Exact Test and (B) Gene Set Enrichment 
Analysis (GSEA) to test whether 207 pro-apoptotic genes are enriched in drug-






Figure 6-5 Summary of (A) Fisher‘s Exact Test and (B) Gene Set Enrichment 
Analysis (GSEA) to test whether 185 anti-apoptotic genes are enriched in drug-
induced signature genes. 
6.6 Bayesian Network 
We next asked the question of how the 13 identified genes work together 
systematically and whether we can recover the underlying network structure of 
their interactions. This would help us to better understand the mechanism of how 
cancer drugs induce the apoptosis pathway at a global systems level. In order to 
infer the underlying signaling, transcriptional, and causality network of the 13 





reconstruction in the literature, the Bayesian Network or Graphical Model [125-
129]. The details of the method are described below. 
6.6.1 Data modeling 
A Bayesian network represents the dependence structure of a joint probability 
distribution of multiple variables, which can be factorized into a product of 
distributions of each individual node conditioning on its parents. To model the 
local distribution of each node conditioned on its parents, a commonly used 
method for continuous data is to discretize data points into bins and then fit a 
multinomial distribution to the discretized data. However, data discretization 
results in a loss of information and can be highly sensitive to the number of bins 
the data is split into.   Furthermore, due to the continuous nature of microarray 
data and the marginal normality of many genes in this study as shown in Figure 
6-6, we determined it would be more accurate to employ a continuous model. We 
therefore used a conditional linear Gaussian model [130] for the local distribution 
of each node as shown below: 
 
This model can be recognized as a linear regression model, in which node gi is 
the response variable, its parents are covariates, and the noise follows a white 













Figure 6-6 Marginal distributions of the 13 selected drug-responsive apoptotic 
genes across all samples in CMAP data. 
6.6.2 Parameter learning 
Given the linear regression model for the local distribution, a classical Maximum 
Likelihood or Least Squares approach can be used to estimate its parameters. 
However, various studies in statistics have suggested that Bayesian approaches 
or Bayes estimators are more robust than Frequentist maximum likelihood 
method [129], especially when the sample size is small or the data is noisy. 
Therefore a Markov Chain Monte Carlo (MCMC) simulation-based Bayesian 
computing method was used to estimate parameters of the model. To select the 
priors for the Bayesian model, two principles were followed: one is conjugation 





prior, and in our case, the prior would be Gaussian for conditional coefficient and 
Inv-Gamma for variance; the other is global and local parameter independence, 
parameter modularity and likelihood equivalence [131, 132].  
6.6.3 Structure scoring and search 
To determine the Bayesian network or Graphical model that can best fit the data, 
we needed a scoring system to compare different potential network structures. 
For structure learning, a Bayesian factor-based method, which compares the 
conditional probability of each graphical structure given observed data, was used. 
As shown below, according to Bayes theorem, the odds ratio between two 
possible structures, G1 and G2 can be decomposed as a product of structure 
prior odds ratio and the Bayesian factor, which is the ratio of the likelihoods of the 
two graphical models.  
 
 
Using the uniform distribution for structure prior, which is reasonable because we 
have no preference on particular graphical structure, the score for a network 
structure, G, can be defined as the following formula, which is the log-likelihood 
of the graphical model. 
 
In our study with 13 variables, there were 1.86766e+31 possible directed acyclic 


























space. To search more efficiently, we used a classical heuristic algorithm: hill 
climbing with random restarts [134, 135]. Using this stochastic algorithm, the 
search-space was reduced dramatically. Using 2 restarts, we only needed to 
compare 12, 655 structures before reaching a maximum score. One risk was that 
we had found a local maximum, rather than the global maximum, but the risk 
would be decreased further by increasing the number of restarts. 
6.6.4 Bootstrapping and model averaging 
With the methods outlined above, we obtained a Bayesian network structure that 
best described the observed data. However, it is possible that the model may be 
over-fitted, which means that a small change to the dataset could make the 
network structure change dramatically. A way to solve this issue is to apply a re-
sampling method or simulating the dataset. The method would learn the best 
graphical model for each sampled dataset, and generate a consensus network 
from the average of the sample models. This method is also known as model 
averaging. The simulation method we used to do model averaging was Efron‘s 
bootstrapping method [136, 137]. To increase robustness, the method only 
considered predicted network structures with a score within 95% of the 
confidence interval.  The distribution of network scores is shown in Figure 6-7. In 
generating the final combined consensus network, edges were selected based 






Figure 6-7 (A) Histogram and (B) Box plot of scores for best-learned graphical 
model in each bootstrapped sampling. 
6.7 Results 
Using the described Gaussian Bayesian network modeling framework, a network 
model was generated for the 13 identified drug-responsive apoptotic genes as 
shown in Figure 6-8-A. The network contains 15 interactions and each edge has 
a confidence of over 75%. The inferred interactions represent dependence 
among these 13 genes of interest, which may be due to direct or indirect protein-
protein interactions, transcriptional regulation, or signal transduction. To validate 
the inferred interactions, we searched the Interactions component of NCBI Gene 
database (http://www.ncbi.nlm.nih.gov/gene), which contains data from multiple 






validated interaction network of the 13 apoptotic genes using their validated 
interactions [Figure 6-9]. The validated network contained 216 interacting genes, 
including our 13 genes of interest. The network also contained 243 interactions 
after removing duplicate interactions (365 interactions with duplicates). When 
compared with our predicted network, 9 out of 15 predicted interactions were 
found to be direct or indirect interactions in the validated network [marked in red, 
Figure 6-8-A]. An indirect interaction means the network does not contain a direct 
edge between the two genes, but there exists a path between them via 
intermediate genes. Since we only considered 13 apoptotic genes in network 
inference, it is highly possible that the inferred interactions are indirect, but 
illustrate the dependence or information transmission between the two 
corresponding genes. More precisely a sub-validated network that includes only 
evidences (20 nodes and 28 interactions) for our predicted interactions was 
extracted as shown in Figure 6-8-B. For indirect evidences, we only counted the 
shortest paths between two apoptotic genes of interest. 
6.7.1 Known direct interactions 
Two edges in our predicted network (marked in thick red, Figure 6-8-A) have 
been validated as direct interactions in literature and are clearly annotated in the 
functional summary of corresponding genes as shown below. 
TAX1BP1 -> TNFAIP3: As seen in the annotation of TAX1BP1, Tax1 (human T-
cell leukemia virus type I) binding protein 1, from the NCBI Gene database, this 





activity [138, 139]. In vivo experiments and yeast two hybrid assays also confirm 
the interaction between TNFAIP3 (zinc finger protein A20) and TAX1BP1. 
TNFAIP3 also interacts with TXBP151, an anti-apoptotic protein and may inhibit 
inflammatory signaling pathways such as TNF-induced NF-κB activation [140, 
141]. TNFAIP3 and TAX1BP1 inhibit the inflammatory signaling pathway by 
interacting with Ubc13 and UbcH5c and triggering their ubiquitination and 
proteasome-dependent degradation [142]. 
PMAIP1 -> BCL2L11: Although there is no evidence showing direct interaction 
between PMAIP1 (also known as NOXA) and BCL2L11 (also known as BIM), the 
functional annotation of PMAIP1 [143] from the UniProtKB/Swiss-Prot database 
shows that the PMAIP1 competes with BCL2L11 to bind with MCL1 and can 
displace BCL2L11 from its binding site on MCL1. The predicted interaction 
between PMAIP1 and BCL2L11 may be explained by the competition between 
PMAIP1 and BCL2L11 in binding MCL1. The competition may occur either 
through a direct interaction between the two proteins, or through a third protein 
that is able to bind both. In addition, both PMAIP1 and BCL2L11 have been 
shown to interact directly with many other BCL2 protein family members 
including BCL2, BCL2A1, BCL2L1 and BCL2L2 [144, 145]. This indicates that 
NXOA and BIM may share common binding regions to BH3-only BCL2 family 
proteins. NOXA and BIM as BH3-only proteins have been recognized as critical 
mediators of anti-cancer drug- and p53-induced apoptotic responses [146, 147], 
which are consistent with our findings in this study that both of them are 





6.7.2 Consistency with two major cell death pathways 
As described previously, there are two major apoptosis programs in mammalian 
cells: the intrinsic or mitochondrial stress-induced pathway and extrinsic or death 
receptor-triggered pathway. Our predicted network captures the important 
players and key interactions in both apoptosis programs. For the intrinsic 
pathway, our predicted network identifies two of the most important mediators, 
BLC2L11/BIM and PMAIP1/NOXA, and their competing interaction in terms of 
regulating many other BH3-only BCL2 family member proteins including BLC2, 
BCL2L1, BCL2L2, BCL2A1 and MCL1, which is illustrated as well as in the 
validated network (Figure 6-8-B). For the extrinsic death receptors-triggered 
pathway, we successfully recovered one representative of cancer-therapy or 
drug-induced cell death pathway: TNF-induced apoptosis. TNFAIP3/A20 and 
TAX1BP1/TXBP151 are two key players of this pathway, and they interact with 
each other to turn on the down-stream cell death machinery. 
6.7.3 BCL2L11/BIM as a gateway gene to drug-induced intrinsic apoptosis 
As shown in our inferred drug-induced apoptotic sub-network, BCL2L11 is 
located downstream of most cell death sub-pathways, which includes drug-
affected apoptotic genes such as BNIP3L, NOL3, PMAIP1, NUP62, and SON. 
This suggests that BCL2L11 may act as a downstream gate or switch for drug- or 
stress-induced apoptosis programs. This finding is consistent with the main role 
of BCL2L11 as an apoptosis facilitator. The mechanism through which BCL2L11, 





keeping them from restraining Bax and Bak.  Bax or Bak can cause the outer 
membrane of the mitochondria to become permeable. This releases 
cytochrome c, which provokes Apaf-1 (apoptotic protease-activating factor 1) to 
activate caspase-9 [120]. The gateway role of BCL2L11 has also been illustrated 
in our literature-generated validation network (Figure 6-8-B). 
6.7.4 TNFAIP3/A20 as a gateway gene to drug-induced extrinsic apoptosis 
As shown in both our predicted network and validated network (Figure 6-8), 
TNFAIP3, a zinc finger protein, acts as a hub by transmitting upstream signals 
from cell death receptors to downstream cell death cascades. This suggests that 
TNFAIP3 may be a gateway protein for drug-induced extrinsic apoptosis. 
TNFAIP3/A20 acts as a key player in TNF-induced apoptosis by inhibiting NF-κB 
activation. These results indicate that TNF-induced signaling may be the most 
common anti-cancer drug or chemical compound-triggered cell death program. 
Many studies have demonstrated the involvement of the TNF-mediated 
apoptosis in cancer therapies such as ionizing radiation or the chemotherapeutic 
agent, daunorubricin [138]. This again confirms our hypothesis that anti-cancer 
drugs induce apoptosis of cancer cells and confirms that apoptosis pathways can 






Figure 6-8 (A) Predicted subnetwork of 13 selected drug-responsive apoptotic 
genes: edges in red are validated interactions in literature, and edges in dark red 





evidences for validated interactions in predicted network including candidate 
genes (colored in yellow) with their validated interactants (in brown). Each 
validated edge in predicted network (red in A) can be mapped to one path in 
evidence network (B) between the two corresponding interacting candidate 
genes. 
 
Figure 6-9 A network from literature for 13 candidate genes (colored in yellow) 
with their validated interactants (in brown). Edges in red are evidences for 






We have demonstrated the value of CMAP data for studying drug-response in 
mammalian cancer cells. We have also validated the hypothesis that the 
apoptosis pathway may be a main program targeted by anti-cancer drugs. 
Furthermore, we have shown that CMAP data contains sufficient information 
about the dynamic activities of human genes for reconstructing gene-gene 
interactions in drug-perturbed cancer cells. We have also successfully applied a 
Gaussian Bayesian network framework to reconstruct a subnetwork containing 
validated interactions between genes with known roles in the apoptosis pathway.  
In addition, our network successfully predicted key players and interactions in 
drug-induced apoptosis, including both the intrinsic and extrinsic apoptosis 
pathways.  
Our framework may be improved in a few ways. First, we only considered the 
general effects of drugs based on the assumption that cancer cells have a similar 
response mechanism to different drugs. However this assumption may be over-
generalized, since there are some drugs to which the cells have no response. 
This can be clearly seen in Figure 1, which contains a heat map of signature 
genes across all drugs (Figure 6-1). One way to deal with this limitation may be 
to cluster drugs by their expression profiles or by their physical or chemical 
properties. A similar comparison analysis may be performed, but would take into 
the account the effects of different drug groups. Second, to reduce computational 





expressed with a Bonferroni-corrected pvalue threshold of 0.05. This threshold 
might have been overly stringent and may have caused us to filter informative 
genes from the analysis.  One way to deal with this problem might be to include 
more candidate genes, but this would increase complexity and computation. 
We have shown that Bayesian network modeling can be a powerful tool for 
reconstructing biological networks from noisy high-throughput microarray data. In 
the Bayesian network modeling approach to network reconstruction, we have 
found that a linear Gaussian model for local probability distribution is able to give 
a more accurate description for continuous data and is also able to reduce the 
number of parameters when compared to discrete methods. In discrete methods, 
data points are separated into multiple levels, and this can result in the loss of 
information, especially in cases where the variable has a large range of values 
and has many parent variables [125-128]. However, one limitation with the linear 
Gaussian model is that although it works well in cases where the data fits a 
normal distribution and there are linear dependences between nodes and their 
parents, the model can easily over-fit the data if these dependencies are not met. 
In this study it was reasonable to apply Gaussian distribution because most 
candidate genes fit a normal distribution, as shown in Figure 6-2. However, a 
possible improvement may come from performing graphical diagnosis and doing 
further transformation on the data, or employing other statistical models to fit the 
data. An alternative approach to learning the structure of the Bayesian network is 
simulated annealing with Markov chain Monte Carlo (MCMC) sampling. This 





 In hill-climbing method, the function finds the nearest optimum value. Depending 
on the starting point, this peak may or may not be the true optimum value. 
However, one limitation with MCMC sampling is that it is significantly more time-
consuming than the hill-climbing method. For network comparison or scoring, 
other asymptotic criteria such as AIC, BIC, or DIC could be tried as well. 
The two major apoptosis sub-pathways of mammalian cells are largely 
independent because over-expressed Bcl-2 does not protect lymphocytes from 
apoptosis induced by death receptor ligands. Literature has shown that in certain 
other cell types such as hepatocytes the two pathways intersect, because 
CASP8 can process the pro-apoptotic Bid into its active truncated form (tBid) and 
prevent catastrophic untimely cell death [121]. However, cross-talk between 
these two programs has been rarely studied in the context of drug-perturbations. 
Our computationally predicted apoptosis network might shed light on how both 
pathways are regulated together by identifying cross-talk interactions such as 
PMAIP1 and TNFAIP3, BCL2L11 and TNFAIP3 via SON. 
In summary, we have extended the usage of CMAP data and reconstructed a 
subnetwork of drug-induced apoptosis in mammalian cancer cells using a 
computational statistical modeling approach. Apoptosis induction is a major 
theme of cancer treatment by drugs, and we confirmed that it is indeed a major 
drug-responsive program. Our findings have added new knowledge of how 
cancer cells respond to drug and provided potential specific targets in apoptosis 





drug-induced program, so our computational framework to CMAP data could be 






Chapter 7 NetBID2 Identifies AKT1 as a Therapeutic 




Glucocorticoid resistance is a major driver of therapeutic failure in T-cell acute 
lymphoblastic leukemia (T-ALL). Here we used a systems biology approach, 
NetBID2, based on the reverse engineering of signaling regulatory networks, 
which identified the AKT1 kinase as a signaling factor driving glucocorticoid 
resistance in T-ALL. Indeed, activation of AKT1 in T-ALL lymphoblasts impairs 
glucocorticoid-induced apoptosis. Mechanistically, AKT1 directly phosphorylates 
the glucocorticoid receptor NR3C1 protein at position S134 and blocks 
glucocorticoid-induced NR3C1 translocation to the nucleus. Consistently, 
inhibition of AKT1 with MK-2206 increases the response of T-ALL cells to 
glucocorticoid therapy both in T-ALL cell lines and in primary patient samples 
thus effectively reversing glucocorticoid resistance in vitro and in vivo. These 
results warrant the clinical testing of ATK1 inhibitors and glucocorticoids, in 
combination, for the treatment of T-ALL. 
                                            
1 Eric Piovan from Adolfo Ferrando Lab did validation experiments. This chapter 





7.2 Clinical Significance 
Glucocorticoids are central drugs in the treatment of T-ALL and glucocorticoid 
resistance is associated with poor outcomes in this disease. Therefore, the 
elucidation of molecular mechanisms contributing to glucocorticoid resistance 
and the identification of therapeutic targets for the treatment of glucocorticoid 
resistant T-ALL have become major imperatives in the field. Our identification of 
AKT1 as a direct inhibitor of glucocorticoid receptor function and a mediator of 
glucocorticoid resistance will facilitate the development of combination therapies 
with AKT1 inhibitors and glucocorticoids for the treatment of T-ALL. Moreover, 
these results further highlight the value of systems biology approaches based on 
reverse engineering of signaling networks to identify key modulators of drug 
resistance in human cancer. 
Keywords: AKT1, glucocorticoid resistance, T-ALL, NetBID2, systems 
biology, NR3C1, phosphorylation 
7.3 Introduction 
Glucocorticoids (GCs) play a fundamental role in the treatment of all lymphoid 
tumors due to their capability to induce apoptosis in lymphoid progenitor cells 
(Figure 7-1) [18, 19, 149]. However, the importance of glucocorticoid therapy in 
lymphoid malignancies is underscored by the strong association of glucocorticoid 
response with prognosis in childhood acute lymphoblastic leukemia (ALL). Thus, 





prognostic factor in this disease [150-152]. Moreover, resistance to 
glucocorticoids, defined as inability by lymphoblastic leukemia cells to initiate the 
apoptotic program in response to glucocorticoid treatment in vitro, is also 
associated with unfavorable prognosis [153, 154]. Finally, the majority of ALL 
patients in relapse show increased resistance to glucocorticoid therapy, 
suggesting glucocorticoid resistance as a potential major contributor to treatment 
failure [153, 155].  
The transcriptional and cellular effects of glucocorticoids in leukemia cells are 
mediated by the glucocorticoid receptor alpha, a nuclear receptor ligand-
activated transcription factor encoded by the NR3C1 gene [156].  In its unligated 
state, the glucocorticoid receptor protein is located primarily in the cytoplasm as 
part of an inactive hetero-oligomeric complex that contains heat shock proteins 
and chaperones [157]. After binding to an agonist ligand, NR3C1 undergoes 
conformational changes, dissociates from the heat shock protein complex, 
partially homodimerizes, and translocates to the nucleus where it binds to DNA 
and activates gene expression via positive glucocorticoid response elements 
located in the promoters of glucocorticoid target genes [158]. In addition to its 
role as a transcriptional activator, the glucocorticoid receptor has also been 
shown to directly participate in transcriptional repression, via binding to negative 
glucocorticoid response elements, which mediate the assembly of cis-acting 
NR3C1-SMRT/NCoR repressing complexes [159] and indirectly, via interaction 
with other transcriptional regulators such as AP-1,  NFKB, TP53, CREBP and 





induces a broad transcriptional program affecting genes responsible for multiple 
cellular functions, including cell cycle progression, cell metabolism and the 
induction of apoptosis [160-163]. 
 
Figure 7-1 Glucocorticoid receptor signaling pathway, adapted 
from SABiosciences. 
A number of different mechanisms have been involved in glucocorticoid 





receptor gene, loss of glucocorticoid receptor auto up-regulation, expression of 
glucocorticoid receptor splice variants, and upregulation of antiapoptotic 
pathways [164-173]. Overall, although multiple distinct genetic and epigenetic 
alterations seem to contribute to glucocorticoid resistance in ALL, complete 
functional loss of glucocorticoid receptor activity is rare, suggesting that 
strategies aimed to enhance glucocorticoid receptor expression and activity in 
leukemic lymphoblasts may be exploited to overcome resistance in the clinic.  
Moreover, even though glucocorticoid resistance is a complex phenotype, 
glucocorticoid resistant leukemias share a distinct gene expression signature, 
suggesting that common effector mechanisms may participate in blunting 
glucocorticoid response in resistant tumors [23]. Correspondingly, several 
therapeutic strategies have been proposed to overcome GC-resistance such as 
inhibition of MEK, HDAC, mTOR, or NOTCH1 [23, 24, 174-178]. However, due to 
strong toxicity of existing therapeutics [179], reversal of GC-resistance remains a  
clinical challenge and new therapeutic strategies are much needed. 
In this chapter, we aimed to identify specific signaling proteins that directly 
modulate the activity of the glucocorticoid receptor and may thus be exploited for 
the reversal of glucocorticoid resistance. To achieve this goal, we applied 
NetBID2 (Figure 7-2), the systems biology framework I developed to infer 
disease drivers from gene expression data in couple with signaling-molecule 
centered network. NETBID2 is based on computationally-assembled regulatory 
networks from a cohort of gene expression profiles (GEPs) and Markov chain 





existing master regulator analysis method, MARINa, which has been successful 
in the identification of transcription factors that are master regulators of high-
grade Glioma subtypes [72] and Germinal Center formation [71], to the analysis 
of signaling proteins as candidate modulators of glucocorticoid resistance in T-
cell acute lymphoblastic leukemia (T-ALL). This approach led to the identification 
of AKT1 as a master regulator of glucocorticoid resistance in T-ALL and 
suggested several additional potential master regulators. To validate these 
findings, we demonstrate that the glucocorticoid receptor, NR3C1, is a direct 
phosphorylation target of AKT1 at S134 and that its AKT1-mediated 
phosphorylation impairs glucocorticoid response via nuclear exclusion and 
targeted degradation of the NR3C1 protein. Consistently, and most importantly, 
pharmacologic inhibition of AKT1 effectively reverses glucocorticoid resistance 
both in T-ALL primary samples and in cell lines (i.e., in vitro and in vivo). Overall, 
these results show that regulatory network analysis is a valuable tool in the 
identification of critical modulators of therapeutic response in human cancer and 
identify AKT1 as an actionable therapeutic target for the reversal of 










Figure 7-2 NetBID2 algorithm to identify drivers of GC-Resistance in T-ALL from 
gene expression profiles. 
7.4 Results 
7.4.1 NetBID2 with signaling network identifies AKT1 as a driver of 
glucocorticoid resistance in T-ALL 
Reverse engineering of transcriptional regulatory or signal transduction networks 
has emerged as a valuable tool to identify master regulators of human 
phenotypes, both physiologic and pathologic [70, 180, 181]. More recently, this 
approach has also been successful in establishing functionally relevant, 
experimentally validated interactions between signaling molecules and 
transcription factor oncogenes [73]. Here we postulated that the gene expression 
signature EGC, associated with glucocorticoid resistance, could be effectively 
used to interrogate the signaling interaction network of T-ALL to identify master 
regulators of resistance. Since data on signal transduction networks is too sparse 
and lacks context specificity, we relied instead on the fact that numerous 
feedback loops results in transcriptional coherence among proteins that are in 
the same signal transduction pathway. This suggests that candidate interactions 
of a signaling proteins S should be enriched among genes with a statistically 
significant Mutual Information with S, computed from transcriptional profiles 
(Figure 7-2). In addition, since these feedback loops are reasonably modeled as 
Markov chains, we hypothesized that using the Data Processing Inequality, a 





targets of transcription factors, could also be used to further enrich the inferred 
interactions in genes whose expression was more directly controlled by a 
signaling protein. We are cognizant that this is only an approximation. Yet, we 
reasoned that if the inferred regulon RS of a signaling protein S were sufficiently 
enriched in genes whose expression is regulated by S, directly or indirectly, the 
MARINa algorithm could then be used to identify the corresponding protein‘s role 
as candidate master regulator of glucocorticoid resistance.  
To define the EGC signature for glucocorticoid resistant vs. glucocorticoid 
sensitive leukemia, we analyzed microarray data from a public series of 32 
leukemias, with detailed information on glucocorticoid sensitivity [23], by Probit 
analysis using a Bayesian MCMC method for robust parameter estimation, see 
methods section. Consistent with previous reports, glucocorticoid resistant T-
ALLs were characterized by a robust transcriptional signature with 53 







Figure 7-3 Top signaling drivers of GC-resistance inferred by NetBID2 and siRNA 
validation results. (a) Signaling factors associated with glucocorticoid resistance 
by NetBID2. (b) Apoptosis analysis in DND41 T-ALL cells electroporated with 
siRNA pools targeting validated candidate regulators of glucocorticoid resistance 
and treated with dexamethasone (1µM) for 48 hours. The apoptotic index 
indicates apoptotic cell number in gene specific siRNA dexamethasone treated 
samples relative to siRNA control dexamethasone treated cells. *, P <0.01; **, P 
<0.05. (c) Quantitative RT-PCR analysis of siRNA knockdown. 
Next, to assemble a T-ALL specific signaling network to interrogate such a 
signature, we used gene expression profile data from a large collection of 223 T-
ALL primary samples to infer groups of genes (S-regulons) whose expression is 
modulated by 2,602 proteins annotated as having signal transduction function, 
using the ARACNe algorithm [70, 111]. This analysis yielded a network 





Finally, we applied the NetBID2 algorithm to rank signaling proteins according to 
the enrichment of their S-regulon (RS) in the glucocorticoid resistance signature, 
based on a two-tail Gene Set Enrichment Analysis (GSEA) [97]. Given that 
signaling pathways can trigger either positive or negative transcriptional feedback 
loops we considered that if S activation induced glucocorticoid resistance, then 
RS genes could be enriched either among overexpressed or underexpressed 
genes in the glucocorticoid resistance signature. All signaling proteins were then 
ranked by their two-tail GSEA statistics, using the Normalized Enrichment Score, 
NES, and associated P-value. This analysis identified 42 signaling drivers of GC-
resistance (P<0.01, set size > 50, involved in at least known pathway, Table 7-1, 
Figure 7-25). We selected top 9 signaling factor-associated gene sets with highly 
significant enrichment scores (P < 0.0025) for validation. SiRNA mediated 
silencing of each of these candidate glucocorticoid resistance modulators 
validated that inhibition of 3 out of 9 (33%) of these predicted genes can increase 
the response of T-ALL lymphoblasts to glucocorticoids. Thus, knockdown of 
PPP2R5D, a protein phosphatase 2A regulatory B subunit; the B3GAT3 
glucuronosyl transferase 1; and AKT1, a central mediator in phosphatidylinositol 
3-kinase (PI3K) signaling, can all enhance glucocorticoid induced apoptosis in 
DND41 T-ALL cells (Figure 7-3). The prominent role of the PI3K-AKT signaling 
pathway in the pathogenesis of T-ALL [182, 183], and the development of 
clinically relevant PI3K-AKT specific inhibitors for the treatment of human cancer, 
prompted us to analyze the mechanistic role of AKT1 in the control of 





More interestingly, in the predicted network of AKT1, three AKT1-associated 
genes (VEGFB, TREX1, B3GAT3) are among the top 9 signaling proteins we 
selected and validated. B3GAT3 is also validated by siRNA (Figure 7-3) to 
sensitize GC-resistant cells upon inhibition. Out of 30 transcription factors or 
signaling molecules (92 genes in total) connected to AKT1 in the predicted 
network, 15 are also inferred as drivers of GC-resistance (Figure 7-4). This may 
suggestion that AKT pathway is highly involved in inducement of GC-resistance 
in T-ALL and may provide a therapeutic avenue to reverse the resistance by 
inhibiting AKT pathway. This also gives us more confidence and interest to follow 
up AKT1 to test it out and to identity the mechanism of AKT1 causing GC-
resistance. 
Moreover, NetBID2 also identifies AKT2 as a signal driver of GC-resistance in T-
ALL (Figure 7-6), which is another important member of PI3K/AKT pathway and 
shares similar functions with AKT1 in many biological processes. Again this 
makes it more interesting to work on AKT pathway. 
One point we want to highlight is that NetBID2 identifies AKT1 as a driver of GC-
resistance (Figure 7-5); however, AKT1 is not a signature gene in GC-resistant 
samples by looking at its own expression (Figure 7-7). It‘s not differentially 
expressed in GC-resistant and sensitive samples and also shows slightly up-
regulation in GC-sensitive samples. This again confirms the power of NetBID2 to 







Figure 7-4 AKT1-subnetwork predicted by ARACNe. Out of 30 (92 genes in total) 
TFs (diamond shape) or signal molecules (circle shape) that are predicted to 
connect with AKT1, 15 as shown are also inferred as drivers of GC-resistance. 
The strength of evidence (p-value) as a driver is color coded. Three signaling 
proteins in red are among top 9 proteins selected for validation. B3GAT3 is also 






Figure 7-5 NetBID2 identifies AKT1 as a driver of GC-resistance in T-ALL. 
 






Figure 7-7 mRNA expression of AKT1 in GC-resistant and GC-sensitive primary 
samples. AKT1 is slightly over-expressed in sensitive samples. 
7.4.2 Constitutive activation of AKT1 impairs glucocorticoid response in T-
ALL  
Mutations and deletions in the PTEN tumor suppressor gene result in constitutive 
activation of AKT1 in T-ALL [182, 183].  Consistently, PTEN inactivation in 
DND41 cells by shRNA knockdown resulted in drastic reduction of PTEN protein 
levels and increased phosphorylation of AKT1 compared to control cells infected 





knockdown and control DND41 cells with dexamethasone showed that loss of 
PTEN and consequent AKT1 activation results in blunted induction of 
glucocorticoid induced apoptosis in T-ALL (Figure 7-8-b,c).  
The glucocorticoid receptor (NR3C1) functions as a ligand activated transcription 
factor [184]. Expression analysis of TSC22D3, a glucocorticoid target gene 
associated with inhibition of cell proliferation; BCL2L11, which encodes BIM a 
proapoptotic BH3-only factor; and the glucocorticoid receptor NR3C1 gene itself, 
showed a significant reduction in activation of these glucocorticoid induced 
transcripts in DND41 PTEN knockdown cells treated with dexamethasone 
compared with controls (Figure 7-8-d). In addition, AKT1 siRNA knockdown 
induced a significant enhancement in the upregulation of glucocorticoid response 
transcripts upon dexamethasone treatment (Figure 7-9). Consistently, expression 
of an activated myristoylated form of AKT1 (MYR-AKT1) diminished the capacity 
of the glucocorticoid receptor to activate a luciferase reporter construct under the 
control of a synthetic glucocorticoid response element (Figure 7-8-e), and blunted 
the response of the physiologic AF11-AF12 glucocorticoid response element 
responsible for the autoupregulation of the NR3C1 hematopoietic specific 
promoter [185] (Figure 7-8-f). Overall these results suggest that AKT1 could 






Figure 7-8 Activation of the PI3K-AKT signaling pathway via PTEN inactivation 
induces glucocorticoid resistance in T-ALL and blunts glucocorticoid-induced 
gene expression. (a) Western blot analysis of PTEN expression and AKT1 
activation in DND41 T-ALL cells expressing a shRNA targeting the PTEN tumor 
suppressor (shRNA PTEN) compared to control cells expressing a hairpin 





(c) of glucocorticoid-induced apoptosis in control and PTEN knockdown DND41 
cells treated with dexamethasone (1µM) for 48 hours. Percentages of viable 
(lower left quadrant), apoptotic (lower right quadrant) and dead (upper right 
quadrant) are indicated.  (d) RT-PCR analysis of glucocorticoid response gene 
induction in control and PTEN knockdown DND41 cells treated with 
dexamethasone. (e,f) Luciferase reporter analysis of dexamethasone-induced 
glucocorticoid receptor transactivation in U2OS cells expressing MYR-AKT1 
compared with GFP only expressing controls using a synthetic glucocorticoid 
response element reporter (e) and the glucocorticoid receptor promoter 1A FP11-
FP12 regulatory sequence (f). 
 
Figure 7-9 Inactivation of AKT by siRNA facilitates glucocorticoid-induced gene 
expression. RT-PCR analysis of glucocorticoid response gene induction in 





7.4.3 Phosphorylation of the glucocorticoid receptor (GCR) by AKT1 
Activation of gene expression by glucocorticoids is a multistep process that 
requires effective release of the glucocorticoid receptor from heat shock protein 
complexes, effective translocation to the nucleus and formation of a multiprotein 
transcriptional complex in the promoter of glucocorticoid target genes. To test if 
AKT1 could directly interact and inhibit the glucocorticoid receptor protein we 
transfected 293T cells with plasmid constructs driving the expression of Flag-
tagged AKT1 and HA-tagged NR3C1 and isolated glucocorticoid receptor-
containing protein complexes via immunoprecipitation using an anti-HA antibody. 
Western blot analysis demonstrated the presence of FLAG-AKT1 in HA-NR3C1 
immunoprecipitates suggesting that AKT1 can interact with NR3C1 in vivo 
(Figure 7-10-a). Reciprocal immunoprecipitation experiments, confirmed the 
association between Flag-AKT1 and HA-NR3C1 (Figure 7-10-b). Moreover, 
immunoprecipitation of NR3C1 protein complexes from the T-ALL cell lines 
DND41 and CCRF-CEM, demonstrated that endogenous NR3C1 and AKT1 can 
interact in T-ALL lymphoblast cells (Figure 7-10-c, Figure 7-11). Finally, 
glutathione-S-transferase (GST)-pulldown assays showed that recombinant 
GST-NR3C1 fusion protein can directly interact with His-tagged AKT1 (Figure 
7-10-d).  
AKT1 kinase target proteins are typically phosphorylated by AKT at RXRXXS/T 
motifs [186-188]. Phospho-AKT motif scanning analysis of NR3C1 revealed a 
potential AKT phosphorylation motif 131RSTS134 (Figure 7-10-e), suggesting that 





134. To test this possibility, we expressed HA-tagged wild type NR3C1 (HA-
NR3C1) or an HA-tagged form of the glucocorticoid receptor with a serine to 
alanine substitution at position 134 (HA-NR3C1 S134A) in cells infected with 
retroviruses expressing MYR-AKT1. Protein immunoprecipitation of NR3C1 with 
an antibody against HA and subsequent Western blot analysis with an antibody 
recognizing the phospho-RXXS/T AKT phosphorylation motif showed the 
presence of a HA-NR3C1 phospho-AKT band in cells expressing the wild type 
glucocorticoid receptor, but not in cells expressing the HA-NR3C1 S134A mutant 
(Figure 7-10-f). Next, we performed in vitro kinase assays in which we analyzed 
the capacity of the AKT1 kinase to phosphorylate the wild type or S134A 
glucocorticoid receptor proteins.  This assay demonstrated that AKT1 can 
effectively phosphorylate recombinant wild type NR3C1 protein in vitro, but not 
the serine 134 to alanine NR3C1 mutant protein (Figure 7-10-g).  Importantly, 
this effect was not mediated by impaired interaction between AKT1 and 
NR3C1S134A as GST-pulldown experiments showed that GST-NR3C1 S134A 
mutant protein can effectively interact with AKT1 in vitro (Figure 7-12). Moreover, 
mass spectrometry analysis of HA-NR3C1 protein isolated from MYR-AKT1 
expressing cells demonstrated the presence of serine phosphorylation at position 
134 of the glucocorticoid receptor by mass spectrometry (Figure 7-10-h,i). Mass 
spectrometry of the digested peptides by nanoLC-ESI-MS/MS verified the 
presence of NRC31 phosphorylation at S134 [ratio non-phosphorylated peptide: 
phosphorylated peptide (non-P:P)= 1.5:1] in addition to other previously 





20:1), S203 (non-P:P= 1:1) and S267 (non-P:P= 25:1). Overall, these results 
demonstrate that the glucocorticoid receptor is a direct phosphorylation target of 
AKT1. 
 
Figure 7-10 AKT1 interacts with and directly phosphorylates the glucocorticoid 
receptor protein in position S134. (a) Western blot analysis of AKT1 after 
glucocorticoid receptor NR3C1 immunoprecipitation in 293T cells expressing 
Flag-tagged AKT1 and HA-tagged NR3C1. (b) Western blot analysis of 
glucocorticoid receptor NR3C1 protein after AKT1 immunoprecipitation in 293T 
cells expressing Flag-tagged AKT1 and HA-tagged NR3C1. (c) Western blot 
analysis of AKT1 after NR3C1 protein immunoprecipitation in DND-41 T-ALL 
cells.  (d) Analysis of AKT1-NR3C1 interaction via AKT1 detection via Western 
blot analysis of protein complexes recovered after NR3C1-GST pull down of 
recombinant His-tagged AKT1.  (e) Partial alignment of the glucocorticoid 
receptor protein sequence flanking S134. (f) Western blot analysis of NR3C1 





protein immunoprecipitates from U2OS cells expressing MYR-AKT1 together 
with HA-tagged wild type glucocorticoid receptor (HA-NR3C1) or an HA-tagged 
glucocorticoid receptor protein harboring a serine 134 to alanine substitution (HA-
NR3C1 S134A). (g) In vitro kinase analysis of AKT1 phosphorylation of 
recombinant wild type NR3C1 (GST-NR3C1) and NR3C1 S134A mutant (GST-
NR3C1 S134A) protein. Top panel shows P32 autoradiography after SDS-PAGE. 
The corresponding protein loading for each reaction is shown in the Coomassie 
blue staining micrograph at the bottom. (h) ESI-MS/MS spectrum of 
monophosphorylated peptide STpS134VPENPK (S-132 to K-140) obtained after 
trypsin digestion of NR3C1 isolated from cells expressing constitutively active 
AKT1.  (i) Collision induced dissociation of the molecular ion, [M+2H]2+ at m/z 
519.72 (M = 1037.42 Da) corresponding to S134. Characteristic b- and y-
fragment ions including y7 which contains pSer and features the loss of 98 Da 






Figure 7-11  AKT1 directly interacts with the glucocorticoid receptor in T-ALL 







Figure 7-12 AKT1 can directly interact with both wild type and mutant S134A 
glucocorticoid receptor. Analysis of AKT1-NR3C1 interaction via AKT1 detection 
via Western blot analysis of protein complexes recovered after wild type (NR3C1-
GST) or mutant (NR3C1 S134A-GST) glucocorticoid receptor GST pull down 
with recombinant His-tagged AKT1. 
7.4.4 AKT signaling inhibits NR3C1 nuclear translocation following 
glucocorticoid treatment  
After establishing the interaction and phosphorylation of the glucocorticoid 
receptor by AKT1 we aimed to elucidate the relevance of the NR3C1 S134 
phosphorylation for glucocorticoid receptor function. Glucocorticoid induced 





activity. U2OS cells, which express undetectable levels of endogenous NR3C1 
(Figure 7-14), showed cytoplasmic localization of retrovirally expressed HA-
tagged glucocorticoid receptor protein, which was completely relocalized to the 
nucleus upon dexamethasone treatment (Figure 7-13-a). Notably, expression of 
MYR-AKT1 in these cells resulted in impaired nuclear relocalization of NR3C1 
after dexamethasone treatment (Figure 7-13-b). In addition, and in contrast with 
wild type glucocorticoid receptor, the NR3C1 S134A mutant protein showed 
increased nuclear localization in basal conditions and effective nuclear 
relocalization upon dexamethasone treatment (Figure 7-13-c), even upon 
expression of MYR-AKT1 (Figure 7-13-d). Next we analyzed the capacity of 
MK2206 a highly potent and selective AKT inhibitor [189], to modulate 
glucocorticoid induced translocation of NR3C1 to the nucleus in T-ALL cells.  
CCRF-CEM and MOLT3, two PTEN null T-ALL cell lines expressing high levels 
of AKT activation (Figure 7-13-e, Figure 7-15) showed cytoplasmic localization 
NR3C1 in basal conditions, which was only partially relocalized to the nucleus 
upon dexamethasone treatment (Figure 7-13-e, Figure 7-15). Inhibition of AKT 
with MK2206 effectively enhanced glucocorticoid-induced translocation of the 






Figure 7-13 AKT1-mediated S134 phosphorylation of the NRC3C1 protein 
impairs dexamethasone-induced glucocorticoid receptor nuclear translocation.  
(a) Confocal microscopy analysis and quantitation of the cellular distribution of 





conditions (DMSO) and after dexamethasone (Dexa) stimulation. (b) NR3C1 
cellular localization in U2OS cells expressing HA-NRC31 and MYR-AKT1 in 
basal conditions and after dexamethasone stimulation. (c) Cellular localization of 
NR3C1 in U2OS cells expressing the HA-NRC31 S134A mutant in basal 
conditions and after dexamethasone stimulation. (d) Cellular localization of the 
HA-NRC31 S134A protein in U2OS cells expressing MYR-AKT1 in basal 
conditions and after dexamethasone stimulation. (e) Cellular localization analysis 
of NR3C1 via nuclear and cytoplasmic cell fractionation and analysis of AKT1 
signaling in cell lysates from CCRF-CEM T-ALL cells treated with vehicle only 
(DMSO), dexamethasone (Dexa), the MK2206 AKT inhibitor and MK2206 plus 
dexamethasone. Tubulin and MAX proteins are shown as controls for cytosolic 






Figure 7-14 U2OS cells do not express detectable levels of endogenous NR3C1. 
Western blot analysis of NR3C1 expression in U2OS cells expressing pMSCV 






Figure 7-15 AKT1-mediated phosphorylation of the NR3C1 protein impairs 
dexamethasone-induced glucocorticoid receptor nuclear translocation in T-ALL 
cells Cellular localization analysis of NR3C1 via nuclear and cytoplasmic cell 
fractionation and analysis of AKT1 signaling in cell lysates from MOLT-3 T-ALL 
cells treated with vehicle only (DMSO), dexamethasone (Dexa), the MK2206 
AKT inhibitor and MK2206 plus dexamethasone. Tubulin and MAX proteins are 
shown as controls for cytosolic and nuclear fractions, respectively. C: 





7.4.5 Pharmacologic inhibition of AKT reverses glucocorticoid resistance 
in vitro and in vivo 
Next we analyzed if AKT inhibition with MK2006 could broadly enhance the 
antileukemic effects of glucocorticoids and reverse glucocorticoid resistance in T-
ALL. Treatment of DND41 T-ALL cells with MK2206 effectively suppressed AKT1 
signaling (Figure 7-16) and showed a synergistic antileukemic effect in 
combination with dexamethasone [MK-2206 and dexamethasone Combination 
Index (CI)= 0.48] (Figure 7-16).   Consistently, treatment of CCRF-CEM cells with 
increasing doses of dexamethasone in the presence or absence of MK2206 
showed effective reversal of glucocorticoid resistance upon AKT inhibition 
(Figure 7-17-a). Similar results were obtained in the MOLT3 cell line (Figure 
7-18). Next we analyzed the effects of MK2206 and glucocorticoid in vivo in a 
xenograft model of glucocorticoid-resistant T-ALL. CCRF-CEM cells expressing 
the luciferase gene were injected intravenously in immunodeficient NOD SCID 
mice and tumor engraftment was assessed by in vivo bioimaging at day 18. 
Animals harboring homogeneous tumor burdens were treated with vehicle only 
(DMSO), MK2206, dexamethasone or MK2206 plus dexamethasone for 3 days.  
In this experiment, animals treated with dexamethasone or MK2206 showed 
progressive tumor growth similar to that observed in vehicle-treated controls, 
while mice treated with MK2206 plus dexamethasone had significant antitumor 
responses (Figure 7-17-b; P < 0.05).  
Next, we evaluated the response to the combination treatment MK2206 plus 





established viable in vitro cultures of T-ALL leukemia samples supported by bone 
marrow MS5 stroma cells expressing the Delta like 1 NOTCH1 ligand [190]. 
Treatment of T-ALL primary leukemia cultures with MK2206 plus dexamethasone 
in combination showed significantly increased antileukemic effects compared 
with treatment with dexamethasone or MK2206 alone in 8/10 primary T-ALLs 
analyzed (Figure 7-22-a, b and Figure 7-19).  
To further test the efficacy of this treatment combination in vivo we established 
leukemia xenografts in Rag2/gamma (c) double knockout mice using two 
independent primary T-ALL samples infected with lentiviruses expressing the 
luciferase gene. Animals harboring homogeneous tumor burdens by in vivo 
bioimaging were treated with vehicle only (DMSO), MK2206, dexamethasone or 
MK2206 plus dexamethasone. In this experiment, mice treated with 
dexamethasone or MK2206 showed progressive tumor growth similar to that 
observed in vehicle-treated controls, while mice treated with MK2206 plus 
dexamethasone showed significant antitumor responses (Figure 7-22-c, d and 






Figure 7-16 Pharmacological inhibition of AKT synergizes with dexamethasone to 
increase the antileukemic effects of glucocorticoids in DND-41 T-ALL cells. (a) 
Western blot analysis of AKT1 activation in DND41 T-ALL cells treated with the 
MK2206 AKT inhibitor. (b) Isobologram representation of cell viability results and 
Combination Index analysis of DND41 cells treated with dexamethasone and 






Figure 7-17 Pharmacologic inhibition of AKT with MK-2206 reverses 
glucocorticoid resistance in human T-ALL cell lines. (a) Representative plots and 





treated with vehicle only, MK2206, dexamethasone or dexamethasone plus 
MK2206 in combination in vitro. (b) Quantification of tumor load by 
bioluminescence in  in vivo imaging and analysis of luciferase activity or human 
CD45 expressing cells in the bone marrow of CCCF-CEM T-ALL xenografted 
mice treated with vehicle only, MK2206, dexamethasone (Dexa) or MK2206 plus 
dexamethasone (Dexa + MK2206). 
 
Figure 7-18 Pharmacological inhibition of AKT reverses glucocorticoid resistance 
in MOLT-3 T-ALL cells (a,b) Representative plots (a) and quantification (b) of 
apoptosis and cell viability (c) in MOLT-3 T-ALL cells for 72 hours with vehicle 







Figure 7-19 Pharmacologic inhibition of AKT with MK-2206 reverses 
glucocorticoid resistance in human T-ALL primary samples. (a,b) Representative 
plots (a) and quantification of loss of viability analysis (b) in primary T-ALL patient 
samples treated with vehicle only, MK2206 and dexamethasone alone or 
dexamethasone plus MK2206 in combination. Percentages of viable (PI −), and 
non-viable (PI +) cells are indicated.  (c-f) Representative examples of primary 
human T-ALL xenografted mice showing changes in tumor load assessed by in 
vivo imaging (c), spleen size (d), spleen weight (e) and luciferase activity in bone 
marrow cells (f) from primary human leukemia xenografted mice treated with 
vehicle only, MK2206, dexamethasone (Dexa) or MK2206 plus dexamethasone 






Figure 7-20 Pharmacological inhibition of AKT in vitro reverses glucocorticoid 
resistance in primary human T-ALL xenografts. Analysis of cell viability in primary 
T-ALL samples treated for 72h with vehicle only, MK2206 and dexamethasone 






Figure 7-21 Pharmacological inhibition of AKT in vivo reverses glucocorticoid 
resistance in primary human T-ALL xenografts. (a,b) Bioimaging quantification (a) 
and analysis (b) of tumor load changes in mice treated with vehicle (control), 
dexamethasone (Dexa), MK2206, MK2206 plus dexamethasone (Dexa + 







Figure 7-22 Pharmacological inhibition of AKT in vivo reverses glucocorticoid 
resistance in primary human T-ALL xenografts. (a,b) Representative images of 
spleens (a) and spleen weights (b) of leukemic mice treated with vehicle only, 
MK2206, dexamethasone (Dexa) or MK2206 plus dexamethasone (Dexa + 
MK2206) for 4 days. (c,d) Quantification of tumor load by determining luciferase 
activity from cells isolated from the spleen (c) and bone marrow (d). (e) 
Quantification of tumor load changes by determining the increase in circulating 
CD45 positive cells in the peripheral blood of mice injected with a human 
xenograft and treated with vehicle (control), dexamethasone (Dexa), MK2206, 





Finally, we generated a mouse leukemia model in which glucocorticoid 
resistance is specifically driven by genetic loss of Pten using a well-established 
retroviral transduction and bone marrow transplantation protocol [191]. In this 
model, transplantation of tamoxifen-inducible conditional Pten knockout 
(Rosa26TMCre Ptenflox/flox) hematopoietic progenitors with retroviruses 
expressing a mutant and constitutively active form of the NOTCH1 receptor 
(NOTCH1 L1601P PEST) resulted in the development of NOTCH1 driven T-
ALL tumors as previously described [191]. Next we infected NOTCH1 
Rosa26TMCre Ptenflox/flox T-ALL lymphoblasts with a luciferase expressing 
retrovirus and transplanted them into secondary recipients which were treated 
with vehicle only or tamoxifen in order to generate Pten-non-deleted and Pten-
deleted isogenic tumors, respectively. Treatment of Pten-non-deleted tumor 
bearing mice with dexamethasone showed a significant improvement in survival 
compared with vehicle only treated controls (P < 0.01)(Figure 7-23-a). In contrast, 
and consistent with a role of Pten loss and AKT1 activation in promoting 
glucocorticoid resistance, all mice harboring Pten-deleted tumors failed to 
respond to dexamethasone treatment and showed no survival differences 
compared to vehicle treated controls (Figure 7-23-b).  
To test the efficacy of MK2206 and glucocorticoid combination we treated mice 
transplanted with NOTCH1-induced Pten-deleted murine tumors expressing 
luciferase in secondary recipients, with vehicle only (DMSO), MK2206, 
dexamethasone or MK2206 plus dexamethasone and monitored their response 





MK2206 in this experiment showed progressive tumor growth similar to that 
observed in vehicle-treated controls, while mice treated with MK2206 plus 
dexamethasone showed significant antitumor responses (Figure 7-23-c, d; P < 
0.01) which translated in significantly improved survival in this group (Figure 
7-23-e). 
Finally, we analyzed the role of NR3C1 S134 phosphorylation in the therapeutic 
response to glucocorticoids and the effects of Pten loss in glucocorticoid therapy 
in this model. Retroviral expression of the glucocorticoid receptor in Pten non-
deleted lymphoblasts (Figure 7-24) enhanced the response of NOTCH1-induced 
leukemias to glucocorticoid treatment; an effect that was effectively abrogated 
upon Pten loss (Figure 7-23-f). In contrast, expression of the AKT-resistant 
NR3C1 S134A mutant protein was equally effective at increasing the 
antileukemic effects of glucocorticoids in Pten non-deleted and Pten null 






Figure 7-23 Pharmacologic inhibition of AKT reverses glucocorticoid resistance in 
a mouse model of glucorticoid resistant T-ALL. (a,b) Kaplan-Meier survival plot in 
mice treated with dexamethasone (Dexa) or vehicle (Control) after allograft 
transplantation of Pten-non-deleted [−Tmx (Pten f/f)] (a) or Pten-deleted [+Tmx 
(Pten −/−)] (b) NOTCH1-induced T-ALL tumor cells. Arrows indicate the time of 
drug treatment. (c,d) Representative images and changes in bioluminescence in 
vivo imaging (c) and analysis of treatment response in mice allografted with 
NOTCH1 induced Pten deleted mouse leukemia cells and treated with vehicle 
only, MK2206, dexamethasone (Dexa) or MK2206 plus dexamethasone (Dexa + 
MK2206). (e) Kaplan-Meier plot of overall survival in mice allografted with 
NOTCH1 induced Pten deleted mouse leukemia cells and treated with vehicle 
only (control), MK2206, dexamethasone (Dexa) or MK2206 plus dexamethasone 





NOTCH1 induced Pten non deleted [−Tmx (Pten f/f)] or Pten deleted [+Tmx 
(Pten −/−)] mouse leukemia cells infected with an empty vector control (MSCV-
puro) or retroviruses expressing the wild type glucocorticoid receptor NR3C1 
(MSCV HA-NR3C1) or the S134A glucocorticoid receptor NR3C1 mutant protein 
(MSCV HA-NR3C1 S134A). 
 
Figure 7-24 Overexpression of NR3C1 and NR3C1 S134A mutant in primary 
murine leukemia cells. (a) Western blot analysis determining the retroviral 
expression of NR3C1 or NR3C1 S134A in Pten non-deleted [-Tmx (Pten f/f)] and 
(b) PTEN deleted [+Tmx (Pten -/-)] NOTCH1-induced T-ALL mouse leukemia 
cells. Beta actin is shown as loading control. 
Overall these results support a direct effect of AKT on the response to 
glucocorticoid therapy mediated by S134 phosphorylation of the glucocorticoid 
receptor protein and show that pharmacologic inhibition of AKT can effectively 






Despite much research, the molecular basis of glucocorticoid resistance in ALL 
remains poorly understood. Genetic abnormalities of the glucocorticoid receptor 
gene are rarely seen in primary glucocorticoid-resistant leukemias [19] or in ALL 
samples at relapse [165]. However, alternative glucocorticoid receptor-centered 
mechanisms of resistance including decreased glucocorticoid receptor 
expression [166, 192] and impaired glucocorticoid receptor auto-upregulation 
[167-172] have been proposed. Notably, increasing glucocorticoid receptor 
expression or glucocorticoid receptor autoupregulation via inhibition of NOTCH1 
signaling can effectively abrogate glucocorticoid resistance in T-ALL primary 
samples and cell lines [193]. In addition, increased expression of antiapoptotic 
factors such as MCL1 [173] and epigenetic silencing of the BCL2L11 proapototic 
gene [194] can impair glucocorticoid induced apoptosis in ALL. Thus, decreasing 
MCL1 expresion via inhibition of mTOR with rapamycin [23], and increased 
BCL2L11 levels via GSK3 inhibition [195] can enhance glucocorticoid induced 
cell death and reverse glucocorticoid resistance in ALL.  
Our results show a new mechanistic role for AKT1 in glucocorticoid resistance in 
T-ALL. Notably, activation of the PI3K-AKT signaling pathway is highly prevalent 
in T-ALL and can result from deletions and mutations in PTEN [182, 183] and 
from activating mutations in the PIK3CA gene [182, 183], but also downstream of 
mutations and autocrine or paracrine receptor triggering the activation of cytokine 





growth, metabolism and survival [23, 196-199]. Thus, constitutive activation of 
AKT1 can potentially antagonize glucocorticoid induced apoptosis via multiple 
indirect mechanisms. Still, our results demonstrate a direct effect of AKT1 in the 
phosphorylation and inhibition of the glucocorticoid receptor protein.  
Protein phosphorylation can modulate the activity of nuclear receptors by 
affecting their transactivation activity, cellular localization, interaction with 
cofactors and stability [200]. Mechanistically, AKT1 phosphorylation of NR3C1 
results in impaired glucocorticoid-induced nuclear localization. Notably, 
phosphorylation of S134 together with the presence of a conserved proline 
residue in position 136 (Figure 7-13-e), creates a potential 14-3-3 binding motif, 
which is a common mode of regulation of AKT1 substrates.  Thus, 14-3-3 binding 
has been implicated in AKT mediated inhibition of the proapototic factor BAD and 
the FOXO1, FOXO3 and FOXO4 transcription factor proteins [196, 201], 
suggesting a potential role for 14-3-3 interaction on the inhibitory effect of AKT1 
on the NR3C1 glucocorticoid receptor function.  
Overall, the results presented here, strongly support that AKT inhibition may 
reverse glucocorticoid resistance and warrant the clinical testing of AKT inhibitors 
and glucocorticoids in combination for the treatment of T-ALL. Finally our results 
demonstrate that reverse engineering of signaling networks can be exploited to 
identify relevant therapeutic targets for the reversal of chemotherapy resistance 





7.6 Materials and Methods 
7.6.1 Reverse engineering signaling molecule-focused network analysis of 
glucocorticoid resistance in T-ALL 
Here we used the mRNA expression of genes globally co-expressed with a 
signaling molecule (S) as a surrogate readout of the activity of S based on the 
assumption that such genes are enriched for both members of the signal 
transduction cascade that includes S (both upstream and downstream members) 
and targets of transcription factors regulated by S. To generate a T-ALL 
transcriptional network, we processed Human U133 Plus2 Affymetrix microarray 
gene expression data from a series of 223 T-ALL primary samples using GC-
RMA normalization and non-specific filtering (removing probes with no Entrez id, 
Affymetrix control probes, and non-informative probes by IQR variance filtering 
with a cutoff of 0.5), to 21,054 probes in total.  Then we run the ARACNe 
algorithm[180], against 4831 probe sets corresponding to 2602 genes with 
annotated functions in signaling transduction (with annotation of ―signal 
transduction‖ (GO:0007165) in Gene Ontology as of 2009) to establish a 
signaling factor-centered Interactome at transcriptional level. Use of ARACNe is 
justified to find minimal regulatory paths, i.e., to eliminate most indirect 
interactions in signal transduction analysis. This produces a minimal 
representation such that if any interaction were removed, information transfer in 
the system could no longer be explained. The parameters of the algorithm were 





number of bootstraps NB = 100. We used the adaptive partitioning algorithm for 
mutual information estimation. 
7.6.2 Glucocorticoid resistance signature analysis 
Out of the 223 primary samples with gene expression profile data, twenty-two 
were diagnosed as glucocorticoid resistant and ten as glucocorticoid sensitive. 
Using this a priori classification, we performed differential gene expression 
analysis to generate an EGC signature for glucocorticoid resistance. A statistical 
Probit model was used to infer the correlation of gene expression and 
phenotypes with the advantage of detecting weak effects, and Bayesian-MCMC 
computing was employed to estimate parameters for its robustness and accuracy, 
even with small sample size. In particular, a t-distribution prior and Gibbs 
sampling were used in this analysis [202]. 
7.6.3 Inferring master signaling drivers of glucocorticoid resistance in T-
ALL by NetBID2 
We used the NetBID2 algorithm to interrogate the ARACNe-inferred signaling 
network with the EGC signature, to identify candidate master modulators that may 
induce or suppress glucocorticoid resistance. It has been shown that feedback 
loops in signaling pathways induce co-expression of their member proteins, once 
the network has relaxed to steady state [203]. Thus, for each signaling gene S, 
we generated a putative S-regulon RS, from the T-ALL signaling interactome by 
selecting the first neighbors of S. This is based on the assumption that such 





includes S (both upstream and downstream members) and targets of 
transcription factors regulated by S. Next, we used Gene Set Enrichment 
Analysis (GSEA) to test the enrichment of the RS genes in the EGC signature as 
previously described [204]. For GSEA method we used ‗maxmean‘ statistic [205] 
to score the enrichment of the gene set in the EGC signature and sample 
permutation to build the null distribution for statistical significance. To generate 
robust signatures, we only used signaling proteins with more than 50 genes in 
their S-regulon. P-values were corrected using Efron‘s procedure [205]. 
7.6.4 Cell lines and primary leukemia samples 
Human embryonic kidney (HEK) 293T and osteosarcoma U2OS (HTB-96) cells 
were maintained in Dulbecco‘s modified Eagle‘s medium (DMEM) containing 10% 
fetal bovine serum and 0.05 mg/ml penicillin/streptomycin. T-ALL cell lines were 
maintained in RPMI-1640 media supplemented with 10% FBS and 0.05mg/ml 
penicillin/streptomycin. T-ALL lymphoblast samples were provided by 
collaborating institutions in the US (Department of Pediatrics, Columbia 
Presbyterian Hospital, New York), Italy (Department of Pediatrics, University of 
Padova), the Hospital Central de Asturias (Oviedo, Spain) and the Eastern 
Cooperative Oncology Group (ECOG). All samples were collected with informed 
consent and under the supervision of local IRB committees. Primary T-ALL cells 
were cultured in vitro with MS5 stromal cells expressing the Delta-like1 NOTCH 





7.6.5 Inhibitors and drugs 
The allosteric AKT inhibitor MK2206 or 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-
1,2,4-triazolo[3,4-f] [1,6]naphthyridin-3(2H)-one hydrochloride [1:1]  was obtained 
from Selleck Chemicals LLC. Dexamethasone and 4-Hydroxytamoxifen were 
from Sigma-Aldrich. 
7.6.6 siRNA validation of regulators of glucocorticoid resistance 
We performed siRNA experiments in the glucocorticoid sensitive T-ALL cell line, 
DND41. For this purpose, DND41 cells were electroporated with smartpool 
siRNAs (Dharmacon) targeting the top nine master regulators identified through 
MARINa analysis using the SF Cell line 96-well Nucleofector Kit (Lonza). Twenty-
four hours after electroporation, cells were treated with Dexamethasone (1µM) 
for 48h. Cells were then collected and analyzed for apoptosis by FACS after 
staining membrane expression of Annexin V and 7-AAD with the PE AnnexinV 
Apoptosis Kit I (BD Biosciences). 
7.6.7 Luciferase reporter assays 
We performed NR3C1 reporter assays in U2OS cells stably expressing 
haemagglutinin (HA) tagged wild type or mutant S134A NR3C1 and infected with 
retroviruses expressing EGFP only (pMSCV IRES GFP) or myristoylated AKT1 
and GFP (pMSCV MYR-AKT1 IRES GFP) and sorted for GFP expression [182]. 
These cells were cultured in DMEM media supplemented with 10% dialyzed fetal 
bovine serum in the presence or absence of increasing doses of dexamethasone 





firefly luciferase reporter containing tandem repeats of the Glucocorticoid 
Responsive Elements (GRE) and a constitutively expressing Renilla construct in 
the Cignal GRE Reporter (luc) Kit (SABiosciences); or alternatively  a luciferase 
reporter construct (pGL3 NR3C1 A1 FP11-FP12) containing the FP11-FP12 
regulatory sequence (5‘-CGTAAAATGCGCATGTGTTCCAACGGAAGCACTGG-
3‘) responsible for autoregulation of the NR3C1 promoter A1[24, 185] and the 
plasmid expressing pRL-CMV Renilla luciferase gene (Promega). NR3C1 
reporter activity and Renilla luciferase activity were analyzed 40-48 hours after 
transfection and 24 hours after dexamethasone treatment with the Dual-
Luciferase Reporter Assay kit (Promega).  
7.6.8 Quantitative real-time PCR 
Total RNA from T-ALL cell lines was extracted using Trizol reagent (Invitrogen). 
cDNA was generated with the Super Script First Strand Synthesis System for 
RT-PCR (Invitrogen) and analyzed by quantitative real-time PCR using SYBR 
Green PCR Master Mix (Applied Biosystems) and the 7300 Real-Time PCR 
System (Applied Biosystems). Relative expression levels were normalized with 
GAPDH expression used as a reference control.  
7.6.9 Western blotting and immunoprecipitation 
Total cell lysates were prepared using RIPA lysis buffer supplemented with 
phosphatase inhibitor cocktail set I and II (Sigma) and protease inhibitor cocktail 
tablets (Roche) and normalized for protein concentration using the BCA method 





gradient Tris-Glycine SDS-PAGE (Invitrogen) and transferred to PVDF 
membrane (Millipore). Membranes were blocked in PBST containing 5% nonfat 
milk, incubated with primary antibodies according to the antibody manufacturer‘s 
instructions, followed by incubation with horseradish peroxidase-conjugated goat 
anti-rabbit, goat anti-mouse or donkey anti-rat IgG (Amersham) and enhanced 
chemiluminescence detection (Perkin Elmer). Antibodies against glucocorticoid 
receptor (E-20), tubulin (TU-02), beta actin (C-11) and MAX (C-17) were from 
Santa Cruz Biotechnology. Antibodies recognizing BIM, phospho-AKT Ser473, 
phospho-AKT Thr308, phospho-mTOR (S2448), mTOR, AKT and phospho-
(Ser/Thr) Akt substrate were from Cell Signaling Technologies. HA epitope 
antibody was from Roche, FLAG epitope antibody from Sigma and an antibody 
against PTEN (clone 6H2.1) was obtained from Cascade Biosciences. For 
immunoprecipitation, cell lysates were incubated with anti-HA or anti-FLAG M2 
affinity gel beads (Sigma) overnight at 4°C.  Beads were washed five times with 
lysis buffer and proteins were eluted by incubating the beads with HA peptide 
(1mg/ml, Roche) or FLAG peptide (1mg/ml, Sigma). Immune complexes were 
analyzed by SDS-PAGE and Western blotting.  
For immunoprecipitation of endogenous NR3C1 bound proteins in T-ALL cells, 
we lysed 100-150 million T-ALL cells for 30 min in RIPA lysis buffer 
supplemented with phosphatase and protease inhibitor cocktails. After 
centrifugation, the cell lysates were pre-cleared with TrueBlot® anti‐Mouse Ig IP 
Beads (eBioscience) before being incubated overnight with 5µg of mouse 





Subsequently, samples were incubated 2 hours with TrueBlot® anti‐Mouse Ig IP 
Beads and immunoprecipitates washed 5 times with CO-IP buffer (50mM Tris-
HCl pH 7.9, 150 mM NaCl, 1mM EDTA, 0.1% NP-40 and protease inhibitors). 
Immune complexes were then analyzed by SDS-PAGE and Western blotting. 
7.6.10 Preparation of Cytoplasmic and Nuclear extracts 
CCRF-CEM, MOLT-3 T-ALL cells were treated with vehicle (DMSO), 
dexamethasone (1µM), MK2206 (0.5-1µM), or the combination dexamethasone 
and MK2206 for 1 hour before being harvested. Cytoplasmic and nuclear 
extracts were prepared using the nuclear extraction kit (Active Motif) according to 
the manufacturer‘s recommendations. 
7.6.11 In vitro GST-pull down protein interaction assays 
For in vitro binding assays, GST fusion proteins of NR3C1 or mutant NR3C1 
S134A were expressed and purified from BL-21 bacterial cells. Approximately 2 
µg of GST fusion proteins bound to glutathione-agarose beads (Immobilized 
glutathione; Thermo scientific) were incubated with 1-2 µg of Histidine-tagged 
activated AKT1 (His-AKT1, Millipore) in GST-lysis buffer (20 mM Tris-HCl, 200 
mM NaCl, 1mM EDTA, 0.5% NP-40 and protease inhibitors) for 2 hours at 4 °C. 
After extensive washing in GST-lysis buffer, proteins were separated on 4-12% 
NuPage gradient gels, transferred to PVDF, and probed by Western blot using 





7.6.12 In vitro kinase assays 
Flag-tagged recombinant GST-NR3C1 wt and GST-NR3C1 S134A mutant 
proteins were expressed, purified from Escherichia coli, and incubated with 
recombinant active His-AKT1 protein (Millipore) in kinase buffer (Cell Signaling) 
containing γ-32P-ATP at 30°C for 30 min. The reaction was stopped by the 
addition of 5X SDS-Laemmli‘s sample buffer. Samples were separated on 3-8% 
Tris-Acetate SDS-PAGE (Invitrogen), and the gels subjected to autoradiography. 
7.6.13 Mass spectrometry analysis of NR3C1 phosphorylation sites 
U2OS cells stably expressing HA-tagged human NR3C1 and Myr-AKT were 
lysed in RIPA buffer and immunoprecipitated with anti-HA antibody conjugated 
beads (Sigma). After overnight incubation, the beads were extensively washed 
with BC-500 (500 mM NaCl, 20 mM Tris-Cl pH =8.0, 20% glycerol, 1% Triton-X, 
1mM EDTA) and, subsequently, proteins were eluted by incubating the beads 
with HA peptide (1mg/ml, Roche). The eluted NR3C1 was diluted in 4X SDS-
PAGE sample buffer and electrophoresed on 3-8% Tris-Acetate gels. Gel bands 
were stained with Simply Blue Stain (Invitrogen), excised, reduced with DTT, 
alkylated with iodoacetamide and digested with trypsin. Afterward, the digest was 
analyzed for phosphorylated peptides by nanoLC-ESI-MS/MS. MS/MS spectra 
were processed using ProteinLynx from the MassLynx 4.0 software and 
searched against the Swiss-Prot protein database using Mascot 
(www.matrixscience.com) with differential modifications for Ser/Thr/Tyr 
phosphorylation (+79.97) and the sample processing artifacts Met oxidation 





and the corresponding non-phosphorylated peptides were manually inspected to 
be sure that all b− and y− fragment ions aligned with the assigned sequence and 
modification sites. For relative quantification of phosphorylation peptide signal 
levels, the total ioncurrent (TIC) for the phosphorylated peptide ion and non-
phosphorylated peptide ion were integrated and calculated according to the 
following equation: TICPO4/(TICPO4 + TICnonPO4) = ratio of phosphopeptide 
signal. Comparison of the ratio of the phosphorylated to nonphosphorylated 
peptide forms using this method provides an accurate measure of signal level 
change since the total peptide signal (modified and unmodified) is measured. 
7.6.14 Immunofluorescence studies 
U2OS cells stably expressing wild type or the S134A NR3C1 mutant together 
with MYR-AKT1 IRES EGFP or EGFP alone were plated on 35-mm dishes with 
glass bottom inserts and treated with vehicle only or dexamethasone (1 µM). 
After 1 hour they were washed with PBS, fixed in 4% paraformaldehyde and 
permeabilized with NP-40 (0.1% NP-40 in PBS). We blocked the permeabilized 
cells with 1.5% goat serum and incubated them with antibodies against NR3C1 
(1:500; Santa Cruz Biotechnology), followed by Alexa Fluor 594 (1:1000; 
Invitrogen) staining. We mounted the stained cells in Vectashield containing 
DAPI (4‘,6‘-diamidino-2-phenylindole; Vecta Laboratories, Burlingame, CA) and 
analyzed them by confocal imaging on a Zeiss LSM510-NLO microscope. 
Quantification of the NR3C1 signal in the cytoplasmic and nuclear compartments 





7.6.15 Cell viability assays and flow cytometric analysis 
We analyzed cell viability via a metabolic colorimetric assay using the Cell 
Proliferation Kit I (MTT; Roche) or Cell Proliferation Reagent WST-1 (Roche). 
Drug concentrations used in these experiments were 10nM to 10 µM for 
dexamethasone and 0.5µM to 5µM for MK2206. We analyzed apoptosis by flow 
cytometry (FACS) after staining membrane expression of Annexin V and 7-AAD 
with the PE AnnexinV Apoptosis Kit I (BD Biosciences). For primary T-ALL 
samples, we assessed cell viability using the BD Cell Viability kit (BD 
Biosciences) coupled with the use of fluorescent counting beads. In these 
experiments, 2×105 leukemic cells were plated with 4×104 MS5-DL1 stroma cells 
into 24-well plates. The next day we treated cells with vehicle only (DMSO), 
dexamethasone (10 nM-1 µM), MK2206 (0.5 µM-10 µM) or the combination 
dexamethasone (10 nM-1 µM) plus MK2206 (0.5 µM-10 µM). After 72 hours we 
harvested the treated cells, passed them through a 50 µM Nylon mesh and 
stained them with an APC-conjugated antibody recognizing human CD45. After 
CD45 surface staining, we incubated the cells with a staining mix containing 
thiazole orange (TO) which labels all cells and PI which labels dead cells. 
Fluorescent BD Liquid counting beads were added to calculate absolute cells 
numbers. The viability of T-cell lymphoblasts was determined gating on CD45 






7.6.16 Retroviral and lentiviral constructs and viral production 
We created the retroviral construct pMSCV-HA-NR3C1 by cloning a pCMV-HA-
hGR BamHI-DraI fragment containing an HA tagged full length NR3C1 cDNA, 
into the pMSCV-puro vector [24].  Site-directed mutagenesis was performed 
using the Quickchange Site Directed Mutagenesis Kit (Stratagene, Windsor, ON, 
USA) according to the manufacturer‘s protocol. Ser 134 on hNR3C1 was 
replaced with alanine (S134A) in the pMSCV-HA-NR3C1-puro with the following 
primers: forward 5'- CTCAATAGGTCGACCGCCGTTCCAGAGAACCC-3' and 
reverse 5'-GGGTTCTCTGGAACGGCGGTCGACCTATTGAG-3'. Flag-tagged 
constitutively active AKT (pBabe-Puro-Myr-Flag-AKT1), which lacks its plekstrin 
homology domain but has a Src myristoylation signal seguence, was obtained 
from Addgene (plasmid number 15294).  PTEN knock-down was done using 
pLKO-shPTEN-GFP [182] and pLKO-shLUC-GFP was used as control. 
Retroviral particles driving the expression of EGFP (pMSCV IRES GFP), 
myristoylated AKT (pMSCV MYR-AKT IRES GFP), NR3C1 (pMSCV HANR3C1 
puro), NR3C1 S134A (pMSCV HA-NR3C1 S134A puro) were generated as 
previously described [207]. Lentiviral particles determining the knock-down of 
PTEN (pLKO shPTEN GFP) or the luciferase gene as control (pLKO shLUC-GFP) 
were generated according to standard protocols. Lentiviral particles expressing a 
luciferase and neomycin phosphotransferase fusion transcript were generated 
with the FUW-Lucneo vector [208]. Retroviral and lentiviral particles were 





7.6.17 Recombinant protein production 
To generate glucocorticoid receptor-GST fusion proteins we amplified the NR3C1 
cDNA by PCR and subcloned it in the pGEX4T-1 prokaryotic expression vector 
(Amersham Biosciences). We introduced a point mutation resulting in the NR3C1 
S134A substitution via site directed mutagenesis. We produced GST-NR3C1 and 
GST-NR3C1 S134A proteins in BL21 bacteria transformed with pGEX4T-1 
NR3C1 and pGEX4T-1 NR3C1 S134A vectors. We induced GST protein 
synthesis in bacteria with 0.2 mM isopropyl-b-D-thiogalactopyranoside (Sigma) 
for 5 hours at 30°C, then harvested the bacteria cells by centrifugation, and lysed 
them in modified BC-500 buffer (500 mM NaCl, 20 mM Tris-Cl pH=8.0, 20% 
glycerol, 1% Triton-X, 1mM EDTA, 0.2% NP-40) for 1h at 4°C. Cleared bacteria 
lysates were subsequently incubated with glutathione-Sepharose 4B beads 
(Amersham Biosciences) overnight at 4°C, and the glutathione-bead bound 
proteins were eluted by adding 15 mM glutathione in 50 mM Tris-HCl, pH=8.0. 
Finally, we removed glutathione by dialysis against PBS and analyzed the 
recombinant proteins for yield and purity by SDS-PAGE followed by Coomassie 
Brilliant Blue R-250 staining.  
7.6.18 Mice and animal procedures 
All animals were maintained in specific pathogen-free facilities at the Irving 
Cancer Research Center at Columbia University Medical Campus. Animal 
procedures were approved by the Columbia University Institutional Animal Care 
and Use Committee. Rosa26 Cre-Tam mice expressing a tamoxifen-inducible 





conditional knockout mice (Ptenfl) have been previously described [211]. To 
generate NOTCH1-induced T-ALL tumors in mice we performed retroviral 
transduction of bone marrow cells with an activated form of the NOTCH1 
oncogene  (NOTCH1 L1601P ΔPEST) and transplanted them via intravenous 
injection into lethally irradiated recipients as previously described [191]. Briefly, 
bone marrow cells were collected from the long bones of 6-9 week-old C57BL/6 
Rosa26 Cre-Tam Ptenflox/flox mice. Linneg cells were isolated using Lineage 
Depletion magnetic beads (Miltenyi Biotech). Purified cells were cultured in 
transplant medium consisting of Optimem (Gibco) supplemented with IL-3 
(10ng/ml), SCF (50ng/ml), IL-6 (10ng/ml) and 5% fetal calf serum overnight, ans 
spin infected by incubation in retroviral supernatant (MigR1-NOTCH1 L1601P 
ΔPEST) containing the same cytokine cocktail and 8 µg/ml polybrene and 
centrifuged at 2500 rpm for 90 minutes. A second round of spinoculation was 
performed after 24 hours. After washing with PBS, at least 50,000 Sca-1+GFP+ 
cells were injected intravenously into lethally irradiated (9.5 Gy) recipients. Mice 
were maintained on antibiotics in drinking water 2 weeks after bone marrow 
transplantation. Tumor bearing mice were euthanized and primary tumor cells 
extracted from the spleens of leukemic mice. These tumor cells were then 
infected with retroviral particles (MigR1 Cherry-LUC), expressing a fusion protein 
between the red cherry fluorescent protein and luciferase and re-injected in sub-
lethally irradiated mice (4 Gy).  After a 5 day window for tumor engraftment, 
secondary recipients of NOTCH1-induced Pten inducible conditional knockout 





with tamoxifen (5mg/mouse) (n=16), to induce deletion of the Pten locus  or 
vehicle only (n=16) by intra-peritoneal injection. After 1 week, Pten-non-deleted 
and Pten-deleted mice were analyzed by luciferase bioimaging [24] and 
segregated into groups of isogenic leukemias containing 8 animals each and with 
homogeneous tumor loads.  A control group of Pten-non-deleted animals and a 
control group of Pten-deleted mice were treated with vehicle (DMSO), while 
glucocorticoid treatment groups of Pten-non-deleted and Pten-deleted mice 
received escalating daily doses of 1mg/kg, 2mg/kg and 5mg/kg of 
dexamethasone. Each dose of dexamethasone was administered for three 
consecutive days. At the end of treatment all mice were monitored daily and 
animals showing overt signs of disease were euthanized following Institutional 
Animal Care and Use Committee guidelines. For intravenous transplantation 
model, we used sub-lethally irradiated C57BL/6 mice (Taconic Farms). We 
injected 2 million Pten deleted NOTCH1 L1601P PEST CHERRY-luciferase 
expressing cells via tail vein injection. After a 10 day window for tumor 
engraftment, we segregated mice with homogeneous tumor loads into treatment 
groups (7-10 mice per group) and treated them daily with vehicle (DMSO), 
dexamethasone (5 mg/kg via intraperitoneal injection), MK2206 (10 mg/kg via 
oral gavage twice a day) or dexamethasone (5 mg/kg) plus MK2206 (10 mg/kg) 
for 7 days. We evaluated disease progression and therapy response after 3 days 
of treatment by bioluminescence. For imaging studies, mice were anesthetized 
by isoflurane inhalation and injected with D-luciferin at 50 mg kg–1 (Xenogen) 





(IVIS, Xenogen) with a collection time of 5-60 seconds. Tumor bioluminescence 
was quantified by integrating the photonic flux (photons per second) through a 
region encircling each mouse as determined by the LIVING IMAGES software 
package (Xenogen). At the end of 7 days of treatment, the disease was allowed 
to progress and all mice were monitored daily and animals showing overt signs of 
disease were euthanized following Institutional Animal Care and Use Committee 
guidelines. 
CCRF-CEM xenograft experiments were performed with 7 to 9-week-old female 
NOG (NOD/scid/IL-2Rnull) mice (Taconic Farms).  We injected 5 ×106 CCRF-
CEM cells expressing luciferase via tail vein injection. After a 15 day window for 
tumor engraftment, we segregated mice with homogeneous tumor burdens into 
treatment groups (3-4 per group) and treated them daily with vehicle (DMSO), 
dexamethasone (5 mg/kg via intraperitoneal injection), MK2206 (10 mg/kg via 
oral gavage twice a day) or dexamethasone (5 mg/kg) plus MK2206 (10 mg/kg) 
for three days. We evaluated disease progression and therapy response by 
bioluminescence (see above), luciferase activity on isolated tumor cells and by 
flow cytometry (CD45 staining). 
For the transduction of primary T-ALL cells, freshly thawed primary T-ALL cells or 
tumor cells obtained from xenografts were infected with lentiviral particles 
expressing the red fluorescent protein CHERRY and luciferase (FUW-CHERRY-
puro-LUC) by single spinoculation on retronectin coated plates. Twenty-four 
hours after transduction primary cells were injected intravenously into NOG 





ALL cells were euthanized and primary tumor cells extracted from the spleens of 
leukemic mice. Subsequently, 5-8 ×106 TALL cells were injected intravenously in 
NOG recipient mice. Leukemia progression was assessed by flow cytometry of 
mouse peripheral blood using anti-CD45 antibodies and bioimaging. When >30% 
human cells were detectable in blood and saturating photon emission was 
recorded with a collection time of 1 minute, animals were randomized into 4 
treatment groups (n=4-5) and treated daily with vehicle (DMSO), dexamethasone 
(5 mg/ kg via intraperitoneal injection), MK2206 (10mg/kg via oral gavage twice a 
day) or dexamethasone (5 mg/kg) plus MK2206 (10 mg/kg) for 4-5 days. We 
evaluated disease progression and therapy response after 3-5 days of treatment 
by bioluminescence.  
7.6.19 Statistical analyses 
We performed statistical analysis by Student‘s t-test. We considered results with 
P <0.05 as statistically significant. We analyzed drug synergism using the 
median-effect method of Chou and Talay [212] and used the CalcuSyn software 
(Biosoft, Great Shelford, Cambridge, UK) to calculate the combination index (CI) 
and perform isobologram analysis of drug interactions. CI values below 1, equal 
to 1, and above 1 represent synergism, additivity, and antagonism, respectively. 
The isobologram is formed by plotting the concentrations of each drug required 
for 50% inhibition (ED50) on the x-and y-axes, respectively, and connecting them 
to draw a line segment, which is ED50 isobologram. Combination data points that 
fall on, below and above the line segment represent additivity, synergy, and 





Kaplan–Meier curves and significance was estimated with the log-rank test 
(Prism GraphPad). 
 






Table 7-1 All predicted signaling drivers of GC-resistance by NetBID2 with 






Table 7-2 Gene Expression Signature of Glucocorticoid Resistance (10 Resistant 





7.7 GC-Responsive Signature of After vs. Before Treatment to 
Sensitive T-ALL Patients 
In addition to the expression profiles of GC-resistant and sensitive primary 
patients before treatment which we used to identify AKT1 as a signaling driver of 
resistance by NetBID2, we also had microarray data of GC-sensitive T-ALL 
patients before and after treatment at 6h or 8h and 224h [213]. With this 
information, we generated a signature of GC response by coming expression 
change at 6h or 24h vs. 0h (Figure 7-26). And then we applied NetBID2 to 
identity master regulators or signaling modulators that control GC-responsive 
signature genes. The drivers of early (6 or 8h) and late (24h) response to 
glucocorticoid show signature overlaps (Figure 7-27). 
 






Figure 7-27 Comparison of drivers regulating or modulating early (6 or 8h) and 
late (24h) responsive signature genes in GC-sensitive T-ALL patients. Sign of 
drivers is taken into consideration. Fisher‘s exact test is used to the significance 
of overlaps. 
We also checked the overlap of GC-responsive drivers, using signature 
treatment after 6h or 24h vs. before treatment in sensitive patients, with GC-
resistant drivers, using signature of resistant vs. sensitive patients before 
treatment. Interestingly, there is a significant overlap between resistant drivers 
with early (6h) responsive drivers, but not with late (24h) responsive drivers 
(Figure 7-28). This may suggest that drivers that are involved in resistance 






Figure 7-28 Overlap of TF master regulators for GC-Resistance and GC-
Response (6h or 24h). Fisher‘s exact is used to test overlap significance. 
7.7.1 NetBID2 identifies AKT1 as driver of GC-responsive signature 
NetBID2 identifies AKT1 (P<0.001) and AKT2 (P=0.024) as drivers of early (6 or 
8h) GC-responsive signature genes (Figure 7-29), but not as drivers of late (24h) 
responsive signature genes. This confirms the role of AKT1 or entire AKT 
pathway in glucocortoid regulatory signaling pathway, which might explain its 






Figure 7-29 NetBID2 identifies AKT1 (P<0.001) and AKT2 (P=0.024) as drivers 
of early (6 or 8h) GC-responsive signature genes, but not as drivers of late (24h) 
responsive signature genes. 
7.8 Preliminary Results of Crossing Signaling Drivers with 
RNAi Screens 
In the next chapter, we will discuss the integration of NetBID2-predicted drivers 
with functional RNAi screening to identify potential therapeutic targets for 
reversal of GC-resistance, however, in the next chapter we will only focus on 
validation of transcription factor-type drivers while this chapter focuses on 





with shRNA-screened candidates because signaling molecules tend to be 
druggable. We checked the overlap of NetBID2-inferred signaling drivers with 
RNAi screening of two resistant T-ALL cell lines (Table 7-3) and selected 
candidates are to be validated by our collaborator. Here I only show you partially 
results relevant to AKT, the major focus of this chapter. 
7.8.1 AKT1 doesn’t show up from shRNA screening as a candidate 
We computationally predicted and validated AKT1 as a therapeutic target to 
reverse GC-resistance in T-ALL. We asked whether it also shows up from 
shRNA screening. However, two hairpins targeting AKT1 in GIPZ library 
demonstrate no significant depletion of sh-AKT1 in the screens of both resistant 
cell lines. It‘s even worse that in CUTLL1, it shows some anti-evidence. However, 
one hairpin targeting AKT2 showed significant depletion in CUTLL1, but no 
evidence in HPBALL. This might be because the quality of shRNAs targeting 
AKT1 or AKT2 is not good and might also reflects the noisy nature of shRNA 






Figure 7-30 shRNA screening results of AKT1 and AKT2 in two GC-resistant cell 
lines. 
7.8.2 PRKAR1A in PI3K pathway shows up in both driver prediction and 
shRNA screens 
PRKAR1A, as shown in Figure 7-31, is a key downstream player of PI3K 
pathway, which is parallel to AKT to trigger apoptosis pathway. It is predicted by 
NetBID2 as a driver of GC-resistance and hairpins targeting PRKAR1A shows 
significant depletion in both resistant cell lines, making it a very interesting 
therapeutic target to reverse resistance. It might be an alternative to AKT 












Table 7-3 Candidates of integrating top signaling of drivers of with RNAi 





Chapter 8 Integrating Functional Genomics with Systems 
Biology on Discovering Therapeutics to Reverse 




Glucocorticoid (GC) resistance is strongly associated with poor prognosis in 
childhood acute lymphoblastic leukemia. We applied Genome-wide RNA 
interference (RNAi) screens, a powerful tool for systematic loss-of-function 
studies, to search for new therapeutic targets to reverse GC-resistance. However, 
due to high false positive rates of screen data, additional knowledge was needed 
to select candidates. In this study, we developed an integrative system biology 
framework, by complementing RNAi screen data with a computational algorithm 
inferring regulatory drivers of phenotypes, to identify therapeutic candidates for 
GC-resistant T-cell Acute Lymphoblastic Leukemia (T-ALL).  The phenotype 
driver prediction algorithm (NetBID2) was based on a computationally assembled 
T-All specific transcriptional network from a large collection of gene expression 
profiles and Markov chain Monte Carlo based Bayesian modeling techniques.  
Our framework identified 16 transcription factors, when repressed, sensitize GC 
resistant cells. Out of 16 candidates, 13 were validated in vitro, and 10 
                                            





outperformed positive controls (NOTCH1 and MCL1). Moreover, 75% of 
computationally predicted drivers demonstrated significant effects on GC-
sensitivity in vitro. Network analysis of validated targets discovered that they 
formed three well-connected subnetworks and might work cooperatively to 
induce resistance. Particularly, we identified TRIM28 as a critical master 
regulator of GC-resistance and a TRIM28-modulated mechanical regulatory 
subcircuit that gave insights on potential synergistic therapeutic strategies to 
rescue GC-sensitivity in T-ALL. 
Keywords: glucocorticoid resistance, T-ALL, RNAi screen, regulatory driver, 
Bayesian, MCMC, systems biology 
8.2 Introduction 
Glucocorticoids (GCs) play a fundamental role in the treatment of all lymphoid 
tumors due to their capability to induce apoptosis in lymphoid progenitor cells [18, 
19, 149]. Resistance to glucocorticoids is strongly associated with unfavorable 
prognosis in childhood acute lymphoblastic leukemia (ALL). Majority of ALL 
patients in relapse show increased resistance to GC-therapy [153, 154, 214]. 
Different molecular mechanisms have been elucidated for GC-resistance in ALL, 
including loss-of-function mutations in the glucocorticoid receptor (GR) gene, loss 
of GR auto upregulation, expression of GR splice variants, and upregulation of 
antiapoptotic pathways [20, 164, 166, 168, 171, 172, 215-219]. Correspondingly, 
several therapeutic strategies have been proposed to overcome GC-resistance 





However, due to strong toxicity of existing therapeutics [179], reversal of GC-
resistance remains a  clinical challenge and new therapeutic strategies are much 
needed. 
Genome-wide RNA interference (RNAi)-mediated genetic screen has emerged 
as a powerful tool for systematic loss-of-function studies in mammalian cells [50-
53].  This technology can be applied to identify genes that form synthetic lethal 
interactions with glucocorticoids in resistant cells, thus making potential 
therapeutic targets to overcome GC-resistance. However, due to a high false 
positive rate arising from high throughput noise and off target effect, additional 
knowledge and powerful analysis tools are needed. 
We have shown that computationally inferred context-specific maps of 
transcriptional or post-translational molecular interactions from large-scaled gene 
expression profiles (GEPs) allow the elucidation of cryptic driver proteins whose 
gain or loss is necessary and sufficient for tumor initiation or progression [70-73]. 
Such master regulators are more robust than traditional signatures to distinguish 
phenotypes [69]. Therefore, we suggest that systematic inference of driver-type 
regulators from genomic data complementing with RNAi screen technology will 
give a more comprehensive molecular understanding of mechanisms of GC-
resistance and provide novel targets for therapeutics. 
We developed a framework, NetBID2, as detailed in Chapter 4, to infer disease 
drivers from gene expression data based on computationally-assembled 





Markov chain Monte Carlo (MCMC) based Bayesian modeling techniques. 
Integrating RNAi screens of GC-resistant cells with NetBID2 algorithm identified 
16 transcription factors that, upon silencing, sensitize GC resistant T-ALL cells, 
out of which 13 were validated in vitro and 10 outperformed positive controls 
(NOTCH1 and MCL1). Moreover, 75% of computational-predicted regulatory 
drivers changed sensitivity of resistant cells in vitro. Network analysis of validated 
targets discovered that they formed three well-connected subnetworks and might 
work cooperatively to induce resistance. Particularly, we identified TRIM28 as a 
super master regulator and a TRIM28-centered mechanical regulatory subcircuit 
that gave insights on potential synergistic therapeutic strategies to rescue GC-






Figure 8-1 The framework integrating genetic RNAi screen with genomic 
inference of phenotype drivers to identify therapeutic targets for reversal of GC-
resistance upon repression. 
8.3 Methods 
8.3.1 Reverse engineering transcriptional regulatory network of T-ALL 
To generate a T-ALL transcriptional network we processed microarray gene 





GC-RMA normalization and cleaned the dataset to 21,054 probe sets with non-
specific filtering. Then we ran the ARACNe algorithm [111] with default 
parameters against 2007 probes corresponding to 1073 TFs to establish a TF-
centered interactome. 
8.3.2 Signature analysis of GC-resistance 
Out of the 223 samples with GEPs, 22 were diagnosed as GC-resistant and 10 
as sensitive. To generate a reference signature of these two phenotypes, part of 
our regulatory driver inference algorithm, we used a Probit regression model [89] 
(Figure 8-2) for its advantage of detecting weak effects. Bayesian-MCMC 
computing was employed to estimate parameters for its robustness and accuracy. 
In particular, a t-distribution prior and Gibbs sampling were used in this analysis 
[90]. 
8.3.3 GSEA of inferring regulatory drivers of GC-resistance 
For GSEA method to predict regulatory drivers of GC-resistance, we used a 
―maxmean‖ statistic [98] as enrichment score and 1,000 sample permutations to 






Figure 8-2 Distribution setup (left) and graphical representation (right) of Probit 
model used for assessing association of phenotypes (GC-resistant or GC-
sensitive) with gene expressions. Nodes in solid square are observation 
variables, in solid eclipse with white background are direct parameters of Probit 
model, in dashed eclipse are latent variables and the others are hyper-
parameters for priors. Y is an indicator variable for phenotypes, X is expression 
level of gene X, Z is a latent variable in Probit model. Inside the white box is 
likelihood section, while outside is for priors. Parameters are estimated by a 
Gibbs sampling procedure.  
8.3.4 Pooled shRNA screening 
We made use of the shRNAmir library [51], comprising 51,830 shRNAs targeting 
12,049 genes. High titer lentiviral pools were prepared and two GC-resistant cell 
lines – CUTLL1 and HPBALL were infected. The infected cells were selected 
with puromycin (1ug/ml) for 5 days. For each infected line we treated three 





1μM). Cell cultures were maintained in exponential growth and in the presence of 
fresh drug. Genomic DNA was extracted from samples collected after 5 weeks of 
treatment. PCR amplification was performed on the barcodes associated with 
each shRNA vector. To ensure homogeneous sampling of the library, 48 
individual PCR reactions containing 2 μg of genomic DNA each were performed. 
PCR products were gel purified, fluorescently labeled with Cy3 and hybridized in 
a custom Agilent DNA microarray together with a Cy5-labeled reference sample 
containing normalized amounts of all barcodes in the library.  
8.3.5 Differential representation analysis of individual shRNA 
To assess the effects on reversal of GC-resistance by individual shRNA, we 
compared abundance of shRNA in DEX-treated with DMSO control using a linear 
model. Bayesian-MCMC procedures were applied to overcome small sample 
size issue and to obtain robust estimation of parameters. 
8.3.6 Integration of multiple shRNAs targeting the same gene 
To estimate the overall effects of a gene targeted by multiple shRNAs on GC-
sensitivity, we applied a hierarchical modeling approach [89]. This model allowed 
―random effects‖ from different shRNAs, and coefficient of ‗fixed effects‘ was 
used to score capability of increasing sensitivity at gene level. Bayesian-MCMC 





8.3.7 Combining differential representation scores of two cell lines 
To identify genes that are depleted or enriched in both RNAi-screened cell lines, 
we used Stouffer‘s z score method [107] shown in the following formula. 
  
        
√ 
    (   ) 
For each gene, ZCU and ZHPB were its differential representation scores in 
CUTLL1 and HPBALL respectively, which followed a standard normal distribution. 
Combined two-tailed p value was calculated based on integrated Z score. 
8.3.8 Silencing by siRNA and cell apoptosis assays 
To validate 46 predicted candidates, we used siRNA (Dharmacon) to knock-
down testing genes. KOPTK1, a GC-resistant cell line, was electroporated with 
the siRNAs using the amaxa system (Lonza, SF solution CM 150). After 24 hours 
of electroporation cells were treated in triplicate either with DEX (100nM) or 
DMSO. After 48 hours of treatment apoptosis was analyzed by annexin, PI 
staining (BD Biosciences). NOTCH1 and MCL1 were used as positive controls, 
and two non-silencing siRNAs as negative controls. Linear modeling similar to 
individual shRNA analysis of RNAi screen was applied to analyze these 
apoptosis readouts. Two negative controls were taken average to be compared 






8.4.1 The framework integrating RNAi screens with regulatory driver 
inference by NetBID2 identifies sixteen potential therapeutic targets 
As shown in Figure 8-1, we developed an integrative framework to identify driver-
type therapeutic targets to overcome GC-resistance in T-ALL. First, we 
performed genome-wide, pooled short hairpin RNA (shRNA) screening on 
resistant T-ALL cell lines exposed to GCs. This negative genetic screen mainly 
aimed to identify under-represented shRNAs in GC-treated cells, whose targeting 
genes increased GC sensitivity. Second, we studied GEPs of large-sampled 
primary T-ALL patients to build a Transcription Factor (TF) centered T-ALL 
regulatory network using a well-developed algorithm, ARACNe [111]. Then we 
utilized phenotypic information, i.e. GC-resistant or sensitive, to perform 
signature analysis studying association between gene expression and GC-
resistance. Instead of identifying classical signature genes that were not robust to 
characterize phenotypes [69], we developed an algorithm to discover uplevel 
regulatory drivers of GC-resistance. Our reasoning was that if a TF induces GC-
resistance, its regulons inferred from the network should be enriched either 
among overexpressed or underexpressed genes in GC-resistant samples or both. 
Gene Set Enrichment Analysis (GSEA) was used for this analysis. Subsequently, 
we overlapped depleted genes in shRNA screen with inferred regulatory drivers 





Genome-wide shRNA screens on two resistant T-ALL cell lines (CUTLL1 and 
HPBALL) identified 1,900 genes that were significantly depleted (P<0.05) in at 
least one cell line. Based on GEPs of 223 primary samples [220], we obtained a 
transcriptional interactome centered by 1,073 TFs (2,007 probe sets) comprising 
21,035 transcripts and 373,327 interactions. Our regulatory driver inference 
algorithm yielded 126 TFs showing significant evidences (set size>40, P<0.05) 
as master regulators of controlling signature genes of GC-resistance, out of 
which 81 had data in shRNA screens. Finally, by crossing the two candidate sets 
(Figure 8-3-A), we obtained 16 regulatory drivers (Table 8-1) as potential 
therapeutic targets with the potential to reverse GC-resistance in T-ALL when 
silenced. 
 
Figure 8-3 Summary of candidates from RNAi screening or genomic inference. 





shRNAs in RNAi screening. B-D display the distribution of 81 TF drivers (blue 
bars) and 26 validated ones (red bars) in RNAi screening results. All 12,049 
genes are ranked from most depleted (left) to most enriched (right) using 
differential representation score (z score) at gene level in combination of two cell 
lines (B) or individual cell line (C-D). Similar summary by considering only TF 
genes in RNAi screening is shown in Figure 8-4. 
 
Figure 8-4 Similar summary with Figure 8-3, but considering only TF genes in 
RNAi screen. 
8.4.2 13 of 16 candidates, when repressed, reverse GC-resistance in vitro  
To validate these 16 candidates, we performed in vitro experiments by knocking 
down candidate genes in resistant cells and measuring cell apoptosis after being 





increase cell death of resistant cells. As summarized in Figure 8-5-A, all 
candidates including controls were ranked by the capability to reverse GC-
resistance. Remarkably, 13 out of 16 showed significantly increase in apoptosis 
of resistant cells. Moreover, 10 out of 13 genes were more effective than positive 
controls, NOTCH1 and MCL1, that were previously shown to reverse GC-
resistance [24, 175]. Additionally, as shown in Figure 8-5-B, top candidates 
(CC2D1A, WHSC1, ZHX2) showed up to 15% increase in apoptosis comparing 
to negative controls. All 16 predicted targets showed consistent directions with 






Figure 8-5 Validation results in vitro of 16 overlapped candidates. (A) 16 
candidates (in red) together with positive controls (in blue) and negative controls 
(in green) are ranked by the score (central dot) for capability to reverse GC-
resistance upon silencing with uncertainty (range line crossing the central dot, 
thick line for one standard deviation, thin line for two standard deviations 





is associated with calibrated p-value: dark red for P<0.005, red for P≈0.05. (B) 
Bar plots of apoptosis level induced by combined treatment of RNAi with DEX (in 
red), and control, RNAi with DMSO (in light blue) for 16 predicted candidates, 
positive controls (labeled in red) and negative controls (labeled in blue). All genes 
are ranked the same as in panel A. The label on top of bar plot represents the 
increased apoptosis level of candidate gene comparing with average of negative 
controls (normalized by its own DMSO control and averaged over triplicates) and 
associated statistical significance level (*** for P<0.005, * for P≈0.05). 
This result with a prediction rate of 81.3% confirmed the power of our framework 
integrating RNAi screen with systematic analysis of genomic data to identify 
therapeutic targets. If we only used pooled shRNA screening and ranked all 
genes by ability to sensitize resistant cells from most depleted to most enriched 
in GC-treated case (Figure 8-3-B, C, D), the top three candidates validated in 
vitro only ranked 89th, 296th, 595th respectively (Figure 8-3-B), and among top 10 
validated candidates, only two ranked within top 50, more precisely, in 44th and 
46th. This suggested that high-throughput RNAi screen itself might not be 
sensitive and accurate enough to discover positive therapeutic targets, and our 






Table 8-1 Overlapped 16 candidates between RNAi screening and genomic 





8.4.3 75% of top genomics-Inferred drivers show significant effects to 
change GC-sensitivity in vitro 
In addition to validating overlapped candidates with depleted genes in RNAi 
screen, we also tested computationally identified regulatory drivers of GC-
resistance from genomic data, because rescuing sensitivity may be achieved by 
both repressing and activating genes. We selected top 30 additional inferred 
drivers (Table 8-2) and performed the same in vitro experiments. Twenty three 
out of thirty genes, when knocked down, showed significant effects to either 
increase (n=8) or decrease (n=15) apoptosis of GC-exposed resistant cells 
(Figure 8-6). Out of the eight targets that increased apoptosis, five had no 
significant evidences from RNAi screen and three were not included in the 
shRNA library. Among the 15 targets that decreased apoptosis, effect of 
knocking down ATF6 (Figure 8-8) was consistent with RNAi screen finding while 
the other 14 genes either had no significant support (n=7) from RNAi screen or 
had no shRNA targeting them (n=7). The overall prediction rate of our algorithm 






Figure 8-6 Validation results in vitro of top 30 additional genomics-predicted 
regulatory drivers of GC-resistance. (A) 30 candidates classified into no data (in 
brown-yellow), no significant evidence (in blue) and significantly over-
represented (in purple) from RNAi screen, together with positive controls (in blue) 
and negative controls (in green) are ranked by the score for capability to reverse 
GC-resistance upon silencing with uncertainty. Extra annotations in panel A and 





8.4.4 Validated targets work cooperatively by forming well-connected 
subcircuits 
Within 36 validated drivers of GC-resistance showing effects in vitro on sensitivity, 
we hypothesized that these key regulators might work cooperatively to induce 
GC-resistance. To test this hypothesis, we pulled out these candidates and their 
interactions from our assembled transcriptional T-ALL interactome. As shown in 
Figure 8-9, these  regulatory drivers were separated into three well-connected 
subgroups  denoted as A, B, and C. Size of the node represented their regulating 
targets in the  network, while color indicated that downregulation of this gene 
increased (blue) or decreased (red) apoptosis of GC resistant cells. 
Interestingly, candidate genes that had similar effects, especially increased 
resistance when silenced, tended to cluster together. For example, in component 
A, MYBL2, TRIM28, CXXC1 formed a clique and connected closely with E2F1, 
E2F2, KDM1A, and CIZ1. This indicated that these red nodes worked 
cooperatively as a key regulatory circuit to repress GC-resistance in T-ALL. This 
circuit might be a promising targeted unit to overcome GC resistance upon 
overexpression. Similarly, UBE2K and ZNF320 in component B, TCF3 and 
HMGB20 in component C represented two additional regulatory units responsible 






Figure 8-7 RNAi screening results and GSEA plots of CC2D1A and WHSC1, the 
top two validated targets in vitro.  
 
Figure 8-8 RNAi screening result and GSEA plot of ATF6, showing the strongest 






8.4.5 TRIM28 is a critical master regulator of GC-resistance in T-ALL 
The subnetwork of our candidates identified TRIM28 as a critical master 
regulator of GC-resistance in T-ALL. Firstly, TRIM28 was one of the biggest hub-
type regulatory drivers among all candidates. It regulated 377 genes in our 
inferred transcriptional regulatory network. Secondly, eight of TRIM28 regulating 
genes (MYBL2, CXXC1, KDM1A, CIZ1 in red, WHSC1, CC2D1A, MTA1, 
SREBF2 in blue) were also confirmed to reverse GC-resistance, making TRIM28 
as the largest hub in this subnetwork.  Our finding was confirmed by several 
studies that TRIM28 epigenetically regulated a broad spectrum of genes and was 
involved in GR activities [221, 222]. 
8.4.6 Silencing TRIM28 increases GC-resistance by down-regulating GR 
In subnetwork of validated targets (Figure 8-9), all interactions between red and 
blue nodes except MYBL2-FOXP1 were positively correlated. However, silencing 
them individually demonstrated opposite effects: This indicated that additional 
pathways were involved to cause these unexpected effects. One possible 
mechanism we found was that TRIM28, the critical regulator of GC-resistance, 
upregulated GR, or was required for GC-induced activities by interacting with GR. 
As shown in Figure 8-10, we recovered direct interactions between TRIM28 and 
NR3C1 or TRIM28 and BUD31 that were removed falsely by Data Processing 
Inequality in ARACNe algorithm [111].  It was observed that TRIM28 activated 
GR via a feed forward loop with BUD31. Validation results suggested that 





and CXXC1 would be sufficient to suppress GR expression, and therefore further 
reducing the sensitivity of resistant cells. 
 
Figure 8-9 Subnetwork from T-ALL interactome of candidates that are validated 
in vitro either to increase (blue nodes) or decrease (red nodes) sensitivity when 
silenced. A, B and C are three well-connected components covering only direct 
interactions among these candidates. Nine isolated effective candidates that 
have no direct interactions with other candidates are not shown. The size of node 
is proportional to the size of its regulons or first neighbors from T-ALL 
interactome. Edge in red is for positive correlation of two interactants, while blue 






Figure 8-10 A TRIM28-centered subnetwork for a novel mechanism of GC-
resistance and a synergistic strategy to overcome resistance. The left square-like 
part is extracted from Fig 5.1 including the top 3 best validated targets (blue 
nodes) and the clique of TRIM28 (red nodes). The right triangle-like part is from 
T-ALL regulatory network illustrating the mechanism of TRIM28 upregulating 
NR3C1 via a feed forward loop. Number on edge represents the mutual 
information between expression levels of two interactants. Dashed edges are 
recovered from false removals by DPI in ARACNe35 algorithm. 
Considering the top three most effective targets CC2D1A, WHSC1 and FOXP1, 
we inferred a transcriptional subcircuit from T-ALL interactome and validation 
results (Figure 8-10). We removed the direction from WHSC1 or CC2D1A (Figure 
8-7) to the triple-clique of TRIM28 based on the observation that repressing 
CC2D1A or WHSC1 had no effects to upregulate GR. This subnetwork might 





therapeutic target. In particular, inhibition of CC2D1A, WHSC1 or FOXP1 already 
demonstrated extraordinary capabilities to sensitize resistant cells. 
8.5 Discussion 
We demonstrated that integration of genome-wide RNAi screen and our 
computational framework to infer regulatory drivers of phenotypes was a 
powerful strategy to discover novel therapeutic targets. Out of 16 overlapped 
candidates from two approaches, 13 showed significant effects on reversal of GC 
resistance upon repression in vitro. Among them, 10 demonstrated stronger 
capabilities to sensitize resistant cells comparing to previously discovered targets. 
Moreover, 75% of top predicted drivers (Figure 8-11) showed effects on changing 
drug sensitivity when silenced. Network topology of all 36 effective targets 
identified three well-connected regulatory subcircuits that might shed lights on 
new mechanisms of GC-resistance and novel pathways as therapeutic targets 
(Table 8-5). 
RNAi screening itself usually gave a long list of candidates with a high false 
positive rate due to off-target effects, small sample size, and noise of microarray 
measurements. For example, our screens identified 1,900 candidates at gene 
level (5,851 at individual shRNA level for 4,783 genes) significantly depleted 
(P<0.05) in at least one cell line (Figure 8-3-A, Table 8-4). Sophisticated 
statistical approach such as Bayesian-MCMC method, or multiple test correction 
and stringent threshold would not solve the problem. The top 5 candidates from 





screen result starting from the most depleted gene, and the best rank of working 
candidates was 19th (Figure 8-3, Table 8-3).  Moreover, 8 predicted regulatory 
drivers from genomic analysis showed significant effects to reduce resistance, 
but there was no evidence from RNAi screen. Besides, shRNAs in the screening 
library did not target all the genes in human genome. For example, out of 23 
candidates validated in vitro, 10 had no shRNAs in the library. Overall, we 
confirmed that RNAi screen might not be sensitive enough to work alone (Figure 
8-3-B, C, D). 
Our inferred regulatory drivers of GC-resistance by NetBID2 showed much 
higher robustness and predictability than signature genes as therapeutic targets. 
Out of 21 effective candidates, only one gene-ZNF770, fell in the signature list 
(P<0.05) of being overexpressed in GC-resistant samples (Table 8-2, Table 8-3).  
There were limitations of our algorithm. For example, we did not identify 
NOTCH1, which was previously shown to reverse GC-resistance upon inhibition 
[24]. One reason might be that our framework assumed activity of a TF could be 
inferred from its transcriptional expression However, NOTCH1 transcriptional 
level did not correlate to protein expression [181]. RNAi screen result did not 
identify NOTCH1 either. Secondly, we only focused on TFs in this study, while 
other types of therapeutic targets such as signaling molecules or anti-apoptotic 
proteins were not included. Signaling proteins might be interesting to us in the 
future due to their potency as drug targets.  We also tested enrichment of our TF 





(Figure 8-3, Figure 8-4), but there was no statistical significance (all Ps>0.1). This 
suggested that other functional groups should be considered for seeking 
therapeutics. 
Moreover, our approach could infer key regulators for GC-resistance but could 
not accurately predict the direction in relation to convert GC resistant phenotype. 
RNAi screen would show the correct directions, thus integrating two approaches 
would provide a much more powerful tool to predict therapeutic targets. 
From the subnetwork of effect candidates (Figure 8-9), we observed that all blue 
node targets were well separated from red ones by sitting either upstream or 
downstream. This suggested these starting or ending blue proteins might 
modulate different subprograms that contributed to diverse mechanisms of GC-
resistance in T-ALL, thus shedding light on multiple therapeutic strategies to 
reverse GC-resistance. For example, a subnetwork of WHSC1, E2F7, and 
HMGB1 in Figure 8-9-A might be an interesting therapeutic targeting program to 
sensitize resistant cells by RNAi. 
Our network analysis identified TRIM28 as a hub master regulator of GC-
resistance in T-ALL. Its centered subcircuit might represent a novel resistant 
mechanism. We showed that knock-down of TRIM28 induced more resistance 
due to subsequent downregulation of NR3C1 thus its low expression causing low 
production of GR that was required by glucocorticoids to induce downstream 
apoptosis. This also suggested that TRIM28 was required for GR activities, in 





each other [222]. Similar effects were also observed when silencing two other 
TRIM28 positively-correlated candidates, MYBL2 and CXXC1. However, 
overexpressing TRIM28 might not work either to reverse GC-resistance. 
Upregulation of TRIM28 would overexpress WHSC1 and CC2D1A which were 
required at low expression to rescue sensitivity. Topology of TRIM28 subnetwork 
indicated that down-stream players including FOXP1, WHSC1 and CC2D1A 
were more likely to induce resistance than their upstream regulators, and they 
may work synergistically to induce resistance. This leads to a potential 
combination therapy.  
We observed dramatic difference between two RNAi-screened cell lines (Figure 
8-3-C, D), probably due to heterogeneity of resistance mechanisms. Simply 
overlapping two cell lines for potential targets would lose a lot of true positives, 
therefore we considered candidates showing evidence in at least one cell line. 
Validations on a third cell line confirmed our strategy: 5 out of 13 validated 
targets including the top 3 came out in only one screened line. 
Successful validation in a separate cell line of 75% genomics-inferred regulatory 
drivers demonstrated the power and robustness of our computational framework. 
However, the non-validated candidates in the cell line didn‘t mean that they were 
not important for GC-resistance. For example, SMARCA4, one of our candidates 
showing up in both RNAi screening and genomic analysis, was a key component 
of SWI/SNF complex that mediated chromatin remodeling and was required for 





associated with GC-resistance, but its knock-down only worked on some cell 
lines to reverse GC-resistance [223], in consistent with our finding. It might be 
because of its dependence on other factors. Thus searching for cofactors or 
synergistic therapeutic targets would be needed in future to overcome 
complicated GC-resistance in T-ALL. 
 
Figure 8-11 Validation results in vitro of all 46 selected genomics-predicted 
regulatory drivers of GC-resistance. (A) 46 candidates classified into no data (in 
brown-yellow), no significant evidence (in blue) and significantly over-
represented (in purple) from RNAi screen, together with positive controls (in blue) 





GC-resistance upon silencing with uncertainty. Extra annotations in panel A and 
B are the same with Figure 8-5. 
 
Table 8-2 Additional top 30 computationally-identified regulatory drivers of GC-





















Table 8-5 Top enriched KEGG pathways by depleted TF genes in RNAi screens 





Chapter 9 Integrating Functional Genomics with Systems 





The ERBB2/HER2 amplified breast cancers, accounting for approximately 30% 
of human breast cancer patients, has the worst survival and prognosis among all 
subtypes of breast tumors. The development of anti-HER2 therapeutic agents 
such as Herceptin has significantly altered the treatment of this disease in clinic. 
However, despite the clinical benefits of these HER2-targeted therapies, all 
HER2+ patients will eventually develop resistance to this therapy, in which about 
50% are initially resistant to Herceptin, whereas the other half that respond to 
Herceptin will develop resistance within 1 to 2 years of treatment. In this study, to 
identify alternative therapeutic targets for HER2-amplfied breast tumors, we used 
a genetically-engineered model cultured in 2D, 3D and in vivo xenograft 
environments and developed a framework to integrate genome-wide RNAi 
screens with NetBID2, a systems biology algorithm of inferring disease drivers 
from gene expression data. With the integrative approach, we discovered that 
STAT3 as a driver-type therapeutic target for HER2+ breast cancers, and we 
                                            





biochemically validated, both in vitro and in vivo, that silencing STAT3 is indeed 
an effective therapeutic target to stop growth of HER2+ tumor cells. Also from 
analysis of primary tumor samples, we demonstrated that STAT3 inhibition for 
killing HER2+ breast cancers has a dependence on ER- subpopulation. We also 
identified downstream targets of STAT3 that are involved in HER2-triggered 
tumor transformation and are also potential therapeutic targets.  
9.2 Introduction 
The ERBB2/HER2 oncogene is overexpressed in approximately 30% of human 
breast cancer patients due to constitutive amplification [224]. HER2+ subtype has 
the worst survival and prognosis in breast cancer population [225]. The 
development of anti-HER2 therapeutic agents, such as trastuzumab (also known 
as Herceptin) and two other drugs – pertuzumab and lapatinib – have 
significantly altered the treatment of this disease in clinic. Despite the clinical 
benefits of these HER2-targeted therapies, however, about 50% of breast cancer 
patients with HER2-amplification have no response to Herceptin, and almost the 
other 50% patients that respond to Herceptin eventually develop resistance 
quickly, usually within 1 to 2 years after treatment [226, 227]. Therapeutics 
aiming to overcome resistance has been proposed such as targeting AKT 
pathway based on the mechanism that tumor suppressor PTEN is loss in over 40% 
of HER2+ breast cancer [228], or blocking Interleukins 6 (IL6) feedback loop 





chapter, we are searching for alternative therapeutic targets for HER2-amplfied 
breast tumors instead of reversing resistance of anti-HER2 agents. 
Genome-wide RNAi screening has emerged as a powerful tool for systematic 
loss-of-function studies in mammalian cells [50-53] that may lead to cancer 
therapeutic target discovery.  This technology can be applied to identify genes 
that form synthetic lethal interactions with ERBB2 in HER2+ breast tumor cells, 
thus making potential therapeutic targets for HER2+ subpopulation of breast 
cancers. However, due to a high false positive rate arising from high throughput 
noise and off target effect, additional knowledge and powerful analysis tools are 
needed. 
We have shown that computationally inferred context-specific maps of 
transcriptional or post-translational molecular interactions from large-scaled gene 
expression profiles (GEPs) allow the elucidation of cryptic driver proteins whose 
gain or loss is necessary and sufficient for tumor initiation or progression [70-73]. 
Such master regulators are more robust than traditional signatures to distinguish 
phenotypes [69]. Therefore, we suggest that systematic inference of driver-type 
regulators from genomic data complementing with RNAi screen technology will 
give a more comprehensive molecular understanding of mechanisms of HER2+ 
breast tumors and provide novel targets for therapeutics. 
We developed a framework, NetBID2, as detailed in Chapter 4, to infer disease 
drivers from gene expression data based on computationally-assembled 





Markov chain Monte Carlo (MCMC) based Bayesian modeling techniques. In 
parallel, we performed pooled shRNA screens on a genetically-engineered model 
by introducing ERBB2 overexpression in MCF10A cells, using both microarray 
and deep sequencing techniques. We also cultured the cells in 2D, 3D and in 
vivo xenograft environments.  Integrating NetBID2 prediction of drivers for 
HER2+ breast cancers using expression profiles of the isogeneic model with a 
panel of genome-wide shRNA screens identified three candidates – STAT3, 
AGRN, and GLRX – that are driver-type lethal proteins to HER2-induced tumors. 
With a focus on STAT3, we confirmed that STAT3 is required for HE2-induced 
tumorigenesis and we biochemically validated, both in vitro and in vivo, that 
silencing STAT3 is indeed an effective therapeutic target to stop growth of 
HER2+ tumor cells. Also from analysis of primary tumor samples, we discovered 
that STAT3 inhibition for killing HER2+ breast cancers has an addiction to ER- 
subpopulation. We also identified downstream targets of STAT3 that are involved 
in HER2-triggered tumor transformation and are also potential therapeutic targets.  
9.3 Results 
9.3.1 The integrative framework of genome-wide RNAi screening with 
systems biology of cancer genomics (NetBID2) to identify therapeutic 
targets of ERBB2+/HER2+ breast cancer 
Following the integrative framework in the previous chapter, we developed a 





inference from genomic data to identify novel therapeutic targets for ERBB2+ 
breast cancer (Figure 9-1). 
To identify synthetic lethal partners with ERBB2 in breast cancer, we did pooled 
shRNA screening on an isogenetic model, by genetically engineering a normal 
breast cell line, MCF10A. MCF10A is ERBB2 null, so we overexpress ERBB2 in 
the cells, and use wild type as control. We transduced shRNA-mir library into 
both mutated and wild type MCF10A cells then grow infected cells for ten 
doubling times. We extracted genomic DNA from both cell populations and 
measure hairpin abundance by using both microarray and next-generation 
sequencing. By comparing shRNA readout in mutated with wild type MCF10A 
cells, we are interested in finding hairpins or genes depleted in engineered 
ERBB2+ cells, which are potential therapeutic targets for ERBB2+ breast cancer. 
For the isogenetic MCF10A model, we culture the mutated and wild type cells in 
2D and 3D culturing system respectively for in vitro studies, and also make 
mouse xenograft models of ERBB2+ MCF10A for in vivo experiments. 
In parallel, we applied NetBID2, the systems biology framework I developed, to 
infer drivers of ERBB2+ breast cancer from gene expression data and crossed 
computationally-predicted ERBB2+ master regulators or signaling modulators 
with functional shRNA screening identified candidates to produce a more 
promising short list of therapeutic target candidates. 
To define a signature of ERBB2+ breast cancer, a key step in NetBID2, we 





microarray. We did this for both 2D and 3D cultured systems. The signature was 
generated by doing differential expression analysis of ERBB2+ vs. wilt type in 2D 
and 3D data respectively. However, these classical signature genes were shown 
to be unstable to characterize phenotypes [69], we confirmed this point by 
looking at the overlaps of top signature genes in 2D and 3D systems (Figure 4-3).  
Therefore, we developed NetBID2 to go beyond expression signatures. 
At the same time, we studied gene expression profiles from a cohort of 359 
breast cancer patients in TCGA project and constructed both TF-centered 
regulatory network and signaling molecule-centered cellular networks specific to 
breast cancer context. The networks were built using a well-developed algorithm, 
ARACNe [111]. Then we performed enrichment analysis for each driver 
candidate, TF or signaling molecule, using BSEA algorithm to predict drivers 






Figure 9-1 The integrative framework of genome-wide RNAI screening with 
systems biology of cancer genomics (NetBID2) to identify therapeutic targets of 
ERBB2+/HER2+ breast cancer. 
 Subsequently, we overlapped depleted genes in shRNA screens with inferred 
drivers to generate a shorter list of candidates as therapeutic targets tor 





9.3.2 Integrating RNAi screens with NetBID2 identifies STAT3 and two 
other signaling molecules as driver-type therapeutic targets of ERBB2+ 
breast cancer 
In pooled shRNA screens, we had data from 2D, 3D and in vivo systems using 
both microarray and NGS technologies, in each of which we generated a list of 
candidates being depleted in ERBB2+ cell population. To identify potential 
candidates in each separate data set, we did the differential representation 
analysis at both individual shRNA level and integrated gene level. The best 
strategy to get a robust candidate list is to combine all evidences together by 
doing meta-analysis. So we combined all results from microarray-based RNAi 
screening data in different analysis levels and identified 134 depleted genes in 
ERBB2+ population. Similarly by combining evidences in NGS-based data, we 
obtained 406 candidates. Furthermore, combining both microarray and 
sequencing data, we generated 355 candidates, and by crossing three separate 
combined results, finally we got 36 candidates (Figure 9-2) as therapeutic targets 
from RNAi screening only. 
For driver inference using NetBID2 algorithm from gene expression data, we 
generated driver lists for 2D and 3D signature reference and combine them 






Figure 9-2 Integration of RNAi screening with NetBID2 driver prediction identifies 
three candidates as driver-type therapeutic targets for ERBB2F+ breast cancer. 
The left is a summary table of candidate selection by combing evidences from 
both NetBID2 driver predictions (blue background) and RNAi screening (green 
background). For driver prediction, we have candidates based on 2D or 3D 
signature of ERBB2+ cells, and we also combine evidences of 2D drivers and 3D 
drivers, finally 137 TFs or signaling molecules are overlapped among the three 
driver lists. For RNAi screening, we have combined microarray or sequencing 
results alone in best.comb (combine hairpin from different datasets first and then 
select the best as representative), comb.gene (combined gene level by BHM 
algorithm), and comb.best (select best hairpin in each data set first and then 
combine them), and combined both microarray and sequencing results. Only 36 
genes came out from RNAi screening. On the firth venn diagram, crossing 137 
drivers and 36 candidates from RNAi screening, only three genes show up, 





With the integrative systems biology framework of combining functional genomics 
with cancer genomics, we identified three candidates, STAT3, AGRN and GLRX, 
that showed significant evidence of depletion in RNAi screens (Table 9-1) and 
were predicted as strong drivers of ERBB2+ cancer cells (Table 9-2). All three 
are signaling molecules which are potentially druggable. 
 
Table 9-1 NetBID2 inference results of three final candidates from integrative 
analysis. Duplicate names for GLRX represent two probes for GLRX in the 
microarray data. In functional type (Func Type), TF is for transcription factor, Sig 
is for signaling molecule. The column of # of pathway indicates the number of 
known pathway from multiple databases the candidate gene is involved in. 
nES.comb.Drivers is the normalized enrichment score of combing 2D and 3D 
NetBID2 outputted nES. Pval.comb.Drivers is based on nES.comb. The GEP 
signature analysis columns show fold change (FC), z score and pvalue of 






Table 9-2 Genome-wide shRNA screening results of three final candidates from 
integrative analysis. In # shRNAs column, ‗All‘ means the number of hairpins 
present in all platforms including hairpin-probed microarray (SH.array), barcode-
probed microarray (BC.array) and sequencing. In combine Array & Seq columns, 
n.Pval is the number of comparisons or evidences, n.sh.Depleted is the number 
of hairpins showing significant depletion (P<0.05). 
Among the three candidates, STAT3 is an interesting one. There are three 
hairpins targeting STAT3 in the shRNA library and integrated RNAi screening 
results showed that it‘s significantly depleted in both microarray and sequencing 
data. It‘s connected to 396 genes in the predicted network. STAT3 has dual roles 
of both transcriptional factor and signaling molecule and participated in 71 known 
pathways, one of which is a well-studied JAK/STAT3 pathway. STAT3 or 
JAK/STAT3 pathway has been shown to have oncogenetic effects in several 
disease contexts [233-242], but it has been associated with ERBB2+ breast 





9.3.3 STAT3 and phosphorylated-STAT3 is confirmed to be active in 
ERBB2+ MCF10A cells 
STAT3 was predicted by NetBID2 from genomic data to be a modulator of 
ERBB2+ transformation, and its depletion showed lethal effects to ERBB2+ cells 
from RNAi screening results. So based on that, we hypothesized that STAT3 is 
abnormally active in ERBB2 engineered MCF10A cells. Literature also suggested 
that STAT3 needs to be phosphorylated to be active [243]. We checked the 
protein level of phosphorylated-STAT3 by doing western blot, and indeed, 
phosphorylated-STAT3 is only active in ERBB2+ MCF10A cells (Figure 9-3), but 
not in wild type and other genetically-engineered (CYCD1, E1A, PTEN, P53) 
MCF10A cells. This suggests that ERBB2 over-expression triggers activation of 
STAT3 thus transforming normal cells into tumor cells and STAT3 seems to be 
required by ERBB2-induced cancer transformation.  
  
Figure 9-3 Western blots of phosphorylated-STAT3 (P-Stat3) and 





(ERBB2+, CYCD1+, E1A+, PTEN-, and p53-) MCF10A cells.  pSTAT3 and 
pSTAT5 are only activate in ERBB2+ MCF10A cells. 
9.3.4 STAT3 is validated in vitro to be lethal to ERBB2+ MCF10A cells 
when being silenced 
STAT3 was identified as a synthetic lethal partner with ERBB2 in breast cancer. 
It was predicted as a driver of ERBB2+ MCF10A cells and was confirmed to be 
activated in ERBB2+ cells. We are interested in testing out whether STAT3 is a 
good therapeutic target to stop ERBB2+ cancer transformation. First, we 
validated this using in vitro system. We knocked down STAT3 by siRNA or two 
shRNAs in ERBB2-muated MCF10A cells. Viability assay results demonstrated 
that silencing STAT3 by both siRNA and shRNAs reduces growth or viability of 
ERBB2+ cancer cells significantly (Figure 9-4). Moreover, time-course curve of 






Figure 9-4 Validation of STAT3 in vitro by siRNA and shRNA. Viability assays 
were performed after knock-down of STAT3 by siRNA or two shRNAs. 
Second, we performed colony forming cell (CFC) assays to validate STAT3 as a 
lethal gene to ERBB2+ breast cancer. Qualitative and quantitate measurements 
of CFC assays showed a significant reduce of cancer cell growth in ERBB2+ 
cells when STAT3 is inhibited by shRNA (Figure 9-5). In the control population 
without ERBB2 overexpression, silencing STAT3 showed no effects on tumor cell 
transformation and growth. If we induced ERBB2 in wild type MCF10A cells, 
tumor colonies were formed quickly and expanded dramatically, but however, if 
we silenced STAT3 in ERBB2-overexpressed MCF10 cells, there is almost zero 
tumor transformation or even decreased tumor formation comparing with wild 
type. This again confirmed that STAT3 is indeed an effective target to stop 






Figure 9-5 Validation of STAT3 in vitro by colony forming cell (CFC) assays with 
shRNA silencing. Colony assays were performed in wild type MCF10A cells with 
and without STAT3 silencing by shRNA, ERBB2-muated MCF1-A with and 
without shSTAT3. Quantitate cell counts were measured for each colony assay.  
9.3.5 STAT3 is validated in vivo to be lethal to ERBB2+ xenograft mouse 
models 
Besides in vitro system, we also tested STAT3 in vivo, by making xenograft 
mouse models of ERBB2+ MCF10A cells with and without STAT3 silencing, 
More strikingly, in mouse models of ERBB2+ MCF10A cells with STAT3 silencing 
by shRNA, there was almost no sign of tumor formation and no growth of tumor 
population, comparing with the exponential growth of tumor cells in the mice 
without STAT3 inhibition. Again, STAT3 is indeed a valid and effect target to 





suggest potential clinical applications to treatment of HER2+ breast cancer, one 
of the most aggressive form in breast cancer.   
 
Figure 9-6 Validation of STAT3 in vivo. Xenograft mouse models were made for 
ERBB2+ MCF10A cells with and without STAT3 silencing by shRNA. Cell 
population with tumor marker were imaged and measured weekly, up to 7 weeks, 
when tumor size was photographed. 
9.3.6 STAT3 inhibition is specific to ERBB2+ breast cancer 
We have shown that silencing STAT3 dramatically stops growth of ERBB2+ 
cancer cells, but we have to test the specificity of STAT3 inhibition to ERBB2 
overexpression in breast cancer. We selected a cell line, MDAMB231, a basal 
type breast cancer cell line which is ERBB2- but STAT3+ (Figure 9-7) to validate 





assays demonstrated that there is no significant viability change of MDAMB231 
cells with and without STAT3 silencing (Figure 9-8). Furthermore, in vivo mouse 
models of MDAMB231 cells showed almost identical tumor growth curves with 
and without STAT3 inhibition (Figure 9-8). Therefore, this suggested that 
silencing STAT3 has no effects on growth or viability of ERBB2- cancer cells 
though STAT3 is expressed in those cells, confirming the specificity of STAT3 







Figure 9-7 Western blots of STAT3, phosphorylated STAT3, ERBB2, 
phosphorylated ERBB2 in different breast cancer cell lines: wild type MF10A, 
ERBB2+ MCF10A, three Luminal lines (SKBR3, MDAMB361, ZR7530), four 






Figure 9-8 In vitro and in vivo validation of STAT3 specificity to ERBB2 using 
MDAMB231 cell line. MDAMB231 is a ERBB2- but STAT3+ line. In vitro 
competition assays and in vivo xenograft mouse models with and without STAT3 
silencing by shRNA were performed to measure viability of tumor cells or tumor 
growth. 
9.3.7 STAT3 doesn’t show up as a driver for HER2+ from NetBID2 analysis 
on expression profiles of primary breast cancer patients 
We identified STAT3 as a signaling modulator of ERBB2 induced tumorigenesis 
by applying NetBID2 algorithm to expression profile generated from a genetically-
engineered isogenetic model, MCF10A with ERBB2 overexpression. However, 





doesn‘t capture the heterogeneity that is commonly present in primary patients 
(Figure 9-9). Therefore, we asked whether we can still identifiy STAT3 if we 
applied the same computational framework (NetBID2) to expression data from 
primary patients. 
 
Figure 9-9 Illustration of genetically-engineered isogenetic model. ERBB2 is 
overexpressed genetically in MCF10A cells to mimic ERBB2+ breast tumors. 
In application of NetBID2 to this project, we constructed breast cancer 
interactomes from gene expression profiles of a cohort of 359 primary breast 
cancer patients, out of which, 58 patients were clearly classified as HER2+ based 
on clinical lab IHC assays and 201 one were defined as HER2-. So we 
performed the signature analysis using those clearly defined HER2+ and HER2- 
patients‘ profiles instead of homogenous MCF10A profiles with and without 
ERBB2 overexpression. And then we applied NetBID2 algorithm to identify 





in both transcription factor-centered network analysis and signaling protein-
focused network analysis, STAT3 didn‘t show up as a driver candidate for 
HER2+ breast cancer (Figure 9-10). 
This reflected the difference of isogenetic models and primary patient samples. 
Particularly, this inferred the heterogeneity of HER2+ breast cancer patients. It 
seems that STAT3 is only modulating a subset of HER2+ breast cancer 
population and STAT3 inhibition seems only work on the patients that are similar 
to the model we used, MCF10A.  
 
Figure 9-10 STAT3 doesn‘t show up as a driver of HER2+ primary samples in 
both transcription factor (TF)-centered network analysis and signaling protein 
(Sig)-focused network analysis. 
9.3.8 STAT3 is addicted to ER status being a driver for ER- and HER2+ 
breast cancer, but not for ER+ ones 
As discussed in previous section, STAT3 inhibition is not a uniform cure for all 
HER2+ breast cancer patients, and we need to identify the co-founding factors 





Patricia Villagrasa Gonzalez, a postdoc from Silva lab reminded me of that 
MCF10A, the model we used to identify STAT3 as a driver of HER2+ subtype, is 
ER-. However, the majority of HER2+ primary patients (83%) from which we 
failed to find STAT3, are ER+. And we know ER is one of the most important 
biomarkers to classify breast cancer patients. Therefore, this motivated me to 
separate HER2+ patients into ER+ and ER- groups and then applied NetBID2 to 
each of them. 
 
Figure 9-11 NetBID2 results of STAT3 on ER- and ER+ groups of HER2+ 
population. STAT3 only shows up in ER- group as a driver. 
Surprisingly, after we differentiate ER+ and ER- in HER2+ population, STAT3 
showed up only in ER- group with exactly the same pattern as we saw in 
MCF10A model (Figure 9-11). This is consistent with what we hypothesized 
based on the fact that MCF10A is ER-. There was no pattern for STAT3 network 
in ER+ and HER2+ population, which is the majority of HER2+ patients, thus 





We have shown that STAT3 is only modulating ER- sub-population of HER2+ 
patients, which is one of the most advanced forms of breast tumors. We also 
tried other characteristic factors to check whether we can find STAT3 in one of 
them. We separated HER2+ patients into Basal or Luminal type according to 
their gene expression profiles and applied NetBID2. Since MCF10A is classified 
into Basal group, we expected to STAT3 coming out from analysis on Basal-type 
HER2+ group, however, STAT3 didn‘t show up as a significant driver candidate 
though the direction is consistent with the one in MCF10A analysis. Interesting 
thing is that STAT3 showed up as a driver for Luminal type and HER2+ group, 
however, the pattern of direction is opposite to the pattern we observed in 
MCF10A model. This suggested that STAT3 is modulating Luminal type of 
HER2+ breast cancer patients but in a different mechanism from ER- and HER2+ 
group.  
 
Figure 9-12 NetBID results of STAT3 in Luminal and Basal subtype of HER2+ 
patients. STAT3 shows up in Luminal group but shows opposite direction pattern 






9.3.9 Searching for downstream targets of STAT3 being involved in 
modulation of ER- and HER2+ breast cancer 
We identified STAT3 as a modulator of ER- and HER2+ breast cancer, but we 
are more interested in identifying the entire pathway specifically responsible for 
tumorigenesis of ER- and HER2+ breast cancer. The reason is because STAT3 
is a well-known upstream signaling transduction modulator and regulator of a 
spectrum of downstream biological processes. We asked what specific 
downstream players or targets of STAT3 are involved in the pathway of tumor 
initialization and growth induced by ERBB2, or in the pathway of inducing 
apoptosis in this type of breast cancer cells when we knock-down STAT3. 
To identify potential targets of STAT3 experimentally in this context, we did 
microarray profiling of whole genome by perturbing STAT3. We did knock-down 
of STAT3 by two shRNAs in ERBB2+ cells and did inducement of STAT3 by 
over-expressing IL6, an upstream activator of STAT3, in ERBB2- cells. Positive 
targets of STAT3 will be down-regulated in STAT3- samples but up-regulated in 
STAT3+ samples, whereas negative targets will show the opposite pattern. We 
identified 66 targets of STAT3 (Figure 9-13) using a stringent threshold (P<0.05, 
fold change > 4). SOCS3 is a well-known activated target of STAT3 showing up 
as one of the top positive targets. STAT3 itself can also be used a positive 








Figure 9-13 Heatmap of top STAT3 targets from perturbation experiments by 
knocking-down STAT3 by two shRNAs or over-expressing IL6, an upstream 
activator of STAT3. Red stands for down-regulation while green means up-
regulation, for example, in sh-STAT3 experiments (the left four samples), genes 
in red are under-expressed when silencing STAT3 or are potential positive 
targets of STAT3, while green ones are potential negative targets of STAT3. 
SOCS3 is a known target activated by STAT3 and STAT3 itself is another 
positive control. 
In addition to experimental searching for STAT3 targets, we also looked at the 





of breast cancer expression profiles. The analysis of ARACNe is on probe level 
and is separated for transcription factor-centered and signaling molecule-
centered networks. There are three probes for STAT3 representing three 
different transcripts of STAT3 and STAT3 has dual role of being transcription 
factor and signaling protein, therefore there are 6 lists of targets predicted by 
ARACNe, and the number ranges from 100 to 250. And all of the six lists of 
predicted targets are significantly enriched in experimentally-identified targets of 
STAT3 (Figure 9-15). 
 
Figure 9-14 Subnet of STAT3 predicted by ARACNe in the signaling-centered 
network. Genes on the right circle are transcription factors (TF in square shape), 
signaling molecules (Sig in diamond shape) or both (TF_Sig in hexagon shape). 
Genes in dark green are also predicted as master regulators or drivers (MR) of 
HER2+ breast cancer. Genes on the left circle are the ones in general. Red edge 







Figure 9-15 Enrichment of ARACNE-predicted targets of STAT3 from 
transcription factor (TF)-centered or Signaling molecule (Sig)-centered network in 
experimentally identified targets of STAT3 by microarray profiling after knock-
downing STAT3 or overexpressing IL6 (activator of STAT3). 
9.3.10 STAT3 targets that are lethal to ER- and HER2+ breast cancer 
With a handful of STAT3 targets from perturbation experiments, we asked how 





analysis of 111 selected STAT3 targets (P<0.05, FC>3) in RNAi screening 
results of ERBB2+ MCF10A cells and there was an enrichment pattern on the 
depleted side, meaning that majority of STAT3 targets are also lethal to ERBB2+ 
MCF10A cells. If we distinguished positive and negative targets of STAT3, there 
was no significant enrichment for 70 positive targets, but there was a significant 
enrichment for 43 selected negative targets. 
Besides MCF10A isogenetic model, we also did shRNA screens for three HER2+ 
breast cancer lines (SKBR3, SUM190PT and MDAMB361).Among these three 
HER2+ cell lines, SKBR3 is ER+ while the other two are ER-. Unfortunately, 
STAT3 didn‘t show up being lethal to all the three lines. MDAMB361 was 
expected because it is an ER+ line, but SUM190PT and SKBR3 were not 
expected. The reason could be either hairpins targeting STAT3 were not working 
well, or the data was noisy or there could be other factors making these two lines 
resistant to STAT3 inhibition. 
However, STAT3 pathway seems to be activated in ER- and HER2+ breast 
tumors. So we went downstream and checked STAT3 targets that are lethal to 
HER2+ population. Fortunately, there are a few STAT3 targets such as S100A9, 
TRDMT1 (activated), FLRT1, NPAS1 (repressed) that are lethal to both HER2+ 
breast cell lines and genetically-engineered MCF10A cells. Those candidates 
might be alternative therapeutic targets for HER2+ breast cancer because of their 
lethal effects to both models and might be more specific than STAT3 because 





targets might specifically involve in tumorigenesis of HER2+ breast cancer, 
making them more promising as novel therapeutics for HER2+ patients. 
 
Figure 9-16 Enrichment of STAT3 targets from perturbation experiments in 
shRNA screening results of ERBB2+ MCF10A cells. Reference genes are ranked 
from the most enriched to most depleted in ERBB2+ vs. wild type MCF10A cells. 
STAT3 targets are selected by P<0.05 and FC>3. Positive targets are defined as 
positive expression in STAT3-induced samples comparing with expression in 
STAT3-silenced samples. Negative targets are defined in the opposite way. Top 






Figure 9-17 Enrichment of STAT3 targets from perturbation experiments in 
shRNA screening results of ERBB2+ breast cancer cell lines (SKBR3, 
SUM190PT, MDAMB361). Reference genes are ranked from the most enriched 
to most depleted in three HER2+ cell lines (using a combined score). STAT3 
targets are selected by P<0.05 and FC>3. Positive targets are defined as positive 
expression in STAT3-induced samples comparing with expression in STAT3-
silenced samples. Negative targets are defined in the opposite way. Top lethal 
positive or negative targets are listed in the boxes on the bottom-right. Yellow 
ones are the common targets lethal to ERBB2+ MCF10A cells (Figure 9-16). 
9.3.11 Other STAT family members (STAT5A and STAT1) show up as 
drivers of ERBB2+ breast cancer in analysis of data from both isogenetic 
models and primary patients 
Besides STAT3, we also identified other STAT family members including 
STAT5A and STAT1 as drivers of HER2+ breast cancer from MCF10A isogenetic 





STAT5A was inferred as a driver from MCF10A isogenetic model (Figure 9-18), 
but didn‘t show up from all HER2+ primary tumors (Figure 9-19). However, 
STAT5A showed the addiction to ER status by being predicted as a driver for 
only ER- and HER+ primary samples, not from ER+ group (Figure 9-20). It turned 
out that in the predicted network, STAT5A is interacting with STAT3 in a positive 
manner (Figure 9-21, Figure 9-22), which might explain the above patterns. 
Unfortunately, STAT5A didn‘t show up from RNAi screening data and was 
confirmed by individual knock-down experiments. 
 






Figure 9-19 STAT5A like STAT3 is not a driver of HER2+ primary tumors. 
 







Figure 9-21 Subnet of STAT5A predicted by ARACNe in the signaling-centered 
network. Genes on the left circle are transcription factors (TF in square shape), 
signaling molecules (Sig in diamond shape) or both (TF_Sig in hexagon shape). 
Genes in dark green are also predicted as master regulators or drivers (MR) of 
HER2+ breast cancer. Genes on the right circle are the ones in general. Red 







Figure 9-22 Subnetwork of STAT3 and STAT5A predicted by ARACNe in the 
signaling-centered network. Annotation is the same as in Figure 9-20 and Figure 
9-21. 
STAT1 also was predicted as a driver of ERBB2+ MCF10A cells (Figure 9-23), 
however it showed different enrichment pattern with STAT3 and STAT5A. 
Moreover, it didn‘t display the addiction to ER- subgroup of HER2+ primary 
population (Figure 9-25) though it showed no enrichment pattern in all HER2+ 






Figure 9-23 STAT1 is a driver of ERBB2+ MCF10A cells, but shows different 
enrichment pattern with STAT3 and STAT5A. 
 







Figure 9-25 STAT1, different from STAT3 and STAT5A, doesn‘t show any 
addiction to ER status being a driver of HER2+ primary tumors. 
9.3.12 RNAi screening from 2D vs. 3D vs. In Vivo environment 
Nowadays, there is increasing awareness of the drawbacks of 2D cell culture and 
the related effect on the value of the research being performed.  Not surprisingly, 
scientists are shifting their focus to cells cultured in 3D or in vivo mouse models 
because cells in 3D or mouse model environments are much more similar to cells 
in the real environment, a living organism (in vivo) than flat, unnaturally thin, 
single layer cells grown on 2D plastic. So in this project to identify therapeutic 






From literature, we learned that there are differences between 2D and 3D culture 
systems such as the following: 
 Shape:  Cells in 3D are typically ellipsoids with dimensions of 10-30 
μm, while cell cultured in 2D are flat with typical thickness of 3 μm. 
 Environment:  Cells in 3D usually have nearly 100% of their surface 
area exposed to other cells or matrix, but cells in 2D have only about 
50% of their surface area exposed to fluid, approximately 50% 
exposed to the flat culture surface or intermediate, and a very small 
percent exposed to other cells. 
 Behavior:  Cells in 3D comparing with 2D show differences in 
differentiation, drug metabolism, gene and protein expression, general 
cell function, in vivo relevance, morphology, proliferation, response to 
stimuli, and viability. 
However, the cons of 3D or in vivo culturing systems might be larger noise than 
2D because of increased dimensions and unknown factors. So we checked the 
shSeq data quality from different environments. We noticed that in vivo data is 
much noisier than both 2D and 3D data in terms of raw NGS data quality (Figure 
9-26) and consistence of replicates (Figure 9-27). There was no significant 
difference between 2D and 3D data quality, or in some cases, 3D data is much 
cleaner than 2D. We also checked the distances between samples, and 
interestingly, 3D and in vivo data are much closer to each other than to 2D 





smaller in 3D than that in 2D, meaning 3D data is less sensitive than 2D in terms 
identifying candidates from shRNA screening data. 
 
Figure 9-26 Overall quality (left) and cycle-based quality (right) of raw NGS 






Figure 9-27 Consistence of replicates of NGS shRNA screening data in 2D, 3D 






Figure 9-28 Distribution (A: boxplot, B: density) plots, Heatmap of sample 







9.4.1 Reverse engineering transcriptional regulatory or signaling networks 
of Breast Cancer 
To generate breast cancer interactomes we processed microarray gene 
expression data (Agilent G4502A platform) of 359 breast cancer primary samples 
from TCGA project [64] using loess normalization and cleaned the dataset to 
24,401 probe sets with non-specific filtering. Then we ran the ARACNe algorithm 
[111] with default parameters against 1775 probes corresponding to 780 TFs to 
establish a TF-centered interactome and against 6475 probes for 2453 signaling 
molecule genes to construct a signaling protein-focused network. There are 319 
probes for 60 genes that are both TF and signaling proteins. 
9.4.2 Signature analysis of ERBB2+ MCF10A model 
We did microarray profiling (Agilent) on the isogenetic model, ERBB2 engineered 
and wild type MCF10A cells to generate a signature of ERBB2+. We cultured the 
cells in 2D and 3D systems with 6 replicates for each condition (5 replicates for 
3D cells) so we can generate two signature reference for 2D and 3D data 
respectively. The microarray data was normalized by VSN [244] and RSN [245] 
methods. To generate a reference signature of ERBB2 overexpression 
phenotype, part of our NetBID2 driver inference algorithm, we used a Probit 
regression model [89] (Figure 8-2) for its advantage of detecting weak effects. 





robustness and accuracy. In particular, a t-distribution prior and Gibbs sampling 
were used in this analysis [90]. 
9.4.3 GSEA of inferring regulatory or signaling drivers of ERBB2+ MCF10 
Cells 
For GSEA method to predict regulatory drivers or signaling modulators of 
ERBB2+ phenotype, we used BESA method in Chapter 5 with a ―maxmean‖ 
statistic [98] as enrichment score and Bayesian statistics. 1,000 sample 
permutations with Efron‘s restandarization technique to build the null distribution 
for statistical significance.  
9.4.4 Pooled shRNA screening of ERBB2+ MCF10A cells 
We made use of the pGIPZ shRNAmir library [51], comprising 58,493 shRNAs 
targeting 18,651 genes. We did shRNA screening for ERBB2 mutated and wild 
type MCF10A cells cultured in 2D and 3D systems separately in triplicates. We 
also did the screening in mouse models by injecting shRNA library-infected cells 
with triplicates as well. All genomic data were extracted at T0 and after 10 
doubling times. Both microarray (barcode-probed and hairpin-probed) and NGS 
deep sequencing technologies were used to read out shRNA abundance. 
In the NGS data of shRNA screening for 2D, 3D and in vivo models, over 75% of 
total reads were identified in each case. All samples have enough identified 






Table 9-3 Summary of deconvolution for NGS data of shRNA screening on 
ERBB2+ and wild type MCF10A cells in 2D, 3D and in vivo systems. Cells with 
sky blue background are data for this study. Numbers in dark red background are 
cases with < 1M identified reads, in light read are cases with 1-5M reads. 
9.4.5 Differential representation analysis of individual shRNA 
To assess the effects on reversal of GC-resistance by individual shRNA, we 
compared abundance of shRNA in ERBB2+ with wild type control using shADER 
algorithm, which is essentially a Bayesian linear model as detailed in Chapter 2.7. 
9.4.6 Gene level activity by integration of multiple shRNAs targeting the 
same gene 
To estimate the gene level effects of a gene targeted by multiple shRNAs, we 
applied BHM algorithm, a hierarchical modeling approach as detailed in Chapter 





‗fixed effects‘ was used to score capability of increasing sensitivity at gene level. 
Bayesian-MCMC computing was set up for accurate estimations. 
9.4.7 Meta-analysis of combining differential evidences 
To combine evidences form different sources for meta-analysis, for example, to 
identify depleted genes in ERBB2+ cells with shRNA screening results from 
microarray data and NGS data under 2D, 3D or in vivo systems, we used 
Stouffer‘s z score method [107] shown in the following formula. 
  
∑   
 
   
√ 
     (   ) 
In the above equation,    is the z-score indicating the strength of evidence, for 
example, differential representation score of a gene or a hairpin, in one source, 
say number i from total number of k sources. zi follows a standard normal 
distribution, so the integrated Z score also follows a standard Gaussian 
distribution assuming independence of all k evidences. Combined two-tailed p 
value was calculated based on the integrated Z score. 
9.5 Discussion 
9.5.1 Phosphorylation of STAT3 is required for STAT3 activity 
We showed that STAT3 inhibition is specific to ERBB2+ breast cancer by 
measuring viability or tumor growth on MDAMB231 cell line, which is ERBB2- but 
STAT3+, with and without STAT3 silencing both in vitro and in vivo. One 





level, phosphorylation of STAT3 is not induced (Figure 9-7, Figure 9-8). This may 
suggest that STAT3 is actually not functionally active in MDAMB231 cells, 
making it resistant to STAT3 inhibition treatment. However, this might be 
explained that ERBB2 induces STAT3 activity by phosphorylation, most likely by 
indirect phosphorylation via IL6 autocrine signaling loop [230, 246]. In ERBB2- 
cells such as MDAMB231, STAT3 is not phosphorylated without ERBB2 
inducement, thus being inactive. 
9.5.2 2D vs. 3D: gene expression signature and NetBID2-predicted drivers 
We also had the gene expression profiles of cells in 2D and 3D environments, 
giving us opportunity to check the gene expression difference between these two 
culturing methods. First, in gene signature results, 2D and 3D showed 
significantly difference. For example, the correlation of differential expression 
scores in 2D (ERBB2+ vs. WT) with those in 3D is poor, only about 0.1. 
Moreover, among top signature genes in 2D and 3D, there are only about 5-6% 
genes that were overlapped (Figure 9-29). However, there was a much increased 
correlation and overlap for NetBID2-predicted drivers for 2D and 3D data (Figure 
9-30). This again confirmed the robustness of NetBID2 to detect true phenotype-






Figure 9-29 Gene expression signature of ERBB2+ MCF10A cells in 2D vs. 3D 
environments. 
Although drivers increased the consistence between 2D and 3D inference, the 
correlation is still only about 0.3 and the overlap is only about 1/3, so there are 
still significant difference between 2D and 3D systems, which probably can be 






Figure 9-30 NetBID2-predicted drivers of ERBB2+ MCF10A cells in 2D vs. 3D 
environments. 
9.5.3 The power of meta-analysis and integration of functional genomics 
with systems biology 
In previous discussion section, we demonstrated again that NetBID2 framework 
is much more robust to infer disease or phenotype-associated biomarkers. 
However, NetBID2 is an application of meta-analysis and actually in shRNA 
screening data analysis of this study, we showed the power of meta-analysis as 
well. For example, we had multiple experiments of shRNA screening, 2D, 3D or 
in vivo environments, microarray or deep sequencing technologies. If we only 
looked at individual data set, STAT3 didn‘t show up as in the top candidate list for 
all of them. However, if we combined all evidences together by meta-analysis, 
STAT3 was ranked 64th in the combined results (Figure 9-31). Moreover, if we 
crossed with NetBID2 predictions from cancer genomic data, STAT3 was the 





by meta-analysis. Identification of STAT3 as a validated and effective target for 
ER- and ERBB2+ breast cancer patients confirmed the success of our strategy 
by integrating noisy functional genomic RNAi screening data with systems 
biology inference of large-scaled cancer genomic data to tail therapeutic targets 
for human cancers. 
 
Figure 9-31 Heatmap of z score for top depleted (in green) or enriched (in red) 
candidates from shRNA screening results of ERBB2 engineered MCF10A cells in 






Chapter 10 Integrating Functional Genomics with Systems 
Biology to Discover Driver-type Therapeutic Targets 
for ABC or GCB-type DLBCL 
10.1 Summary 
We have performed genome-wide RNAi screens on four DLBCL cell lines 
including one ABC-type (HBL1) and three GCB-type (BJAB, Ly7 and SUDHL4), 
by both microarray and deep-sequencing technologies. To obtain robust 
candidates from such high-throughput experiments, we designed a procedure to 
combine results from both microarray and sequencing data. Our analysis led to a 
genome-wide functional profile for each cell line, indicating gene-silencing effects 
on cell proliferation. Un-supervised clustering showed a clear separation between 
ABC and GCB. Supervised comparison of RNAi screen between ABC and GCB 
generated 587 candidate genes (P<0.001) that are specifically lethal to ABC or 
GCB. Besides, based on a cohort of 260 DLBCL gene expression profiles, we 
built a B-cell interactome computationally and performed NetBID2 analysis to 
identify drivers that are specific to ABC or GCB subtype. This analysis gave us 
125 master regulators or signaling factors (P<0.001) meditating expression 
signature of ABC vs. GCB. By integrating RNAi screened candidates with 
genomics-inferred drivers of ABC vs. GCB, we obtained 20 transcription factors 
and 47 signaling molecules that are both lethal to and critical of meditating ABC-





PTPRG) also showed significant gain or amplification in ABC patients from copy 
number variation data, which may constitute promising therapeutic targets for 
ABC, which is usually associated with poor prognosis.  Further biochemical 
experiments are being conducted to validate selected candidates both in vitro 
and in vivo. 
10.2 Introduction 
The goal of this project is to identify novel therapeutic targets that are specific to 
ABC or GCB-type of DLBCL. The approach we developed to address this task is 
similar to what we have developed in Chapter 10 and chapter 11, an integrative 
framework of crossing genome-wide RNAi screens with systems biology analysis 
of cancer genomics (Figure 10-1). On one side, we performed genome-wide 
shRNA screens on four DLBCL cell lines including one ABC-type (HBL1) and 
three GCB-type (BJAB, Ly7 and SUDHL4), by both microarray and deep-
sequencing technologies. With sophisticated meta-analysis of combining 
microarray and sequencing data, we were able to identify candidates that are 
lethal to ABC or GCB-type DLBCL lines as potential therapeutic targets. However, 
this list is usually too long to validate all of them. On the other side, we had a 
cohort of 260 gene expression profiles from primary patients or cell lines in the 
context B cells, among which 35 are ABC and 50 are GCB-type. With this data, 
we applied the NetBID2 algorithm to identify drivers, both master regulators and 
signaling modulators, which are specific to ABC or GCB subtype. We also had 





us to identify genes that are amplified or depleted in ABC or GCB groups. Then 
we integrated all these evidences together and produced a short list of 
candidates as therapeutic targets for ABC or GCB subtype of DLBCL. 
 
Figure 10-1 The integrative framework to identify therapeutic targets for ABC or 
GCB-type DLBCL by integrating genome-wide RNAi screens (left) with systems 






10.3.1 Pooled shRNA screens of DLBCL lines by microarray and NGS 
We did pooled shRNA screens for four DLBCL cell lines using both microarray 
(Barcode-probed and hairpin-probed) and NGS technologies. All screens except 
SUDHL4 with shRNA-probed microarray and BJAB with sequencing are in good 
quality (Table 10-1).   There were significant batch effects for sense-probes and 
anti-sense probes in hairpin-probed microarray data of SUDHL4 line (Figure 
10-2). Two samples of BJAB shSeq data didn‘t have enough total number of 
identified reads, which caused the data noisy (Table 10-2). The best way to get 
robust candidates out of all these data is to exclude the bad screening data, 
perform analysis on individual data set and then integrate the others together. 
The Stouffer‘s or naïve Bayesian method was used to combine multiple 
evidences. 
 
Table 10-1 Summary for genome-wide shRNA screens of four DLBCL cell lines. 
Green check sign indicates the data quality is good while red one represents that 






Figure 10-2 Batch effects detected for shRNA hairpin-probed microarray data of 






Table 10-2 Summary of deconvolution of NGS-based shRNA screening data of 
four DLBCL cell lines. Red ones are the run with not enough signals. SUDHL4 
was run three times to get good quality data. 
10.3.2 Clustering of shRNA screening samples  
First we did hierarchical clustering of all T10 or T0 samples for each of the four 
DLBCL lines in both NGS and microarray platforms to check the consistence of 
replicates and to check biological relationships among T0 and T10 data. As 
shown in Figure 10-3, most replicates for each condition are clustered together, 






Figure 10-3 Clustering of T0 or T10 shRNA screening data in NGS, BC-probed 





10.3.3 Functional profiles separate well ABC from GCB, BCL2-rearranged 
from non-rearranged DLBCL subtypes 
The four DLBCL cell lines can be classified into ABC and GCB subtype based on 
their gene expression profiles, or BCL2-rearranged or non-rearranged based on 
BCL2 translocation status. We wondered whether we can still separate those 
subtypes by using the functional profiles from shRNA screening data. The 
answer is yes.  
First, we generated a new profile of differential representation for each cell line 
using the difference of T10 and T0 data (log (T10/T0). This profile indicates the 
functional effects of each hairpin or gene to cell growth or survival of the cell line, 
for example, positive value for enriched hairpins meaning the targeting genes are 
suppressors of cell growth, while negative value for depleted hairpins 
representing that corresponding genes are lethal to this cell line. Then we did 
clustering of the four lines based on their functional profiles. Here we only 
showed you the results using NGS-based shRNA screening data, but the results 
from microarray data are similar. Since there are triplicates for each cell line, we 
enumerated all six possible pairs of T10 vs. T0 therefore generated six new 
functional profiles for each cell line (except Ly7 for which we removed two bad 
replicates, therefore it only has three profiles).  
As shown in Figure 10-4, first, we noticed that all generated profiles for each cell 
line are clustered together as expected; second, HBL1 in blue, the only ABC cell 





lines, BJAB in red and SUDHL4 in purple stayed together showing clear 
difference from Ly7 because both of them are BCL2-translocated, while Ly7 is 
close to HBL1 as both of them are not BCL2-translocated. We saw exactly the 
same pattern if we averaged all generated profiles for each cell line as shown in 
Figure 10-5.  
In conclusion, shRNA screens-produced functional profiles are able to separate 
ABC and GCB, the two major subtypes of DLBCL and are also able to classify 
BCL2-rearranged and non-rearranged samples. Also the difference of ABC with 
GCB subtype is larger than the signal of BCL2-rearrangement. 
 
Figure 10-4 Heatmap with hierarchical clustering (Ieft) and PCA plot (right) of 
generated functional profiles from NGS-based shRNA screening data on four 
DLBCL cell lines. Six profiles for cell lines with triplicates for both T10 and T0 







Figure 10-5 Heatmap with hierarchical clustering (Ieft) and PCA plot (right) of 
generated functional profiles from NGS-based shRNA screening data on four 
DLBCL cell lines. All generated profiles for each cell line are averaged to produce 
only one profile. 
10.3.4 Differentially represented genes from shRNA screens 
We performed differential representation analysis at gene level using BHM 
algorithm for each of the four DLBCL lines to identify genes whose hairpins in the 
library are either enriched or depleted at T10 time. Deleted genes are of interest 
as they are genes that are lethal to the cells and are potential therapeutic targets 
to kill DLBCL cells of study. We did the analysis for individual cell lines. Statistical 






Figure 10-6 Histogram of p-values (left) and density plot of z-scores (right) for 
gene-level differential representation analysis of each cell line. The bin width for 
p-value histogram is 0.05. 
We also performed a meta-analysis to combine results of four lines for each gene 
by Stouffer‘s method. The combined z score for gene X indicates the overall 
effects of silencing X on all four DLBCL lines. The number of significantly 
depleted or enriched genes in each cell line and combined analysis is 
summarized in Table 10-3. For example, there are 1962 significantly differentially 
represented genes in HBL1, in which 1783 are depleted and 179 are enriched. 
There is a significant bias between depleted genes and enriched ones in HBL1, 
BJAB and SUDHL4, which might reflect the sensitivity difference of different type 
of cells. 
Cell line n.total n.over n.under 





BJAB 2329 770 1559 
Ly7 1204 627 577 
SUDHL4 6184 4738 1446 
Combined 2468 870 1598 
Table 10-3 Summary of enriched or overrepresented and depleted or under-
represented genes in shRNA screening for each cell line. ―Combined‖ is using 
Stouffer‘s method to integrate all four cell lines. It‘s based on gene level results 
with selection threshold of P<0.05. 
We also calculated the number of genes that are depleted in at least a certain 
number of cell lines (Table 10-4) to indicate its lethal effects on the majority of 
DLBCL cells. 
n.lines 1 2 3 4 sum 
n.all 5936 2237 379 33 8585 
n.over 4775 708 41 0 5524 
n.under 3716 716 71 1 4504 
Table 10-4 Number of genes depleted (under) or enriched (over) in at least 1 or 2 
or 3 or 4 cell lines, based on gene level results with selection threshold of P<0.05. 
10.3.5 Top differentially represented genes cross all cell lines 
We applied a stringent criteria and selected top depleted or enriched genes in all 
cell lines. With a threshold of p-value less than 0.05, 33 genes showed up as 





10-5). Unfortunately, there is only gene RFC3 that is depleted in all four lines. 
This reflects the heterogeneity of DLBCL.  
We also did clustering using the profiles of selected 33 genes, and again there 
was a clear separation between ABC (HBL1) and GCB lines. The majority of 
these 33 genes are exclusively either depleted in ABC or depleted in GCB lines. 
However, there are a few genes that are specific to BCL2-translocaiton. For 
example, ACCS and AKT1 are depleted in BJAB and SUDHL4, two BCL2-
translocated lines, while THS07A is depleted in two BCL2 non-translocated lines 
(Ly7 and HBL1). 
 
Figure 10-7 Top genes selected by a threshold of P<0.05 in all four lines. Red is 






Table 10-5 Top genes depleted in all cell lines, and depleted in ABC or GCB cell 
lines only. Red indicates depletion while green indicates enrichment. ―n.shRNAs‖ 
is the number of shRNAs in NGS-based data and ―n.shRNAs.array‖ is the 
number of hairpins in microarray data. ―numPathways‖ is the number of known 
pathways being involved in. 
We also tried to loosen the threshold and selected genes by combined statistics. 
The goal was to identify genes that showed consistent effects cross all cell lines, 
either lethal to all of them or suppressing their growth upon silencing. With a 
combined p-value threshold of 0.001, 293 genes were selected (Figure 10-8) and 
clustering analysis showed the same pattern as we observed using all genes or 






Figure 10-8 Top genes selected by combined p-value with a threshold of 0.001. 
10.3.6 Enriched pathways by RNAi screening identified candidates 
With a long list of candidates for each cell line, we were interested in whether 
those lethal candidates are enriched in any known pathways, or whether there 





we performed the functional enrichment analysis by using my BSEA (Chapter 5) 
algorithm. As shown in the top enriched pathways (Table 10-6) in at least one of 
the four cell lines, there are a significant number of pathways that are lethal to 
HBL1, the ABC type of DLBCL. Details about top two pathways that are lethal to 
HBL1 are shown in Figure 10-9 and Figure 10-10. 
 
Table 10-6 Top pathways enriched in shRNA screening-identified candidates. 
Red means genes in the pathway are significantly enriched in the under-







Figure 10-9 IL23-mediated signaling pathway is enriched by lethal genes in HBL1, 






Figure 10-10 Alternative NFKB pathway is enriched by lethal genes in HBL1, but 
not by lethal genes in other cell lines. 
10.3.7 Crossing RNAi screening with signature genes of ABC vs. GCB 
Out of the cohort of 230 gene expression profiles from DLBCL primary samples 
and cell lines, 35 are ABC type and 50 GCB type. Although I mentioned the 
chapter of NetBID2 algorithm that gene expression signature is not robust, the 
signature for ABC and GCB might be an exception because these two subtypes 
are classified based on gene expression signature data. So using the profiles of 
35 ABC and 50 GCB samples, we generated a signature for ABC vs. GCB type 
of DLBCL (Figure 10-11). And crossed top signature genes with RNAi screening 





 GEPs: as a signature, P<0.05 
 RNAi Screen: 
o Significant in combined ABC vs. GCB: P<0.05 
o Depleted in either only HBL1 (ABC) or only all three GCB lines 
 Significant in combined GEP and shRNA: P<0.05 
With the above selection, 141 genes showed up as shown in Figure 10-12. 
 
Figure 10-11 Heatmap of top signature genes of 35 ABC vs. 50 GCB DLBCL 
profiles. Red means under-expression in ABC relative to GCB, while green is for 






Figure 10-12 Heatmap of top candidates overlapped between signature genes of  
ABC vs. GCB and RNAi screening identified candidates lethal to ABC or GCB. 
―z.GEP‖ is the z score indicating differntial expression of ABC vs. GCB. ―z.shRNA‖ 
indicates the z score of comparing RNAi screening data of ABC vs. GCB cell 
lines. ―z.negGEP.shRNA‖ is a combined z score of negative z.GEP and z.shRNA. 
Negative z.GEP is used because negative z.shRNA for gene X indicating X is 
depleted in ABC samples and we expect it‘s over-expressed in GEP data or 





negative z.GEP is used to indicate the evidence of being depleted and over-
expressed in one subtype. 
10.3.8 Crossing RNAi screening with NetBID2-predicted drivers of ABC vs. 
GCB 
More interesting and more robust integration is to cross our NetBID2-predicted 
drivers with RNAi screening results to identify driver-type therapeutic targets for 
ABC or GCB-type DLBCL. We used the cohort of 230 DLBCL samples to build a 
B-cell interactome and applied NetBID2 on the signature of 35 ABC vs. 50 GCB 
samples. We applied the following selection criteria and identified 64 driver-type 
therapeutic targets for ABC or GCB-DLBCL (Figure 10-13). 
 GEPs: as a MR, P<0.05 
 RNAi Screening: 
o Significant in combined ABC vs. GCB: P<0.05 
o Depleted in either only HBL1 (ABC) or only all three GCB lines 
If we loosed the selection criteria from requiring depletion in all GCB lines to 







Figure 10-13 Heatmap of top candidates crossing RNAi screening results with 
NetBID2-predicted drivers specific to ABC or GCB-DLBCL. ―nES‖ is the 
normalized enrichment score as evidence of being a driver. ―z.GEP‖ is the 






Figure 10-14 Heatmap of top candidates crossing RNAi screening results with 
NetBID2-predicted drivers specific to ABC or GCB-DLBCL, based on a loosed 
threshold. ―nES‖ is the normalized enrichment score as evidence of being a 





10.3.9 Crossing RNAi screening with CNV data 
In this study, we also had copy number variants (CNV) data for 29 ABC and 26 
GCB DLBCL primary samples. So with CNV data, we identified a list of genes 
that are amplified or depleted in ABC vs. GCB samples (Figure 10-15). Then we 
crossed with RNAi screening results and identified 48 candidates (Figure 10-16) 
with the following criteria: 
 CNVs: as a signature, P<0.05 
 RNAi Screen: 
o Significant in combined ABC vs. GCB: P<0.05 
o Depleted in either only HBL1 (ABC) or only all three GCB lines 
 Significant in combined CNV and shRNA: P<0.05 
 
Figure 10-15 Heatmap of top candidates from CNV profiles of ABC vs. GCB 






Figure 10-16 Heatmap of top candidates crossing CNV results with RNAi 
screening results for ABC vs. GCB-DLBCL. ―z.CNV‖ indicates amplification (red) 
or depletion (green) in ABC vs. GCB samples. ―z.negCNV.shRNA‖ is the 
combined z score of CNV result with shRNA differential represention score. The 





10.3.10 Crossing RNAi screening with NetBID2-predicted drivers and 
amplified genes from CNV data 
We further filtered the candidates by integrating RNAi screens with NetBID2-
predicted driver and with CNV results, and finally selected only eight driver-type 
candidates (Figure 10-17) that are lethal to ABC or GCB type DLBCL and show 
evidence of amplification in corresponding subtype with the following criteria: 
 GEPs: as a MR, P<0.05 
 CNVs: as a signature gene, P<0.05 
 RNAi screens: 
o Significant in combined ABC vs. GCB: P<0.05 
o Depleted in either only HBL1 (ABC) or only at least one GCB lines 






Figure 10-17 Selected eight candidates crossing RNAi screens with NetBID2-
predicted drivers and CNV results for ABC or GCB-DLBCL. 
―z.MR.negCNV.shRNA‖ is the combined z score of driver evidence, negative 






10.4 On-going and Future Work 
In the results section, I only showed the prediction results and selected promising 
candidate therapeutic targets specific to ABC or GCB type DLBCL. All selected 
targets are being validated by our collaborators. 
Another interesting genetic feature we were interested in is BCL2 translocation. 
We also talked a little about this in this chapter. Literature suggested different 
clinical outcomes of BCL2-translocated and non-translocated patients and needs 
to be treat differently. We have two BCL2-rearranged cell lines (BJAB and 
SUDHL4) and clustering analysis based on functional profiles showed significant 
difference of these two BCL2-rearranged lines with the other two non-rearranged 
cell lines. We have performed similar analysis with ABC vs. GCB subtype and 
identified potential therapeutic targets specific for BCL2-rearrangemnt, which are 





Chapter 11 Integrating Functional Genomics with Systems 
Biology on Therapeutic Target Discovery for Subtype 
or Genetic-feature Specific Breast Cancer 
11.1 Introduction 
The goal of this chapter is to apply the integrative framework of crossing RNAi 
screening with systems biology to identification of therapeutic targets that are 
specific to subtype-based breast cancer and genetically-defined breast cancer. 
For subtype-based breast cancer, we focused on luminal and basal types which 
are two well-classified forms of breast tumors based on transcriptional profiles. 
We did genome-wide shRNA screens using NGS technology on 16 breast cancer 
cell lines in which four are luminal subtype and eight are basal subtype. From 
RNAi screens, we identified candidates that are lethal to each cell line and lethal 
to only luminal or basal subtype cell lines. In parallel, we applied our NetBID2 
algorithm to TCGA gene expression data of breast cancer and identified drivers 
for basal vs. luminal subtype. Then integrating RNAi results with computationally-
predicted drivers suggested potential therapeutic target candidates for luminal or 
basal type of breast cancer. The graphical explanation of the integration 






Figure 11-1 The integrative framework of RNAi Screening with NetBID2 to 
identifiy potential therapeutic targets specific to basal or luminal type of breast 
cancer. On the left, we did shRNA screening on 16 breast cancer lines including 
8 basal and 4 luminal by NGS. On the right, we applied NetBID2 to TCGA breast 
cancer gene expression profiles to identify drivers of basal vs. luminal subtype. 
Breast cancer can also be classified by various genetic features such as 





with tumorigenesis or progression. In this study, we applied the same idea in 
Chapter 9 by employing an isogenetic model and mimicking genetic alternations 
in a normal breast cell line, MCF10A. We focused on oncogenes of PI3K, MYC, 
ERBB2, CCND1, and tumor suppressors of E1A (RB1), PTEN. We did shRNA 
screens on those genetically-engineered models. Comparing shRNA abundance 
in mutated cells with the control of wild type, we identified candidates that are 
functionally related to the corresponding oncogene or tumor suppressor, forming 
a synthetic lethal pair. 
11.2 Drivers and Therapeutic Targets for Basal or Luminal type 
Breast Cancer 
11.2.1 Summary for shSeq data of 16 breast cell lines 
We did shRNA screens using high-throughput sequencing or NGS on 16 breast 
cell lines, which are characterized in Table 11-1. Among 16 breast cell lines, 
there are four basal A, four basal B, two normal but basal B like based on 
transcription profiles, and two inflammatory breast cancer (IBC) lines. The 
deconvolution of shSeq data for 16 cell lines is summarized in Table 11-2. In 
generally, over 75% of total reads can be identified in terms of sample conditions 
and shRNA hairpins, and most samples have enough identified reads (over 5 
million in total or 80 per hairpin on average). The default Illumina filtering 
procedure might be useless (last two columns in Table 11-2) because the 
sequence we care about is the first 6 nucleotides for barcodes of samples and 





The shSeq data for all 16 cell lines are in good quality, except T47D highlighted 
as an outlier in Figure 11-2. 
 
Table 11-1 Characteristics of 16 breast cell lines with shRNA screening data.  
BaA=Basal A; BaB=Bsal B; Lu=luminal, ER/PR/HER2/TP53 status: ER/PR 
positivity, HER2 overexpression, and TP53 protein levels and mutational status 
(obtained from the Sanger web site; M=mutant protein; WT=wild-type protein) are 
indicated. Square brackets indicate that levels are inferred from mRNA levels 
alone where protein data is not available. A/B: A is from Neve, et al, Cancer Cell, 
2006; B is from Kao et al, Plos One, 2009. AC=adenocarcinoma; 
AnCa=anaplastic carcinoma; C Sar = carcinoma sarcoma; DC=ductal carcinoma; 
F=fibrocystic disease; IDC=invasive ductal carcinoma; Inf=inflammatory; Met AC 
= metastatic adenocarcinoma PB=primary breast; RM= reduction mammoplasty; 











Table 11-2 Summary for deconvolution of shSeq data for 16 breast cell lines. 
Numbers in red are the samples that have < 5M identified reads. The last two 
columns are using the default Illumia filtering criteria. 
 
Figure 11-2 Clustering of shSeq samples by normalized data. Each row is for one 
sample condition. Three boxes on each row are the biological triplicates. One 
replicate T47D.T0 is highlighted as an outlier. 
11.2.2 Results of differential representation analysis 
For each cell line, we performed differential representation analysis comparing 





BHM algorithm. Summarized statistics including p value and z score are plotted 
in Figure 11-3 and Figure 11-4. 
 
Figure 11-3 Histogram of p value at gene level activity analysis for shRNA 






Figure 11-4 Density plot Histogram of z score at gene level activity analysis for 
shRNA screens of 16 breast cell lines. 
11.2.3 Unsupervised clustering of functional profiles separate subtypes 
well 
With functional profiles indicating silencing effects in each line, we asked whether 
the clustering of functional profiles showed consistence with the clustering of 
gene expression profiles that defined different subtypes of breast cancer. So we 
performed unsupervised clustering analysis of 14 breast tumor cell lines using 





be separated into five clusters: the red one on the left is for HER2+ subtype; the 
yellow one is for luminal; the green one is IBC, the most aggressive form of 
breast cancer, showing very different performance with the others; the blue one 
is for basal B, and the purple one is for basal A. If we only considered two 
clusters, one big cluster on the left is more like luminal subtype including HER2+, 
and the other on the right is more like basal subtype. This suggested that 
functional profiles from shRNA screening are able to separate different subtypes 
well. 
 
Figure 11-5 Clustering of 14 breast tumor cell lines by funtional profiles. 





11.2.4 Top candidates that are common in all breast tumor lines 
Before discussing about essential genes specific to any subtype of breast cancer, 
we first asked whether there is any common gene that is depleted or enriched in 
all breast tumor lines. Those candidates might be potential targets for the 
majority of breast tumors. We used Stouffer‘s method to combine shRNA 
screening data of 12 tumor lines with good data and 912 genes were selected 
with a combined p value less than 0.01 (Figure 11-6). 
 
Figure 11-6 Heatmap of functional profiles for top depleted or enriched genes 





a combined z score of all 12 tumor lines using Stouffer‘s method. ―12T‖ is the z 
score of combining 12 tumor lines. Similarly, ―4Lu‖ is combining 4 luminal lines, 
―3BaA‖ for basal A lines, ―5BaB‖ for 5 basal B lines including SUM149PT, and 
―2N‖ for two normal lines. 
11.2.5 Sensitivity analysis: difference between depleted essential genes 
and enriched tumor suppressor genes 
With shRNA profiles of a panel of 16 breast cancer lines, we have the ability to 
do so-called ―sensitivity analysis‖ (Figure 11-7) to address the question of how 
sensitive each cell line is to respond RNAi perturbation or how easily to kill a cell 
line by RNAi. Details were discussed in 2.9.2. 
 





11.2.6 Supervised clustering analysis of functional profiles identifies 
subtype specific lethal genes 
We performed supervised clustering analysis on basal vs. luminal breast cancer 
cell lines using their functional profiles. Interestingly, top differentially-behaved 
genes in basal vs. luminal types also classify other subtypes well such as HER2+, 
IBC, basal A, and basal B (Figure 11-8).  
 
Figure 11-8 Heatmap of top shRNA screening identified candidates using 
functional profile. Functional profile is defined by differential representation score 





11.2.7 Functional enrichment of lethal genes specific to basal or luminal 
subtype 
We performed the functional enrichment analysis to identify potential pathways 
that are essential to either basal or luminal type of breast cancer. A combined z 
score was generated for each gene for all luminal lines or basal lines. BSEA 
method was used to estimate the enrichment of known pathways. We identified 
that ESRRA up-regulated targets are lethal to luminal type, ESRRA down-
regulated targets, COPI mediated transport pathway, ribosome pathway are 
lethal to basal type (Figure 11-9). More interestingly, E2F family proteins with 
their targets showed lethal effects to basal type of breast cancer (Figure 11-10). 
 







Figure 11-10  Top enriched pathways by depleted genes in luminal or basal 
subtypes. Top lethal genes in the pathways are listed. 
11.2.8 Crossing with NetBID2-predicted drivers of basal vs. luminal subtype 
Out of 359 TCGA primary breast cancer patients with gene expression profiles, 
78 are classified as basal type and 188 are luminal. With these data, we applied 
the NetBID2 algorithm to predict drivers of basal or luminal breast cancer, and 
then crossed with shRNA screening identified basal or luminal specific lethal 
genes. The integrative analysis with stringent threshold yielded only three 
candidates, in which two signaling proteins, GNA14 and ATP6V1G2, were 
predicted as drivers and showed lethal effects in luminal breast cancers, while 






geneSymbol funcType n.shRNAs nES z.DE z.BaVSLu.geneLevel 
GNA14 Sig 3 -2.23 -3.28 4.29 
ATP6V1G2 Sig 3 -2.75 -6 2.26 
E2F2 TF 1 2.39 7.51 -2.34 
Table 11-3 Overlapped candidates of NetBID2-predicted drivers and RNAi 
Screening identified lethal candidates for basal or luminal subtype. ―nES‖, 
normalized enrichment score, indicates the driver prediction strength. ―z.DE‖ 
indicates the differential expression of the gene itself. ―z.BaVSLu.geneLevel‖ is 
the z score of comparing shRNA screening profiles of basal with luminal cell lines. 
GNA14, ATP6V1G2 are potential therapeutic targets for luminal subtype, while 
E2F2 is for basal subtype. 
11.2.9 Consistency with drug sensitivity data 
Out of the 16 breast cell lines we did shRNA screening, we also had the 
sensitivity data for 12 lines treated by 74 small molecules or compounds [247]. 
Known targets for those 74 drugs were also collected from drugbank database 
[248]. We used the drug targets to connect shRNA screening data with drug 
sensitivity data and checked the consistence of drug effects with shRNA 
silencing effects on cell viability. 
Here we only focused on a specificity study of basal and luminal, the two major 
subtypes of breast cancer. The basic idea was to perform specificity analysis of 
comparing basal vs. luminal cell lines using drug sensitivity data only, shRNA 
screening data of drug targets only and a combined meta-analysis of both. The 





subtype-specific drugs also show up in the specificity analysis of shRNA screen 
data and half of which show the same direction. 
 
Figure 11-11 Specificity analysis by linear model using drug sensitivity data and 
shRNA screening data, also combination. Combination using known targets of 
drugs matched with shRNA screening data. Combined analysis is done using 






Figure 11-12 Number of significant drugs that are specific to basal or luminal 
using different data source at various p value cutoffs. ―n.drugs‖ is using drug 
sensitivity data only. ―n.drugs.shRNA‖ is based on shRNA data of drugs‘ targets.  
―n.overlap.drugs‖ is the number of overlapped drugs between ―n.drugs‖ and 
―n.drugs.shRNA‖. ―n.consist.drugs‖ is the number of overlapped drugs showing 
consistent direction in both shRNA screening results and drug sensitivity results. 
Green dashed line is half of the green line, and so is the red dashed line. 
We used the functional profiles of targets from top drugs that are specific to basal 
or luminal type to classify basal and luminal breast cancer cell lines, and they 
separated the two subtypes well (Figure 11-13). This again confirmed a large 






Figure 11-13 Heatmap of top drugs using their sensitivity data and their targets‘ 
shRNA scores. 
Out of top candidates, we observed that luminal breast tumors are sensitive to 
inhibitors of HDAC4 (Figure 11-14) and HDAC1 (Figure 11-15), confirmed by 
their shRNA performance; and basal breast tumor cells are sensitive to inhibitor 








Figure 11-14 HDAC4 is specific to luminal type breast cancers shown by 
sensitivity data of HDAC4 inhibitors (left) and shRNA screening data of HDAC4 
hairpins (right). 
 
Figure 11-15 HDAC1 is specific to luminal type breast cancers shown by 







Figure 11-16 IKBKB is specific to basal type breast cancers shown by sensitivity 
data of IKBKB inhibitor (left) and shRNA screening data of IKBKB hairpins (right). 
However, there might be some issues with the drug sensitivity data we have to 
be careful with. For example, drugs targeting the same targets might show 
different sensitivity. The sample size of cell lines in each subtype might make the 
analysis less powerful. More data might the produce more accurate results. 
11.3 RNAi Screens to Search for Synthetic Lethal Partners of 
Genetic-features in Breast Cancer 
Breast cancer are also characterized by a number of genetic features such as 
PI3K, MYC, CCND1, ERBB2 oncogenes and PTEN, RB1 tumor suppressors. We 





features in breast cancer. We used shRNA screening to search for lethal genes 
that are specific to genetic-feature defined breast cancer. To avoid heterogeneity, 
we used an isogenetic model – MCF10A cell line – and genetically introduced 
engineered amplification of PI3K, ERBB2, MYC, CCND1 and depletion of PTEN 
and E1A individually. Then we did shRNA screening using NGS for each of those 
engineered models. 
11.3.1 Summary for the shSeq data of genetically-engineered models 
We performed shRNA screening using NGS technology for six genetically-
engineered MCF10A models including PI3K, ERBB2, MYC, CCND1, PTEN and 
E1A. The cell culture was under 2D system and the infected cells were harvested 
for 10 generations. Most of the shSeq data had enough signals expect MYC 
(Table 11-4). And QC report of normalized data showed all the shSeq data were 
in good shape (Figure 11-17, Figure 11-18). 
 
Table 11-4 Summary of deconvolution of shSeq data for six genetic-engineered 






Figure 11-17 Distribution of hairpin count in samples of six genetic-engineered 
models. 
 






11.3.2 Overall gene level activity for each genetic-feature defined breast 
cancer 
As usual, we performed differential representation analysis at both individual 
shRNA level and gene level for each of the six shSeq datasets. Summary 
statistics including p value (Figure 11-19) and z score (Figure 11-20) showed 
reasonable results as the uniform distribution of non-significant p values. With a p 
value threshold of 0.05, numbers of significant candidates in each of six models 
or in at least 1 to 6 models were summarized in Table 11-5. One interesting thing 
we noticed is that there is a significant bias between number of depleted and 
enriched genes in most of the genetic features: number of depleted genes in 
CCND1, PTEN, PI3K and E1A is much smaller than enriched ones, while ERBB2 
and MYC are on the opposite. 
 
Figure 11-19 Histogram of p values for gene level differential representation 






Figure 11-20 Density plot of z scores for gene level differential representation 
analysis of shSeq data from six genetic-engineered models. 
 
Table 11-5 Number of significant depleted or enriched genes in each of six 
genetically-engineered models (left) and in at least 1 to 6 these models (right). 





11.3.3 Sensitivity difference between genetic-features in breast cancer 
We were interested in the sensitivity difference of various genetic backgrounds, 
especially the difference between oncogenes and tumor suppressors. Therefore, 
we performed sensitivity analysis by counting the number of depleted or enriched 
genes in each case. As shown in Figure 11-21, for the depleted genes or 
synthetic lethal partner genes, there is a significantly decrease from ERBB2 to 
MYC to PI3K to PTEN to E1A and to CCND1, which can be grouped into ERBB2 
class, PI3K and MYC class, PTEN, E1A and CCNC1 class. In general, 
oncogenes (ERBB2, MYC, PI3K) are much more sensitive than tumor 
suppressors (PTEN, E1A). However, for the enriched genes, there is no such 
clear pattern, consistence with what we have seen in other screening data. 
 






11.3.4 Unsupervised clustering genetic-features in breast cancer by 
functional profiles 
We also did unsupervised clustering of six genetic features using their functional 
profiling scores (Figure 11-22). Interestingly, there is a clear separation between 
tumor suppressors and oncogenes, which might reflect intrinsic and fundamental 
difference between these two types of tumor casual genes. 
 
Figure 11-22 Unsupervised clustering of six genetic-engineered models by their 
shRNA screening functional profiles. 
11.3.5 Top candidates genetic-features in breast cancer by functional 
profiles 
Top candidates or synthetic lethal pair genes were selected by the criteria of p 





11-23). There are only 16 genes (P<0.05) essential for all 6 driver mutations. The 
clustering based on these depleted candidates also classified tumor suppressor 
genes and oncogenes well. 
 






11.4 Ongoing and Future Work 
Identified candidates for basal or luminal type of breast cancer are being under 
validation. Other analysis to identify drivers and therapeutic targets specific to 
basal A, basal B, IBC type of breast cancer will be conducted. This is a joint 
project with Archana Iyer, Celine Lefebvre, Mariano Alvarez and Yao Shen from 





Chapter 12 Additional shSeq Applications 
12.1 Overview 
In addition to all the projects that employed the NGS-based shRNA screening 
(shSeq) technology for therapeutic target discovery as I demonstrated previously, 
I have also been involved in many other projects by applying shSeq technology 
in different contexts for different purposes. These additional applications are in 
collaboration with over ten labs at Columbia. I have analyzed all shSeq data 
generated at Columbia Genome Center. In total there are over 50 screens with 
over 10 billion of reads, and the data size is over 5 TB data. The following are a 
few examples. 
12.2 Therapeutic Targets for MYCN-amplified Neuroblastoma 
Amplification of MYCN is one of the most important genetic prognosis factors for 
nueroblastoma (NBL). Nueroblastoma patients with amplification of MYCN have 
much worse survival than non-MYCN-amplified patients. In this project, 
collaborating with labs of Darrell Yamashiro and Jose Silva, we aimed to search 
for therapeutic targets for MYCN-amplified NBL by using shRNA screening. We 
used an isogenetic model by introducing MYCN amplification in a MYCN- NBL 
cell line under normoxia and hypoxia environments and did shRNA screening 
using both microarray and NGS technologies. The results shown below were 





are lethal to MYCN-amplified NBL cells were selected from individual analysis of 
normoxia and hypoxia conditions. Pathway analysis revealed that PI3K and GSK 
pathways (Figure 12-2) seemed to mediate MYCN amplification and serve as 
potential targeting avenues to stop MYCN+ NBL cells.  Interestingly, known up-
regulated targets of MYC showed a significant enrichment in depleted genes of 
MYCN+ NBL cells (Figure 12-3) and top depleted MYC activated targets (Figure 
12-4, Figure 12-5, Figure 12-6) might be interesting therapeutic targets for 
treatment of MYCN amplified NBL. 
 
Table 12-1 Summary of deconvolution for shSeq data of MYCN-amplified and 
non-MYCN-amplified nueroblastoma samples under normoxia and hypoxia 
enrionments. ―OFF‖ is dox-off representing MYCN-amplification, while ―ON‖ is for 







Figure 12-1 Heatmap of shSeq profiles for top hairpins depleted or enriched in 






Figure 12-2 Top pathways enriched by depleted hairpins in MYCN-amplified NBL 
line under normoxia condition. 
 
Figure 12-3 MYC up-regulated targets is enriched by depleted hairpins in MYCN-






Figure 12-4 RPL13 and HNRNPA2B1 as MYC activated targets are lethal to 
MYCN-amplified NBL cells. 
 







Figure 12-6 CDC25C as MYC activated target is lethal to MYCN-amplified NBL 
cells. 
12.3 Overcoming Cisplatin or PARP Inhibitor Resistance in 
Small Cell Lung Cancer 
Cisplatin is one of the most commonly used chemotherapeutic agents for solid 
tumor, such as small cell lung cancer because Cisplatin is able to trigger 
apoptosis by causing crosslinking of DNA. However, over 70% of patients with 
Cisplatin treatment are resistant or relapse to develop resistance. PARP1 is 
important for repairing single-strand break and its inhibition causes multiple 
double strand breaks. PARP inhibitor is a new on-trial drug for treatment of lung 
cancer and it has been that shown to have dependence on BRCA-mutated 
cancer cells. However, a large percentage of lung cancer patients have no 
response to PARP inhibitor treatment. Collaborating with Haiying Cheng and 
Jose Silva, this project aimed to search for therapeutic targets or modifiers to 





lung cancer. Pooled shRNA screens by NGS were performed for a lung cancer 
cell line with and without Cisplatin (IC20 dose) treatment or PAPR inhibitor (IC50 
dose) treatment. DMSO was used as control. Potential modifiers of resistance 
would be dropped out in the treated cells comparing with DMSO control. In the 
NGS data, nine samples were mixed together for barcode sequencing and all 
samples except one were successfully deconvoluted (Table 12-2). Analysis of 
individual hairpins was done using both statistical shADER method and simple 
fold change analysis (Figure 12-7, Figure 12-8 and Figure 12-9). Top candidates 
to reverse resistance to Cisplatin or PARP inhibition treatment were selected 
(Figure 12-11), and top enriched pathways were identified (Figure 12-10). 
 
Table 12-2 Summary of shSeq data for small cell lung cancer with and without 
Cisplatin or PARP inhibitor treatment. Cis=Cisplatin, PARP=PARP inhibitor, 






Figure 12-7 Histogram and boxplot of fold change (log2 transformed) of averaged 
and three individual replicates of shSeq data Cisplatin treatment vs. DMSO. 
 
Figure 12-8 Histogram and boxplot of fold change (log2 transformed) of averaged 






Figure 12-9 Cumulative distribution plot of log2-transformed fold changes of 
shSeq data of Cisplatin or PARP inhibitor treatment vs. DMSO. 
 
Figure 12-10 Heatmap of top depleted genes in Cisplatin or PARP inhibitor 






Figure 12-11 Top enriched pathways by depleted candidates from shSeq results 
of Cisplatin treatment comparing DMSO control.  
12.4 Genetic Modifiers of SMN as Therapeutic Targets for Spinal 
Muscular Atrophy 
Spinal muscular atrophy (SMA) – the most common genetic cause of death in 
infancy – is a motor neuron disease caused by reduced expression of the 
survival motor neuron (SMN) protein. SMA patients have homozygous loss of the 
SMN1 gene and retain at least one copy of the nearly identical SMN2 gene. 
Currently, there is no effective treatment for SMA and most therapeutic efforts 
focus on identifying strategies that enhance expression of SMN from the SMN2 
gene. However, discovery efforts for SMA therapeutics are hampered by the 
limited knowledge of suitable targets. Collaborating with Livio Pellizzoni and Jose 





expression and function of the SMN protein with the ultimate goal of identifying 
novel avenues of therapeutic intervention for SMA via genome-wide RNAi 
screening. Preliminary results were reported in Table 12-3 and Figure 12-12. 
 
Table 12-3 Summary of deconvolution of shSeq data for SMA project.   
 
Figure 12-12 Histogram of p values and density plot of z scores from differential 





12.5 Positive shRNA Screens to Identify Novel Modulators of 
P53 Pathway 
In collaboration with Wei Gu and Jose Silva, this project aims to identify genes 
that are able to survive P53 induced apoptosis as potential modulators of P53 
pathway. A positive shRNA screen using NGS was carried out on a P53 null cell 
line with and without P53 inducement in four replicates. The deconvolution of 
shSeq data looked fine (Table 12-4), however, the distribution of read counts 
(Figure 12-13) and results of differential representation analysis (Figure 12-14) 
reflected some flaws of this experiment. For example, there is one or two hairpins 
which have a count of over 2M, about 1/5 of total reads in each sample, and the 
majority of hairpins have zero or very low count. Also the distribution of non-
significant p values showed abnormal behavior. 
 






Figure 12-13 Consistence of replicates for shSeq data of P53 positive screen.  
 
Figure 12-14 Histogram of p values and density plot of z scores from differential 





12.6 Overcoming Resistance to Glucocorticoid or NOTCH-
inhibition in T-ALL 
This study continued the project of glucocorticoid resistance in Chapter 7 and 
Chapter 8 by using NGS technology and screening one more cell line, and also 
aimed to identify therapeutic targets to reverse resistance of NOTCH-inhibition, 
another major strategy for treatment of NOTCH1-mutated T-ALL. Genome-wide 
shRNA screens by NGS were performed on three cell lines with and without 
glucocorticoid or NOTCH-inhibitor treatment, in which all three are resistant to 
glucocorticoid and two are resistant to treatment of NOTCH inhibition. 
 
Table 12-5 Deconvolution of shSeq data for glucocorticoid or NOTCH-inhibition 
resistance in T-ALL. The sequence run in dark red is the re-sequenced because 






Figure 12-15 Heatmap of sample distances and PCA plot of samples showed 
consistence with biological meanings. 
 
Figure 12-16 Unsupervised clustering of conditions in shSeq studies for 






Figure 12-17 Sensitivity analysis of shSeq studies for glucocorticoid or NOTCH-
inhibition resistance in T-ALL. 
 
Table 12-6 Number of significant (P<0.05) candidates in each of the five cases or 
in at least one to five cases of shSeq studies for glucocorticoid or NOTCH-






Figure 12-18 Top candidates that are depleted in at least one of five cases in 
shSeq studies for glucocorticoid or NOTCH-inhibition resistance in T-ALL. 
Deconvolution (Table 12-5) and QA (Figure 12-15) showed all shSeq data were 
in good shape. In unsupervised clustering (Figure 12-16), functional profiles from 
the same cell line were clustered together, revealing intrinsic difference between 
the three cell lines. Sensitivity analysis (Figure 12-17) showed a decrease of 
sensitivity from CUTLL1 to HPBALL to JUKAT. Top candidates (Table 12-6, 






Chapter 13 A Dynamic Web System for Collaboration 
Management 
13.1 Overview 
To facilitate our research and to manager a large number of collaborative 
projects, in winter 2009, I developed a user-friendly and dynamic web system for 
the lab (http://califano.c2b2.columbia.edu). This system is under Apache-PHP-
MySql framework. It is based on Drupal [249] an open-sourced content 
management system and Open Atrium [250], an Drupal-enabled team 
collaboration tool. It is project or group-oriented: each project is a group and 
within the group, you can create accounts for your collaborators and add existing 
users into this group. You can share documents, blogs, events, tweets, 
comments, or anything within the group. You can make the group public or 
private. This system also supports different user roles with different level of 
permissions. So far over 60 groups have been created and over 120 users, of 
which half are collaborators, have been added. 
13.2 Features 
In the following, I will demonstrate with snapshots a few representative features 






Dashboard is the default home page after you log into the system (Figure 13-1). 
It shows the latest activities in your groups including shoutbox messages, blog 
teasers and list of group-tagged activity titles. ―All activity‖ shows all activities you 
are permitted to view. ―My threads‖ shows the posts that you are subscribed to. 












Figure 13-2 Collaborative web system: site dashboard - files 
13.2.2 Group 
The key feature of this system is to organize contents in groups (Figure 13-3, 
Figure 13-4, Figure 13-5, and Figure 13-6). A group could be created for (only by 
current member) 
 an on-going project by who is mainly in charge (group admin) 
 a topic of interest: e.g. Computational Group 
 general membership: Lab General Activities. 
The user who creates the group is automatically as group admin, which can 
add/approve new members, give member admin permission, add new account 
for collaborator and modify group settings, etc. 





 Public group: everything is public to all users in the system 
 Private group: only available for group members. 
 
Figure 13-3 Collaborative web system: my groups 
 






Figure 13-5 Collaborative web system: users-groups 
 





13.2.3 User Roles 
This system is customized to have different roles for different levels of permission 
to control the management and collaboration (Figure 13-7). It supports the 
following roles: 
 Manager: manage all projects and all members 
 Current Member: create groups, access their own and all public content, 
access view profiles 
 Collaborator: only access their groups and public content, cannot create 
group and view group directory, cannot view other people‘s profiles 
 Intern or Rotation Student: similar with collaborator except they can view 
group directory 
 Past Member: similar with collaborator. 
 





13.2.4 Document / Wiki 
The most commonly used content type to share and communicate within a group 
is document or wiki page (Figure 13-8, Figure 13-9). A document could be 
 a web page for project description, software usage, useful resources 
 a collection of presentation slides (in the attachment) 
 a manuscript by many authors. 
The document content type has the following features: 
 Organized by the format of book (Figure 13-11) 
 Wiki: editable by any people in the group 
 revision control: revert, show diff (Figure 13-10). 
 






Figure 13-9 Collaborative web system: a document 
 
 







Figure 13-11 Collaborative web system: document creating page 
13.2.5 Calendar Event 
The calendar event is used for manage and record lab meetings or meetings with 
collaborators (Figure 13-12). An event could be 
 a lab meeting 
 a seminar or talk you would like to share with people 












A blog entry (Figure 13-13) is generally used for 
 a discussion for anything about the project or group 
 a review or comment on interesting papers 
 a further discussion about a seminar talk or a presentation 
 any suggestion to your group or the lab 
 anything about your life and research. 
 





13.2.7 Project and case tracker 
You can create projects within a group, assign it to any group members and keep 
track of the project status using the feature of ―Case Tracker‖ (Figure 13-14). The 
status of a case can be Open, Resolved, Deferred, Duplicated, Closed. The 
priority can be defined as High, Normal, or Low. You can also define case types. 
 





13.2.8 Shoutbox / Twitter 
The shoutbox feature (Figure 13-15) is like the twitter or facebook status function 
to share a short message, a link, a comment, a word about your mood, etc. 
 
Figure 13-15 Collaborative web system: shoutbox or twitter in a group 
13.2.9 Images 







Figure 13-16 Collaborative web system: image or photo collection 
13.2.10 Notification and others 
Notification feature allows the user to send out email notification when a content 
entry is created or updated. The user can choose subscribe to all content type in 
the group or to author so that the notification will be automatically sent out. 
There are many other web 2.0 or web 3.0 features that this system supports, 
such as personalization, in which you can customize background color, logo, 
layout of your group and customize your personal page including background 
color, avatar, profiles, editor, etc. The content in the system is context-dependent, 
which only shows related links or tabs when you are view a page. It also supports 






13.3 Insights into Biological Systems from Software Systems 
This website I created for lab collaboration management is a software 
engineering system which is built by different elements on different layers. 
Actually from the architecture of this engineering system, we might gain some 
insights into reverse-engineering and better understanding the nature or 
biological system (Figure 13-17). For example, the data content in this web 
system is similar to DNA, RNA or protein in the cells of biological system; the 
underlying modules in the web system are like the signaling transduction,  
 
Figure 13-17 An analogy among software system, hardware system and 





transcription, translation, regulation, and other basic and fundamental units in the 
living cells; blocks or menus that are built on those underlying modules in the 
web system are the functional pathways or biological processes that are formed 
by basic units; also in the web system different users or units have various 
permissions to function normally and similarly in the cellular system, different 
players have specific rules to function well; finally the beautiful web styles and 
themes we view are like the phenotypes of biological system. The ―bottom-up‖ 
construction framework to engineer a functional software system helps us on ―up-
down‖ reverse-engineering of biological system. Additionally, the improvement of 
modules in current system on reusability, scalability and robustness also shed 
light on how to decipher underlying pathways in biological system (Figure 13-18). 
 






Chapter 14 Conclusions 
14.1 Key Contributions and Findings 
In this dissertation, I have showed you the power of integrating functional 
genome-wide RNAi screens with systems biology of cancer genomics to discover 
driver-type therapeutic targets for reversal of drug-resistance or treatment of 
aggressive human tumors.  
14.1.1 NGS-based shRNA screening (shSeq): an analytical pipeline 
For high-throughput RNAi screening, I have focused on NGS-based pooled 
shRNA screening (shSeq). The shSeq technology is new and there are no 
established tools to analyze such new data. I have developed a computational 
pipeline with a series of algorithms and software packages to deconvolute, QC 
and post-analyze shSeq data as detailed in Chapter 2. Specifically, the 
ShortRead+ package is used to do QA of raw NGS data; the shScanner package 
is for deconvolution of shSeq raw reads; shSEQ package is to annotate, 
normalize and do a secondary QC of shRNA abundance profiles; the method of 
shADER is for differential representation analysis at individual shRNA level, and 
the package of shMA/BHM is at gene level to identify potential depleted or 
enriched hits or candidates. 
In particular, I have developed a novel ―Modeling-All-Together‖ strategy using 





integrate multiple shRNAs targeting the same gene and estimate gene level 
activity. I have demonstrated that this algorithm consistently outperforms existing 
―Separate-And-Combine‖ methods such as RIGER, RSA, etc, especially when 
the data is in low-quality. 
14.1.2 Systems biology of cancer genomics: NetBID2 
In parallel, for systems biology of cancer genomics, I have developed a 
computational algorithm, Network-based Bayesian Inference of Disease Drivers 
(NetBID2), to infer regulatory or signaling drivers of diseases from high-
throughput transcriptomic data or gene expression profiles as detailed in Chapter 
4. NetBID2 is based on reverse-engineering cellular network and Bayesian 
inference. I have demonstrated that NetBID2 is more robust than conventional 
expression signature analysis; it is able to detect not only known drivers of 
human cancers but also, more importantly, the hidden drivers that traditional 
methods fail to find. Furthermore, experimental validation results have showed 
high prediction rates (>75%) of NetBID2. 
Additionally, for a key step of NetBID2 framework, I have developed a new 
enrichment analysis algorithm, Bayesian Set Enrichment Analysis (BSEA), as 
described in Chapter 5. BSEA uses ―maxmean‖ statistic to summarize 
enrichment score but is under Bayesian framework. According to evaluation 





14.1.3 Successful studies of integrating functional genomics with systems 
biology for driver-type therapeutic target discovery 
By integrating functional RNAi screens with NetBID2, I have identified known and 
novel driver-type therapeutic targets in various disease contexts. For example, in 
Chapter 7, I have discovered that AKT1 is a driver for glucocorticoid (GC) 
resistance, a significant clinical problem in the treatment of T-ALL. We have 
validated, both biochemically and pharmacologically, that the inhibition of AKT1 
is able to reverse GC-resistance in T-ALL. Additionally, integration of systems 
biology predictions with shRNA screens (Chapter 8) identified 16 master 
regulators of GC resistance, out of which 13 have been validated to significantly 
overcome resistance upon silencing, and more surprisingly, 10 have showed 
stronger effects than positive controls to sensitize GC-resistant T-ALL cells. 
In breast cancer, I have discovered that STAT3 is required for transformation of 
HER2+ breast cancer, an aggressive breast tumor subtype (Chapter 9). The 
suppression of STAT3 has been confirmed in vitro and in vivo to be an effective 
therapy for HER2+ breast cancer. Moreover, my analysis has revealed that 
STAT3 silencing has a co-dependence on ER-. 
With my integrative framework, I have also identified potential therapeutic targets 
for ABC or GCB-type DLBCL (Chapter 10) and subtype-based breast cancer 





14.1.4 Collaboration model between computational and experimental 
biologists 
This dissertation has demonstrated a perfect collaboration model between 
computational and experimental biologists. As a computational biologist, I have 
been interacting well with my biologist collaborators and have achieved a few 
successful interdisciplinary stories as shown in previous section. Additionally, I 
have been collaborating with over ten biological labs (Chapter 12) to apply my 
computational framework of shSeq technology for therapeutic target discovery or 
genetic modifier identification. Besides, I have developed a user-friendly and 
dynamic web system to manage collaborative projects (Chapter 13), which has 
helped to facilitate and speed up the communication between computational 
biologists and experimental biologist collaborators. 
14.2 Future Directions 
In this dissertation, I have shown that genome-wide RNAi screening technology, 
especially NGS-based pooled shRNA screening (shSeq), is indeed a powerful 
tool for therapeutic target discovery. However, there is much space to improve 
this technology and analysis of shSeq data. First, design of high quality shRNA 
library is much needed due to low silencing efficiency and off-target effects of a 
significant number of hairpin constructs in current libraries. A recent study [61] of 
enumerating RNAi performance of all possible hairpins sequences using a tilled 
sensor assay approach provides an opportunity to learn and develop an 





genes, therefore yielding a quality-improved and coverage-enlarged shRNA 
library. Second, with a design algorithm of shRNA construct, we can predict the 
knock-down efficiency or quality of existing hairpins in current library and filter or 
weight them when estimating gene level activity by integrating all shRNAs 
targeting the same gene. Third, the deconvolution of shSeq raw reads can be 
improved, in both time and space efficiency, by using optimal data structure such 
as suffix array or suffix tree. Additionally, Poisson distribution is currently used to 
model shSeq count data in differential representation analysis; however, negative 
binomial distribution might be a better try as widely used in RNA-Seq data 
analysis. Besides, it‘s challenging to extend the biological models of shRNA 
screening from 2D to 3D or in vivo systems, which are more close to the true 
living system. 
In this dissertation, we mainly focus on transcriptomic data or gene expression 
profiles, and use them to integrate with RNAi screening data. However, there are 
many other types of cancer genomic data such as copy number variations, SNPs, 
epigenomic, proteomic profiles and microRNA expression data, which are widely-
available and might be mined to cross with functional RNAi screens for discovery 
of underlying genetic mutation causes or dependence or translational and 
regulatory modifiers. 
Additionally, large amounts of context-specific small-molecule screens provide 
valuable resources and information for study of mechanism of actions for small 





screens would be able to identify drugs or compounds targeting RNAi screening 
identified therapeutic targets in specific tumor contexts, which will boost up 
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RNA interference (RNAi), a cellular process that regulates gene expression, has 
emerged as a powerful genetic venue to functionally interrogate the entire 
genome by loss-of-function studies. Small regulatory RNAs (siRNAs and miRNAs) 
bind to the enzymatic RNAi machinery and suppress the expression level of 
targeting mRNAs [2]. This process can be experimentally controlled to knock 
down the expression of any specific gene. 
Response to transfected siRNAs is transient, from 3 to 7 days, making this 
approach unsuitable for the analysis of silencing long-term effects. The search 
for a sustained silencing response has resulted in the development of a class of 
RNAi triggers denominated short hairpin RNAs (shRNAs). Plasmids expressing 
shRNAs are integrated into the cell genome, so that by continuously supplying 
the RNAi trigger, stable gene silencing can be achieved [3].  
Several groups have previously described the construction of shRNA libraries 
that cover a significant fraction of all human genes [4-7]. In this chapter, we use 
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Thermo Scientific Open Biosystems GIPZ Lentiviral Human shRNAmir Library as 
a model to illustrate the accomplishment of genome-wide RNAi screening. The 
library is composed of 58,493 hairpin constructs, in which 39,458 shRNAs are 
known to target 18,661 human genes, about 75% of the human genome. These 
shRNA-mirs are modeled after endogenous miRNAs, specifically contained in the 
backbone of the primary miR-30 microRNA [6]. Additionally, targeting sequences 
were selected, by a mathematical algorithm, to fit thermodynamic asymmetry 
rules. Overall, these shRNA libraries offer a convenient, flexible, and highly 
effective tool for studying gene function in human cells. 
There are two main approaches for screening large collections of silencing 
triggers for their effects on mammalian cells: cell-based assay and pooled 
screening. In the first method, individual siRNA or shRNA is transfected and 
screened in a multi-well format for the activation or repression of a reporter [8, 9]. 
In this format, individual genes are transiently suppressed 'one-by-one' and 
analysis is carried out in a high-throughput manner using a robotic platform. 
However, this method is expensive, labor intensive, and time consuming. On the 
other hand, pooled screening allows the ability to analyze the effects of the whole 
library at once. If, for example, a gene targeted by a particular shRNA induces 
response to a growth inhibitor stimulus, then its representation should increase 
after treatment. If a given shRNA sensitized a population to a specific stress, 
then, the relative abundance this shRNA should diminish after the stress. Using 





entire genome in loss-of-function studies and to find genes relevant to any 
biological process.  
The RNAi library can be used to perform either positive or negative screening 
(Figure 1). In a positive screen, cells that survive a selection pressure or that 
show a differentiating phenotype are selected. The specific shRNA leading to the 
recognizable cell population can be sequenced from the genomic DNA of 
isolated colonies or analyzed in a high throughput fashion. When performing a 
negative screen, populations that are sensitive to a selection pressure or that 
show an impaired growth are selected. In this case, the integrated shRNA will be 
depleted in the final population; microarray hybridization or next generation 
sequencing (NGS) technologies can be used to read out hairpin abundance. 
Careful design of the experimental pipeline is essential to answer the biological 
question. In the following sections, a protocol for conducting both positive and 






Figure 1 Procedure of a shRNA screen: transduce shRNA lentiviral library into 
cells of study with a MOI of ~ 0.3, filter out uninfected cells, grow cells for X 
doubling times, extract genomic DNA from T0 and TX, PCR amplify them, and 







1.2.1 shRNA Library 
The library pool consists of 58,493 shRNAs integrated into the backbone of 
miR30 and cloned into the pGIPZ lentiviral vector (Open Biosystems GIPZ 
Lentiviral Human shRNA Library). It is known that 39,458 of these shRNAs target 
18,661 human genes, which accounts for about 75% of the human genome. 
Number of haiprins varies in different platforms (Table 1-3), but on average, each 
gene has two to three shRNAs. Combining RNA polymerase II promoters with 
shRNAs in miR30-backbones permits efficient suppression even with the 
integration of a single copy. Each shRNA cassette contains two unique identifiers: 
the shRNA itself and a random 60-nucleotide barcode that was determined for 
the identification of a single shRNA amongst the human shRNA library. Overall, 
the shRNA library offers a convenient, flexible, and effective tool for studying 
gene function in human cells [10]. 
# 
shRNAs 
1 2 3 4 5 6 7 8 9 10 13 total 
Freq 
(genes) 
4092 4238 2792 1065 347 110 30 10 2 2 1 12689 
Table 1 Barcode-probed microarray platform: number of shRNAs frequency. 
# 
shRNAs 
1 2 3 4 5 6 7 8 9 10 11 12 13 15 total 
Freq 
(gene) 
2801 4362 4278 1837 678 248 88 27 13 8 2 1 1 1 14345 







1 2 3 4 5 6 7 8 9 10 11 13 Total 
Freq 
(genes) 
6934 5983 3628 1355 480 167 60 24 12 4 4 1 18652 
Table 3 Next generation sequencing platform: number of shRNAs frequency. 
1.2.2 Bacterial media 
Prepare, sterilize, and store the solutions at room temperature.  
1) SOC media: In a glass beaker, mix 0.5 g of NaCl, 5.0 g of yeast extract, 20 g 
of tryptone, 2.5 mL of 1M KCl, and 10 mL of 1M MgCl2. Add about 900 mL of 
ultrapure water and adjust the pH to 7.0 with NaOH. Using a cylinder, 
complete with water to one liter. Autoclave the solution, and while still warm 
add 10 mL of 40% Glucose.  
2) LB low salt media: In a beaker mix, 5 g of NaCl, 10 g of tryptone, and 5 g of 
yeast extract. Add 900 mL of ultrapure water and adjust the pH to 7.5 with 10 
M NaOH. Using a cylinder, complete with water to one liter. Before using, 
autoclave the solution. 
3) LB Ampicillin plates: In a beaker, mix 10 g of NaCl, 10 g of tryptone, 5 g of 
yeast extract, and 15 g of agar. Add 900 mL of ultrapure water and adjust the 
pH to 7.4. Using a cylinder, complete with water to one liter and autoclave the 
solution in a bottle. Once the LB agar is warm, add 1 mL of Ampicillin 
prepared as described in section 2.2.3. 






Prepare the solutions as described below. Once resuspended, filter and then 
prepare 1 mL aliquots. Store at -20 °C. 
1) Ampicillin: Weigh 1 g of Ampicillin and put into a conical tube. Add 10 mL 
of ultrapure water and dissolve by shaking.  
2) Zeocin: Weigh 1 g of Zeocin, put into a conical tube, and dissolve in 10 mL 
of ultrapure water.  
3) Puromycin: On a precision scale, weigh 20 mg of Puromycin. Add 10 mL 
of ultrapure water and dissolve by gently shaking the tube.  
1.2.4 Linear PEI  
Polyethylenimine (PEI) [11] is available in branched and linear forms and can be 
found in different molecular size polymers. However, low molecular Linear PEI 
(25kDa) is the one that shows the best transfection efficiency in our hands. The 
preparation of Linear PEI may be difficult because it is not highly soluable in 
water. To mix the linear PEI, it is necessary to stir and heat for a long time. As 
described in the Methods section, the drop by drop addition of HCl to the water is 
necessary to fully dissolve the Linear PEI. 
1. On a precision scale, weigh 323 mg of Linear PEI 25,000 Da. 
2. In a glass beaker, add 90 mL of ultrapure water and mix by warming and 
stirring the solution. Add HCl drop-wise until the product is completely 





3. Using a cylinder, adjust the volume of the solution to 100 mL. Store at -20 °C 
as a concentrated stock. 
4. Prepare the working Linear PEI solution by diluting the stock 1/10: In a 
conical tube, mix 9 mL of ultrapure water and 1 mL of concentrated Linear 
PEI. Mix by inverting the tube several times. Store the transfection reagent at 
4 °C until use.  
1.2.5 DNA precipitation 
3M NaOAc: In a glass beaker, dissolve 24.6 g of NaOAc in 80 mL of ultrapure 
water. Adjust the pH to 4.8 with Glacial Acetic Acid. Complete to 100 mL with 
ultrapure water. Autoclave the solution and store at room temperature.  













































5‘-  CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGTAATCCAGAGGTTGATTGTTCCA -3‘ 
Table 4 Sequence of example PCR primers including Illumina barcode for PCR 
preparation of RNAi screening 
1.2.7 Labeling 
1) Random primers: A random sequence of 6 nucleotides is used (NNNNNN). 
Dissolve dry hexamers in ultrapure water to a concentration of 100 OD 
units/mL; this corresponds with 15X concentrated primers. Make 5X primer 
Prepare aliquots and store at -20°C. 
2) 
1 M MgCl2
of ultrapure water. Mix by inverting the tube several times. Prepare 1 mL 





1.3 Experimental Procedures of a RNAi Screen 
1.3.1 Library preparation 
1.3.1.1 Bacterial transformation 
1) Thaw two vials of high efficiency electrocompet




careful not to generate bubbles and be careful to keep the cubette on ice at 
all the times. 
4) Prepare four polypropylene round-bottom tubes with 5-10 mL of SOC media 
(each tube will correspond with an electroporation cubette). 
5) Dry the cubette, put into the electroporator, and switch the electroporator on. 
Immediately, add 1 mL of SOC media to the cubette and pipette up and down 
gently. Collect the bacteria and pipette in to the previously prepared SOC 
media. Note that having an optimal bacterial transformation is critical to 
maintain the representation of the library. To ensure this it is important to 
perform every step gently and to keep the bacteria on ice at all times. After 
electroporation, the bacteria have to be pipetted in to SOC media immediately. 
This works better if the cubettes are electroporated one by one. 






of the transformation. Testing the efficiency of the transformation is an easy 
control for the efficiency of this process. The library is composed of almost 
60,000 shRNA and it has been determined that a good representation is 
having at least a representation of 1,000 times per shRNA; thus 6*107 
bacteria have to be transformed. From the 1 mL of bacteria that you remove, 
prepare the following dilutions: 
a. Dilution 1- 
colonies. 
b. Dilution 2- 1): You 
expect about 60 colonies. 
c. Dilution 3- 
expect more than 6 colonies. 
over night. Count the colonies the next day. 
8) Put to grow in a 37 °C shaker until saturation-usually about 24 hours.  
1.3.1.2 Plasmidic DNA extraction 
1) Harvest the bacterial cells by centrifugation at 6,000 x g for 15 minutes at 4°C. 
2) Using the QIAGEN Plasmid Mega Kit, follow the manufacturer‘s instructions 





1.3.1.3 Library validation 
It is necessary to confirm that the representation of each shRNA in the new 
plasmid library is equal to the representation of each shRNA in the original one. 
This can be checked by either hybridization to custom microarrays or by NGS of 
the PCR product (as described in section 2.3.7). 
1.3.2 Virus production 
Following sterile procedures, carry out all of the cellular manipulation in a hood.  
1.3.2.1 Plate Phoenix cells (Day 1) 
Aspirate the media from the Phoenix cells plate and wash with sterile PBS. 
Remove the PBS and add 1.5 mL of trypsin to cover the plate. Place 3 mL of 
PBS + 20% FBS into a conical tube. Once the cells have detached from the 
surface of the plate, take the liquid with a pipette and add to the conical tube. 
Centrifuge the cells at 1,200 rpm for 5 minutes at room temperature. Aspirate the 
media and resuspend the pellet in 5 mL of DMEM + 10% FBS. Count the cells 
and plate the amount necessary to have a confluency of 50-70% the next day. 
The number of cells plated the day before depends on the size of the plate, being 
optimal: 
a. In a 6-well plate: 6*105 - 8*105 cells 
b. For a 10 cm plate: 3*106 - 4*106 cells 





1.3.2.2 Transfection (Day 2) 
The following protocol has been constructed to perform a transfection in a 10 cm 
plate. If there is a need to increase the volumes, follow the instructions as 
described in Table 5 for DNA amount and Table 6 for linear PEI amount. 
Plate Total Lentiviral PMD CMV NaCl 
6-well      
10 cm 12      
15 cm      
Table 5 DNA amount reference for plate volume adjustment during transfection 
of RNAi screening 
Plate Linear PEI 
volume 
NaCl 
6-well   
10 cm   
15 cm   
Table 6 Linear PEI amount reference for plate volume adjustment during 
transfection of RNAi screening 
1) 
[12], and then pipette up and down several times. 
To the DNA mix, add 150 mM NaCl to Vortex 
gently and spin down briefly. 
2) 





3) solution. Mixing 
the solution in the reverse order may reduce the transfection efficiency. 
4) Vortex the solution immediately and spin down briefly. 
5) Incubate for 20 minutes at room temperature 
6) -wise to the cells in in a 
10 cm plate containing 10 mL of serum-containing medium and homogenize 
by gently swirling the plate. Return the plates to the cell incubator. 
1.3.2.3 Change media (Day 3) 
Carefully remove the media from Phoenix cells and replace with fresh DMEM + 
10% FBS media. The efficiency of the transfection can be assessed by 
visualizing the green cells with a fluorescence microscope. 
1.3.2.4 Collect the virus (Day 4) 
Collect the virus-
sterile filter. This virus-containing media can either be used to directly infect the 
cells or can be concentrated.  
1.3.3 Infection (Figure 2) 
Following sterile procedures carry out all of the cellular manipulation in a hood. 
The conditions for infection must be determined for each different cell line and 
batch of virus prepared, as described in section 2.3.4. 
1) Day 1: In a 6-well plate, plate the appropriate number of cells that is needed 





2) Day 2: In a conical tube, prepare a mix of fresh media and virus-containing 
media at the ratio calculated to produce a low infection efficiency. Add 
 
Remove the media from the 6-well plates and add the previously prepared 
mix. Centrifuge the plates at 1,000 rpm for one hour at room temperature. 
After the centrifugation, place the plates back in to the cell incubator. 
3) Day 3: Change the media of the infected cells. 
 
Figure 2 Pipeline for transfection and infection protocol in RNAi screening. 
Transfection procedure is schematized in the upper part of the panel. Plate 
Phoenix cells for a confluency of about 50 -70% the next day. On the second day 
follow transfection protocol and change the media 24 hours after. Finally, collect 
and filter the virus-containing media, this media can be directly used to infect the 
target cells or stored at -20 °C. The infection protocol is outlined under the 





The next day, remove the media and replace with media/virus-containing media, 
centrifuge the plate, and place back into the incubator. Change the media the 
next day and allow the cells to recover. Infection efficiency can be tested the next 
day or antibiotic can be added this same day to remove the uninfected cells. 
1.3.4 Infection efficiency test 
It is crucial to have a multiplicity of infection (MOI) lower than 1 (usually between 
0.1 and 0.3) to ensure that any observed effects are in response to the effects of 
a single shRNA. To ensure this, the number of cells and the ratio media to virus 
must be adjusted to have an efficiency of infection of 10 - 30% (see Note 7). In all 
the procedures, the manipulation of the cells must be performed in sterile 
conditions.  
The success of the screen depends on the fact that only single viral particle 
infects every cell, thus transductions should be performed at multiplicity of 
infection of less than 1 (typically between 0.1 and 0.3) having in account the 
Poisson distribution (Table 7). 
MOI 0 1 2 3 4 
0.1 0.90 0.09 0.00 0.00 0.00 
0.2 0.82 0.16 0.02 0.00 0.00 
0.3 0.74 0.22 0.03 0.00 0.00 
0.4 0.67 0.27 0.05 0.01 0.00 
0.5 0.61 0.30 0.08 0.01 0.00 
0.6 0.55 0.33 0.10 0.02 0.00 
0.7 0.5 0.35 0.12 0.03 0.00 





0.9 0.41 0.37 0.16 0.05 0.01 
1.0 0.37 0.37 0.18 0.06 0.02 
Table 7 Poisson Distribution Reference of Multiplicity Of Infection (MOI) 
1.3.4.1 FACS determination of infected cells 
1) Infect the target cells as described in section 2.3.3. 
2) 48 hours after infection collect the cells and spin down at 2,000 rpm for 5 
minutes at room temperature. Resuspend in 1 mL of PBS + 2% of serum and 
PBS + 2% serum. Pass the suspension of cells through a round-bottom tube 
with cell-strainer cap. 
3) Analyze the efficiency of infection by Cytometer by quantifying the percentage 
of cells that express green fluorescence protein (GFP). 
1.3.4.2 Cell number 
The efficiency of infection will change depending on multiple aspects of the target 
cell line; therefore it is necessary to determine the conditions for each case and 
for each new batch of virus prepared. The main factors to be determined are the 
number of plated cells and the dilution of the virus. Follow the following 
instructions as a first test and modify depending on the results attained. 
1) Day 1: Plate different amount of cells in every well of a 6-well plate. As an 
example, 1*105/2*105/3*105/5*105/7*105/1*106 cell per well can be seeded in 





2) Day 2: Infect the cells as described in section 3.3. The infection mix may be 
done in a ratio 1/1 or 2/1 (media/virus-containing media).  
3) Day 3: Change the media. 
4) Day 4: Determine the efficiency of the infection in every well by FACS.  
1.3.4.3 Ratio media/virus 
1) Day 1: In a 6-well plate, plate the number of cells to ensure an infection 
efficiency of around 50%.  
2) Day 2: In 3 conical tubes prepare 3 different infection mixes: 
3) Tube 1: 1 mL of fresh media + 1 mL of virus-containing media 
4) Tube 2: 1.5 mL of fresh media + 0.5 mL of virus-containing media 
5) Tube 3: 1.75 mL of fresh media + 0.25 mL of virus-containing media 
a.  
b. Aspirate the media from the 6-well plate and add a different mix to 
each well. Centrifuge the plate at 1,000 rpm for 1 hour at room 
temperature. Return the plates to the cell incubator 
6) Day 3: Change the media on the 6-well plates 
7) Day 4: Determine the efficiency of the infection in each well by FACS. 
1.3.5 Screening 
1.3.5.1 Infection 
The infection of a single particle of virus per cell is critical for de-convoluting the 
resulting phenotype, but it is also necessary to ensure that a minimum number of 





accepted that having a minimal representation of 50 - 100 times the number of 
shRNAs is enough for performing a positive screen, while a representation of 500 
– 1,000 is necessary for a negative screening. Thus, for positive screen, the 
minimum number of infected cells has to be 6*106 cells (while 6*107 in a negative 
screen). You must keep at least this same number in every passage, freezing 
aliquots or preparing pellets as you go.  
1) Day 1: Plate the previously determined number of target cells in 6-well plates 
(Section 2.3.4.2). Prepare as many plates needed to maintain the minimal 
representation of the library and prepare an additional plate to be used as an 
uninfected control. The number of plated cells has to be calculated taking in 
to account the minimal representation of the library and that not all of the cells 
will be infected. Typically, assuming a MOI of 0.3, it is necessary to plate 1.8 
*107 cells to obtain the 6*106 infected cells needed for a positive screen 
(1.8*108 in a negative screening). 
2) Day 2: In a conical tube, mix fresh media with the virus-containing media in 
accordance with the ratio established in section 3.4.3. Add polybrene to a 
 
Aspirate the media from the 6-well plates and add 2 mL of the diluted virus 
prepared in point 2. Add only fresh media to the uninfected control plate. 
Centrifuge the plates at 1,000 rpm for 1 hour at room temperature. Return the 
plates to the incubator after centrifugation. 
3) Day 3: Collect the infected cells from the 6-well plates and mix together in a 





confluency of about 70%. In a separate tube, mix the uninfected cells and 
plate in a separate 15 cm plate. 
4) Day 4: Add Puromycin to the 15 cm plates in the appropriate concentration to 
kill the uninfected cells in 2-4 days.  
Monitor the cells daily. When all the cells in the uninfected plate have died, 
the selection has been completed.  
1.3.5.2 Passages 
Once the 15 cm dishes are subconfluent, collect the cells from all the plates and 
mix them in a tube. Count the live cells and split them in to three tubes that 
contain at least the minimum number of cells to maintain the representation of 
the library: 
1) Tube 1: Time 0 pellet. Spin down the cells. Aspirate the media and wash the 
pellet with PBS. Centrifuge and aspirate the media again. Resuspend the 
pellet in 1 mL of fresh PBS and transfer the suspension to a 1.5 mL tube. 
Centrifuge at 2,000 rpm for 2 minutes. Aspirate the supernantant and freeze 
the pellet in liquid nitrogen. This is the t=0 of the screening. 
2) Tube 2: Storage. Spin down the cells and resuspend the cells in 1 mL of 
serum + 10% DMSO. Place the cells on dry ice immediately and store in 
liquid nitrogen. 
3) Tube 3: Screening. Split the cells in to three replicas that each contains the 
minimum representation of the library. Replate the cells following the pipeline 





1.3.6 Genomic DNA 
1.3.6.1 Cell pellet 
1) Collect the cells and spin them down at 1,200 rpm for 5 minutes at room 
temperature.  
2) Aspirate the supernatant and resuspend the pellet in 1 mL of PBS. Transfer 
the cells to a previously labeled 1.5 mL tube. Centrifuge in a microcentrifuge 
at 2,000 rpm for 5 minutes at room temperature. When preparing the cells for 
the genomic DNA extraction, it is recommended to save to aliquots of the final 
time point, as a backup in every pellet, remember to freeze the minimum 
number of cells for maintaining the representation of the library. 
3) Aspirate the supernatant and lyse or freeze the cell pellet. 
1.3.6.2 Genomic DNA extraction 
1) Resuspend the cell pellet in 10 mL of cold PBS 
2) Extract genomic DNA using QIAGEN Blood & Cell Culture DNA Kit (Genomic 
Tip 500/G) following the manufacturer‘s instructions. 
3) Quantify the DNA concentration and the quality of the DNA and store at -
20 °C. The optimal concentration of the DNA to have a good PCR quality is 
around 0.5 – 1 mg/mL. If the resulting DNA is more concentrated, increase 





1.3.7 Sequencing PCR 
1.3.7.1 PCR conditions 
The conditions for PCR have been set up withusing the FastStart Taq DNA 
Polymerase, dNTP Pack from Roche, and may have to be modified if using a 
different polymerase. To avoid the contamination of the reaction, it is critical to 
set up the PCR in a clean hood and to never expose to the library plasmid.To 
ensure the reliability of the PCR, always include a negative control. Include also 
a positive control in which the reaction is performed used the original library (10 
ng of the plasmidic DNA). A minimal representation of each shRNA is also 
required when setting up the PCR. The DNA from 6*106 cells has to be amplified 
when doing a positive screen (6*107 in a negative one).  It is calculated that 
every cell contains about 3 pg of DNA, therefore to get the minimal 
in a negative). This procedure results in a PCR product of 490-500 bp depending 
on the primers used. 
1) A for the 
library plasmid. 
2) PCR Mix (Table 8). Per reaction prepare. Frequently, primer dimers occur 
when running the PCR; to avoid primer dimers it is recommended to keep the 


















Table 8 PCR mix in PCR step of RNAi screening. 
3) PCR Conditions (Table 9) 










Table 9 PCR conditions of PCR step in RNAi screening 
4) In a conical tube, mix all of the PCR products obtained from the same sample.  
5) Prepare a 1.5% agarose gel and run 20 
that the reaction worked properly. To visualize the PCR prepare a 1.5 % 






run for a long time with a low voltage to avoid the generation of secondary 
structures and separate the amplified product from the dimers. 
1.3.7.2 DNA precipitation 
1) Take the conical tube containing the total PCR product for every sample and 
add 1/10 volume of 3M NaOAc pH 4.8 and 1/100 volume of Glycogen. Mix it 
well by inversion. 
2) Add 0.8 volume of Isopropanol and mix well by balancing gently. At this point, 
a turbid solution should appear. 
3) Spin down at 4,000 rpm for 30 minutes. 
4) -free 
water and transfer to a 1.5 mL tube.  
5) Precipitate the DNA again by adding 1 mL of 100% Ethanol to the tube. 
6) Pellet DNA at 13,000 rpm for 30 minutes. 
7) Aspirate the supernatant and wash the pellet with 1 mL of 70% Ethanol and 
spin at 13,000 rpm for 15 minutes. 
8) Aspirate supernatant and air dry DNA. Do not over dry pellet because it will 
be difficult to resuspend. 
9) -free water to the DNA and resuspend at room 
temperature for at least 2 hours. 
1.3.7.3 PCR product purification 
1) Once resuspended, run the PCR product in a 1.5% agarose gel. Loading 100 





It is possible to connect 2 or 3 wells with tape to get a bigger well. Also, the 
product could be split in 3 wells and mixed at the end. 
2) Cut with a razor the band that appears at 490-500 bp size and pass it to a 
previously labeled 1.5 mL tube.  
3) Extract the DNA from the agarose using a DNA gel extraction kit and 
following the manufacturer instructions. NOTE: Elute DNA in the minimum 
amount permitted. 
1.3.7.4 DNA quantification 
The quantification of DNA concentration has to be very precise to keep the 
correct proportion between conditions when preparing the samples. To ensure 
this, it is recommended to quantify the DNA concentration by 2 different methods, 
as for example: 
1) Quantification of DNA using an accurate equipment, such as Nanodrop or 
Qubit. 
2) Quantification in gel. Prepare a 1.5% agarose gel and load 200 ng of each 
sample according to the concentration that has been previously measured. 
The intensity of all of the bands must be equal. 
3) The resulting PCR product can be analyzed by hybridization of customized 
microarray (2.3.7.5) or by NGS (section 2.3.7.6). 
1.3.7.5 Sample preparation for hybridization 
1) Place 1-






down. Incubate the mixture at 98 °C for 5 minutes and immediately place on 
ice for 5 minutes. 
3) e. 
4) - -
dCTP to each reference sample. Pipette the mix up and down. 
5) 
Incubate at 37 °C for 4 hours in a thermocycler. Let it cool down to 4 °C. 
6)  
7) -water. 
Pipette the mix into an Amicon Ultra -0.5 mL 30 K disposal to clean the 
unbound dye. Centrifuge at 10,000 X g for 15 minutes. 
8) -
free water to the sample. Centrifuge the tube at 10,000 x g for 15 minutes. 
Repeat this procedure until the drained liquid appears clear. 
9) Collect the sample and store in a new previously labeled 1.5 mL 
tube.Quantify the DNA amount and the incorporation of the dye using a 
Nanodrop device. 
10) 





1.3.7.6 Sample preparation for sequencing 
The conditions of the sample to be deep sequenced may vary between different 
facilities, but, as a general statement, in a 1.5 mL, mix 100 ng of each sample. 
Add H2
the instructions received. 
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Summary 
Genome-wide RNA interference (RNAi) screening has emerged as a powerful 
tool for functional genomic studies of disease-related phenotypes and discovery 
of molecular therapeutic targets for human diseases. Commercial short hairpin 
RNA (shRNA) libraries are commonly used in this area and state-of-the-art 
technologies including microarray and next generation sequencing are available 
to read out shRNA-triggered phenotypes. However, computational analysis of 
this complex data remains challenging due to noise and small sample size from 





statistical methods of processing, quality assessment and post-analysis for both 
microarray and sequencing-based screening data. 
Key Words: genome-wide, pooled shRNA screen, microarray, Next-
Generation Sequencing, barcode, QA, normalization, decoding, differential 
representation, GSEA 
1 Introduction 
RNA interference (RNAi) has emerged as one of the standard techniques for 
studying phenotype-specific gene function from plants to fungi to animals via 
suppression of gene expression [1-4]. RNAi-based gene silencing can be 
achieved by the use of short interfering RNAs (siRNAs) or short hairpin RNA 
(shRNA) expression vectors. Among the two approaches, shRNA is more 
feasible because siRNA has the problem of transient inhibition of gene 
expression and inefficient transfection into non-dividing cells; however, shRNA 
can be stably integrated into a target cell genome via retroviral or lentiviral gene 
transfer, resulting in the permanent reduction of the targeted gene product. 
Several shRNA expression libraries targeting entire human genome have been 
generated to facilitate functional analysis of the whole transcriptome through 
loss-of-function genetic studies [5-8]. 
In genome-wide shRNA screening, a large population of cells is infected or 
transfected with a pool of different shRNA lentiviral vectors and shRNA hairpins 





of these transduced cells. One is growing the cells for a sufficient number of 
doubling times, extracting the genomic DNA at initial time (T0) and after 
harvesting (T10), and then comparing quantity of shRNAs in these two time-
points. This usage is to identify genes that are essential for cell survival or growth, 
thus making potential therapeutic targets for cancer and other type of human 
diseases, and hairpins of those lethal genes will be depleted or under-
represented in T10 population. The other application is splitting infected cells into 
two groups, treating the two groups differently, for example treating one group 
with drug and nothing to the other as control. After this selective pressure, grow 
cells from both populations and then compare shRNAs extracted from genomic 
DNA of each population. This approach is to identify genes that modulate 
response to the perturbation. In the example of drug treatment, this screen can 
help to identify genes that increase sensitivity or resistance of cells to the drug. 
To read out shRNA hairpins extracted from genomic DNA, microarray 
hybridization is commonly used with the advantage of low cost and flexibility. It 
employs PCR-amplified shRNA template sequence pools extracted from shRNA 
library-transduced cells under test as well as reference conditions. Each PCR 
fragment is labeled with a different fluorophore, followed by hybridization of both 
pools to the same array, or labeled with the same fluorophore followed by 
hybridization to multiplex arrays. Taking the two-color microarray as example, the 
ratio of signal intensities of two colors (Cy3, Cy5) for each probe sequence 
reflects the relative abundance of cells expressing the corresponding shRNA 





shRNA hairpins that sensitize cells in the selective condition will be depleted from 
the pool, showing low values of signal ratio, whereas shRNA constructs that 
render cells resistant will be enriched, showing high values of signal ratio. Three 
types of molecular tags have been used as microarray probes, namely full-length 
hairpin, half hairpin, and external barcode sequence. Half hairpin is able to 
overcome the self-annealing problem during PCR amplification happening to full-
length hairpin, and correspondingly has more efficient labeling and microarray 
hybridization than full-length hairpin [4, 9]. Barcodes are not necessary for 
enrichment screens or positive selections such as designs to detect shRNA 
constructs for cell proliferation [10], but are critical for depletion screens or 
negative selections such as studies designed to detect cell-lethal or drug-
sensitive shRNAs [9, 11-13]. 
Next generation sequencing (NGS) has recently emerged as a cost-effective 
technology of quantitatively measuring abundance of short-length DNA or RNA in 
a short time. This massively parallel sequencing has been used in pooled shRNA 
screens [14-16], and comparing to microarray-based approaches, it offers 
several potential advantages in terms of coverage of targeting genes, flexibility of 
input library, scalability and dynamic range.  As the cost of NGS is rapidly 
decreasing, this means might dominate high-throughput shRNA screening in the 
near future. 
In this chapter, we will discuss computational analysis of both microarray and 





quality assessment metrics for raw data of microarray and NGS respectively, the 
pipeline to decode shRNA NGS data, preprocessing of screening data including 
background correction and normalization, quality controls of processed data to 
detect biological artifacts of experiments, statistical methods for differential 
representation analysis at individual shRNA level and gene level to identify 
candidates of interest and functional enrichment of selected candidates. 
2 Materials 
2.1 shRNA Library: Thermo Scientific Open Biosystems GIPZ Lentiviral human 
shRNAmir library is used to illustrate the analysis of RNAi screening data. 
The library is composited of 58,493 hairpin constructs, in which 39,458 
shRNAs are known to target 18,661 human genes, about 75% of the genome. 
In the GIPZ library, one gene might have multiple shRNAs and as shown in 
the distribution table of number of shRNAs per gene (Table 1), the majority of 
genes has at least 2 or 3 shRNAs. 
2.2 Microarray Data: Two types of microarray probe designs based on the 
structure of shRNA construct are introduced in this chapter: barcode and half 
shRNA hairpin. For each type of design, the oligonucleotide probes for 
hybridization have both sense and anti-sense sequences of the molecular 
tags. 
2.3 Next-Gen Sequencing: NGS-based screening data used in this chapter is 





2.4 Software: all analysis is performed under the platform of R [17] and related 
Bioconductor [18] packages. 
2.5 Experimental Design: A negative RNAi screen experiment in both microarray 
and NGS platforms is employed (see Note 1) to illustrate the computational 
analysis procedures.  
3 Methods 
3.1 Preprocess of Microarray Data: extract intensity signals of two-colors (red 
for sample, green for reference) from DNA microarray readout, and use the score of 
log10(Ired/Igreen)  as representation of shRNAs, separate data for barcode or shRNA 
probes and control probes, and then perform background correction (see Note 2) 
for each array. 
3.2 Normalization of Microarray Data: assemble the microarray data of all 
samples together and conduct quantile normalization (see Note 3) across all arrays. 
3.3 QA of Raw Sequencing Data: transform millions of short-reads generated 
from NGS machine into FASTQ format, and conduct quality assessment (QA) using 
different metrics (see Note 4) before any further analysis. 
3.4 Decoding of shRNA Sequencing Data: decode each short read by 
identifying its experimental condition and represented shRNA construct (see Note 
5), and count number of short reads for each shRNA in each sample. 
3.5 Normalization of Processed NGS Data: normalize the profiles of shRNA 






3.6 QA of Normalized Data: perform advanced quality assessment on 
normalized microarray or sequencing data to identify outlier experiments using MA 
plot (see Note 7), variance-mean dependence plot (see Note 8), distribution plot 
(see Note 9), clustering of samples (see Note 10), Principle Component Analysis 
(PCA) and plot of the first two components, (see Note 11).  
3.7 Consistence of Replicates: plot and calculate correlations (see Note 12) 
between biological replicates of the same experiment to further check consistence 
of experiments and to detect outlier samples. 
3.8 Differential Representation Analysis: conduct case-control comparison 
(T10 vs. T0) to identify differentially-represented shRNAs, either depleted or 
enriched in case samples. Depletion or under-representation of a shRNA means the 
targeting gene is lethal to experimental cells, thus making it a good candidate as 
potential therapeutic targets of diseases. Due to the fact that multiple shRNAs could 
target the same gene in the library, silencing effects of shRNA on cell viability are 
estimated at individual shRNA level (see Note 13), best shRNA level (see Note 14), 
and integrated gene level (see Note 15). Corresponding statistics including fold 
change (FC) (see Note 16), Z-score (see Note 17), p-value, False Discovery Rate 
(FDR) (see Note 18) are reported. 
3.9 Heatmap of Selected shRNAs/Genes: to visualize the pattern of 
differentiated shRNA-silencing effects such as similarity between genes or samples, 
plot clustering-enabled heatmap of z score and microarray or NGS data of pre-





3.10 Functional Enrichment Analysis: to identify functional similarities of genes 
identified by RNAi screens, perform Gene Set Enrichment Analysis (GSEA) using 
public available functional database including Gene Ontology, KEGG pathways, etc 
(see Note 20).  
4 Notes 
4.1 Four Diffuse-Large B-Cell Lymphoma (DLBCL) cell lines are prepared for 
shRNA screening. For each cell line, genomic DNA is extracted at T0, the initial 
time after transduction of lentiviral shRNA library and at T10 when cells are 
harvested after 10 doubling times. Triplicates are conducted for each time point. 
4.2 Negative control probes that targeting no genes are used to estimate the 
background signal of each array, which is proportional to the total amount of 
sample DNAs. Background correction is performed by subtracting the 
mean/median of negative controls from signal of each shRNA within the same 
microarray. 
4.3 Quantile-normalization method [19] is suggested to normalize microarray data 
across multiple arrays to preserve the rank of shRNAs and to make it 
comparable between conditions by forcing the same distribution of each array. 
4.4 An R Bioconductor package ‗ShortRead‘ [20] is used to do quality assessment of 
Genome Analyzer output. It takes FASTQ format as input. The report summary 
includes read distribution (Figure 1A), read count (Figure 1B), read overall 





4.5 According to the construction of each 51nt-length sequence read(Figure 2), the 
first 6 nucleotides (in blue) are used to mapping back to the barcodes for 6 
experimental conditions, and the 22 nucleotides (in red) in the middle are used 
to identify shRNA hairpin in the library it belongs to. 
4.6 The normalization of sequencing count profile is scaling reads of each shRNA to 
equalize the total number of reads for all samples, which is proportional to the 
cell population size of each experiment. 
4.7 M and A are defined as: 
                
  
             
 
 
V1 is the intensity ratio (microarray data) or shRNA count (sequencing data) 
of the sample studied, and V2 is for a "pseudo"-sample that consists of the 
median across all samples. Generally, we expect the mass of the distribution 
in an MA plot (Figure 3A) to be concentrated along the M = 0 axis, and there 
should be no trend in M as a function of A. If there is a trend in the lower 
range of A, this often indicates that the samples have different background 
signals; this may be addressed by background correction. A trend in the 
upper range of A can indicate saturation of the measurements; in mild cases, 
this may be addressed by non-linear normalization. 
4.8 Variance-mean dependence plot (Figure 3B) is the standard deviation of the 
representation values across samples on the y-axis versus the rank of their 
mean on the x-axis. The red dots, connected by lines, show the running median 





horizontal, that is, show no substantial trend. In some cases, a hump on the right 
hand of the x-axis can be observed and is symptomatic of a saturation of the 
measurements. 
4.9 Boxplots (Figure 3C) represent summaries of the signal distributions of the 
samples. Each box corresponds to one sample. Typically, we expect the boxes 
to have similar positions and widths. If the distribution of a sample is very 
different from the others, this may indicate an experimental problem. Outliers 
based on the Kolmogorov-Smirnov statistic between each sample's distribution 
and the distribution of the pooled data, are marked by an asterisk (*). Density 
plots (Figure 3D) are smoothed histograms of the data. Typically, the 
distributions of the samples should have similar shapes and ranges. Outliers, 
according to the same criterion as in the boxplots, are highlighted by color. 
4.10 Heatmap (Figure 4A) of between sample distances and dendrogram of 
sample clustering (Figure 4B) can help to detect batch effects, as well as 
clustering of samples based on biological effects. The color scale is chosen to 
cover the range of distances encountered in the dataset. Datasets for which the 
sum of the distances to the others is much different from the others are detected 
as marked by * as outliers. The distance between two samples is the mean 
absolute difference (L1-distance) between the vectors of M-values (see Note 7) 
of the samples. 
4.11 Scatter plot (Figure 4C) of the samples along the first two principal 
components is used to check whether the samples cluster, and whether this is 





unintended reasons such as "batch effects". Outliers, according to the same 
criterion as in the heatmap plot, are indicated by larger symbols. 
4.12 Scatter plot (Figure 5) of between biological or technical replicates is 
another quick visualization method to check the consistence of experimental 
replicates. Empirical distribution of each replicate sample is plotted in the 
dialogue, and they are expected to have similar shape and scale. Upper triangle 
shows the Pearson and Spearman correlation between two replicated samples 
without any filtering on shRNAs. 
4.13 To estimate the differential representation of individual shRNAs, a 
moderated t-type test [21, 22] can be used to test the statistical significance, or a 
linear modeling approach [23] can be used to fit the data. For the modeling 
approach, the likelihood needs to be regularized by classical Frequentist‘s 
stabilization method [22], Bayesian or empirical Bayesian approach [23] due to 
small sample size issue. The regression coefficient represents the level of 
difference between case and control groups, and the statistical significance can 
be estimated by Chi-square test or Wald‘s z-test. 
4.14 To obtain the effects of shRNA on cell viability at gene level, one simple 
approach is to perform individual shRNA analysis first, and from all shRNAs 
targeting the same gene, select the one showing the most significant depletion 
or enrichment, namely the best shRNA for the corresponding gene. However, 
this approach is heuristic and might cause a high false positive rate. 
4.15 Another idea to estimate the effects at gene level is to integrate all shRNA 





shRNA analysis first and then combine statistics of all shRNAs for the same 
gene by either signed Fisher‘s method [24] or Stouffer‘s method [25], or one can 
use hierarchical modeling approach [26, 27] by introducing an indicator variable 
for shRNA level and allowing random effects along with different shRNAs and 
use the fixed effects to estimate the overall gene level effects. The first separate-
and-combine approach might introduce many false positives due to inaccurate 
estimation of individual shRNAs effects from small sample size and noisy nature 
of high-throughput design, but the second modeling-together method might 
overcome this problem by increasing sample size. Also, the likelihood of 
statistical model needs to be penalized by Bayesian approach to obtain robust 
estimation of parameters. 
4.16 To estimate the fold change between case and control samples, one need 
to calculate the mean within case or control samples. Two methods can be used: 
arithmetic or geometric mean, and the latter one is suggested for robustness. 
4.17 For the linear modeling approach, the Z socre (Figure 6A) is calculated by 
estimate of regression coefficient over its standard deviation, which 
asymptotically follows a standard Gaussian distribution, therefore the two-tailed 
p value (Figure 6B) for statistically significance can be calculated based on this 
null distribution. 
4.18 FDR for correction of multiple comparisons is calculated by BH procedure 
[28]. 
4.19 The Heatmap with both row and column clustering of Z scores (Figure 7A) 





between shRNAs or sample conditions. Euclidian or correlation can be used for 
distance metrics and Wald method is suggested for hierarchical clustering. 
4.20 Gene Set Enrichment Analysis of pathways (Figure 8) or GO terms uses 
differential representation results of all shRNAs or genes as the reference, for 
example, ranking from the most enriched to the most depleted. Classical 
weighted K-S statistic [29] or Maxmean statistic [30] can be used to estimate the 
enrichment score, and gene label shuffling is commonly used to estimate 
significance in this small sample size situation. 
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Tables and Figures 
Table 1: Distribution of Number of shRNAs per Gene 
# shRNAs 
Per Gene 
1 2 3 4 5 6 7 8 9 10 11 13 total 
Freq of 
Genes 







Figure 1: Quality assessment plots of raw NGS data. (A) Read count distribution 
(B) Cycle-specific nucleotide count (C) Distribution of average base quality (D) 
Boxplot of cycle-specific base quality 
 
Figure 2: Decomposition of each NGS short-read. The first 6 bases in blue are 





sequences of shRNA hairpins in the library, out of which 19 nucleotides are 
perfectly matched to the genome sequence. 
 
Figure 3: Quality assessment part 1 of normalized microarray or NGS data. (A) 







Figure 4: Quality assessment part 2 of normalized microarray or NGS data. (A) 
Heatmap of sample distances (B) Scatter plot the first two principal components 
(C) Hierarchical clustering of all samples: dots on the upper left plot indicates 
where to split the three to obtain specific number of clusters, in which the yellow 






Figure 5: Scatter plots and correlations between biological replicates. Plots in 
the dialogue are density distributions of data in each replicate. Texts in the upper 






Figure 6: Density plots of Z score and histograms of p values for differential-
representation results. Negative Z score means depletion of shRNA in 
experiment of study. 
 
Figure 7: Heatmap of (A) Z scores and (B) normalized data of shRNAs showing 






Figure 8: An example GSEA plot of pathway or GO gene sets in differentially-
represented shRNAs. Y axis shows the z score of differential representation at 
shRNA level or gene level. The red dashed lines indicate normalized Enrichment 
Score (nES) and P value. 
 
